vcnx-10q_20200930.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001564590-20-053729.txt : 20201113 0001564590-20-053729.hdr.sgml : 20201113 20201113073037 ACCESSION NUMBER: 0001564590-20-053729 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201113 DATE AS OF CHANGE: 20201113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 201309170 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 10-Q 1 vcnx-10q_20200930.htm 10-Q vcnx-10q_20200930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38624

Vaccinex, Inc.

(Exact name of registrant as specified in its charter)

Delaware	16-1603202
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
1895 Mount Hope Avenue Rochester, New York	14620
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (585) 271-2700

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	VCNX	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 10, 2020, the registrant had 22,385,628, shares of common stock, $0.0001 par value per share, outstanding.

VACCINEX, INC.

FORM 10-Q

TABLE OF CONTENTS

		Page

	PART I – FINANCIAL INFORMATION


Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets (Unaudited)	3

	Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	4

	Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited)	5

	Condensed Consolidated Statements of Cash Flows (Unaudited)	6

	Notes to Condensed Consolidated Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29

Item 4.	Controls and Procedures	29


	PART II – OTHER INFORMATION


Item 1A.	Risk Factors	30

Item 6.	Exhibits	34

	Signatures	35

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

VACCINEX, INC.

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share data)

	As of September 30, 2020			As of December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	17,092		$	2,776
Accounts receivable		443			898
Prepaid expenses and other current assets		702			336
Total current assets		18,237			4,010
Property and equipment, net		488			594
TOTAL ASSETS	$	18,725		$	4,604
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable		2,944			3,208
Accrued expenses		2,993			3,670
Senior secured convertible debt, net		7,890			-
Total current liabilities		13,827			6,878
Long-term debt		1,134			-
TOTAL LIABILITIES		14,961			6,878
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of September 30, 2020, and December 31, 2019; 22,380,351 and 14,887,999 shares issued as of September 30, 2020 and December 31, 2019, respectively; 22,379,499 and 14,887,147 shares outstanding as of September 30, 2020 and December 31, 2019, respectively		3			1
Additional paid-in capital		250,843			222,403
Treasury stock, at cost; 852 shares of common stock as of September 30, 2020 and December 31, 2019, respectively		(11	)		(11	)
Accumulated deficit		(271,034	)		(248,630	)
Total Vaccinex, Inc. stockholders’ deficit		(20,199	)		(26,237	)
Noncontrolling interests		23,963			23,963
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		3,764			(2,274	)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$	18,725		$	4,604

The accompanying notes are an integral part of these condensed consolidated financial statements.

VACCINEX, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue	$	50		$	404		$	50		$	523
Grant revenue		575			-			575			-
Costs and expenses:
Cost of revenue		2			8			2			199
Research and development		7,334			6,543			17,300			21,259
General and administrative		1,872			1,531			5,565			4,741
Total costs and expenses		9,208			8,082			22,867			26,199
Loss from operations		(8,583	)		(7,678	)		(22,242	)		(25,676	)
Interest expense		(148	)		-			(150	)		-
Other income (expense), net		(23	)		36			(14	)		139
Loss before provision for income taxes		(8,754	)		(7,642	)		(22,406	)		(25,537	)
Provision for income taxes		-			-			-			-
Net loss		(8,754	)		(7,642	)		(22,406	)		(25,537	)
Net loss attributable to noncontrolling interests		-			-			-			-
Net loss attributable to Vaccinex, Inc. common stockholders	$	(8,754	)	$	(7,642	)	$	(22,406	)	$	(25,537	)
Comprehensive loss	$	(8,754	)	$	(7,642	)	$	(22,406	)	$	(25,537	)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$	(0.44	)	$	(0.56	)	$	(1.27	)	$	(2.09	)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted		20,074,726			13,759,602			17,587,219			12,246,599

The accompanying notes are an integral part of these condensed consolidated financial statements.

VACCINEX, INC.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited)

(in thousands, except share data)

	Common Stock							Treasury Stock
	Shares		Amount		Additional Paid-in Capital			Common Stock Shares		Amount			Accumulated Deficit			Total Vaccinex, Inc. Stockholders’ Deficit			Noncontrolling Interests		Total Stockholders’ Equity (Deficit)
Balance as of January 1, 2019		11,476,601	$	1	$	208,156			852	$	(11	)	$	(216,767	)	$	(8,621	)	$	23,963	$	15,342
Stock-based compensation		-		-		60			-		-			-			60			-		60
Net loss		-		-		-			-		-			(9,067	)		(9,067	)		-		(9,067	)
Balance as of March 31, 2019		11,476,601		1		208,216			852		(11	)		(225,834	)		(17,628	)		23,963		6,335
Exchange of Vaccinex Products LP Units for common shares		4,455		-		-			-		-			-			-			-		-
Stock-based compensation		-		-		113			-		-			-			113			-		113
Net loss		-		-		-			-		-			(8,828	)		(8,828	)		-		(8,828	)
Balance as of June 30, 2019		11,481,056		1		208,329			852		(11	)		(234,662	)		(26,343	)		23,963		(2,380	)
Issuance of common shares		3,382,332		-		13,800			-		-			-			13,800			-		13,800
Stock-based compensation		-		-		136			-		-			-			136			-		136
Net loss		-		-		-			-		-			(7,642	)		(7,642	)		-		(7,642	)
Balance as of September 30, 2019		14,863,388	$	1	$	222,265			852	$	(11	)	$	(242,304	)	$	(20,049	)	$	23,963	$	3,914


	Common Stock							Treasury Stock
	Shares		Amount		Additional Paid-in Capital			Common Stock Shares		Amount			Accumulated Deficit			Total Vaccinex, Inc. Stockholders’ Deficit			Noncontrolling Interests		Total Stockholders’ Equity (Deficit)
Balance as of January 1, 2020		14,887,999	$	1	$	222,403			852	$	(11	)	$	(248,630	)	$	(26,237	)	$	23,963	$	(2,274	)
Issuance of common shares		1,468,563		1		7,475			-		-			-			7,476			-		7,476
Stock-based compensation		20,000		-		204			-		-			-			204			-		204
Exercise of stock options		1,025		-		4			-		-			-			4			-		4
Net loss		-		-		-			-		-			(7,149	)		(7,149	)		-		(7,149	)
Balance as of March 31, 2020		16,377,587		2		230,086			852		(11	)		(255,779	)		(25,702	)		23,963		(1,739	)
Issuance of common shares		642,112		-		2,350			-		-			-			2,350			-		2,350
Common shares issuance costs		-		-		(54	)		-		-			-			(54	)		-		(54	)
Exchange of Vaccinex Products LP Units for common shares		4,125		-		-			-		-			-			-			-		-
Stock-based compensation		-		-		366			-		-			-			366			-		366
Net loss		-		-		-			-		-			(6,501	)		(6,501	)		-		(6,501	)
Balance as of June 30, 2020		17,023,824		2		232,748			852		(11	)		(262,280	)		(29,541	)		23,963		(5,578	)
Issuance of common shares		5,339,329		1		18,648			-		-			-			18,649			-		18,649
Common shares issuance costs		-		-		(659	)		-		-			-			(659	)		-		(659	)
Exchange of Vaccinex Products LP Units for common shares		14,440		-		-			-		-			-			-			-		-
Stock-based compensation		-		-		91			-		-			-			91			-		91
Exercise of stock options		2,758		-		15			-		-			-			15			-		15
Net loss		-		-		-			-		-			(8,754	)		(8,754	)		-		(8,754	)
Balance as of September 30, 2020		22,380,351	$	3	$	250,843			852	$	(11	)	$	(271,034	)	$	(20,199	)	$	23,963	$	3,764

The accompanying notes are an integral part of these condensed consolidated financial statements.

VACCINEX, INC.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

	Nine Months Ended September 30,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(22,406	)	$	(25,537	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		237			181
Debt related charges included in interest expense		113			-
Net amortization of premiums and discounts on marketable securities		-			(44	)
Stock-based compensation		661			309
Change in fair value of derivative liability		(65	)		-
Changes in operating assets and liabilities:
Accounts receivable		455			(449	)
Prepaid expenses and other current assets		(366	)		418
Accounts payable		(202	)		21
Accrued expenses		(692	)		189
Net cash used in operating activities		(22,265	)		(24,912	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales of marketable securities		-			14,150
Purchase of property and equipment		(291	)		(77	)
Net cash (used in) provided by investing activities		(291	)		14,073
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from private offering of common stock		11,475			13,800
Proceeds from issuance of common stock		17,000			-
Proceeds from issuance of convertible debt, net of discount		8,000			-
Redemption of convertible debt		(108	)		-
Payments of convertible debt issuance costs		(50	)	-
Proceeds from long-term debt		1,134			-
Payments of common stock issuance costs		(598	)		-
Proceeds from exercise of stock options		19			-
Net cash provided by financing activities		36,872			13,800
NET INCREASE IN CASH AND CASH EQUIVALENTS		14,316			2,961
CASH AND CASH EQUIVALENTS–Beginning of period		2,776			5,618
CASH AND CASH EQUIVALENTS–End of period	$	17,092		$	8,579
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Purchase of property and equipment in accounts payable	$	(161	)	$	-
Offering costs in accounts payable	$	100		$	-
Offering costs in accrued expenses	$	15		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

VACCINEX, INC.

Notes to Condensed Consolidated Financial Statements (Unaudited)

Note 1.

COMPANY AND NATURE OF BUSINESS

Vaccinex, Inc. (together with its subsidiaries, the “Company”) was incorporated in Delaware in April 2001 and is headquartered in Rochester, New York. The Company is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Since its inception, the Company has devoted substantially all of its efforts toward product research, manufacturing and clinical development and raising capital.

The Company is subject to a number of risks and uncertainties common to other early-stage biotechnology companies including, but not limited to, dependency on the successful development and commercialization of its product candidates, rapid technological change and competition, dependence on key personnel and collaborative partners, uncertainty of protection of proprietary technology and patents, clinical trial uncertainty, fluctuation in operating results and financial performance, the need to obtain additional funding, compliance with governmental regulations, technological and medical risks, management of growth and effectiveness of marketing by the Company. The Company is also subject to risks related to the ongoing COVID-19 pandemic, discussed under “COVID-19 Pandemic” below. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.

Going Concern

These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $22.3 million and $24.9 million for the nine months ended September 30, 2020 and 2019, respectively, and an accumulated deficit of $271.0 million and $248.6 million as of September 30, 2020 and December 31, 2019, respectively. The Company anticipates that cash and cash equivalents at September 30, 2020 will be sufficient to fund our planned operations into the third quarter of 2021. The Company plans to raise additional funds in the first half of 2021. The uncertainty of these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the date of these financial statements. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

net of commission, and 47,319 shares were sold through the Purchase Agreement for proceeds of $300,000, net of discount. In August 2020, we entered into a Securities Purchase Agreement (the “SPA”), with 3i, LP, (“3i”) as collateral agent and purchaser (the “Convertible Debt Financing”). Pursuant to the SPA, on August 3, 2020, we issued a 7% Original Issue Discount Senior Secured Convertible Debenture (“Senior Secured Convertible Debenture” or “the Debenture”), in the principal amount of $8.64 million for a purchase price of $8.0 million, which reflects an original issue discount of approximately 8%. The Debenture will mature on August 3, 2021. The Debenture accrues interest at 7% per year and is convertible into shares of our common stock at a conversion price of $9.4125 per share, subject to certain customary adjustments. In the third quarter of 2020, we raised total proceeds of approximately $26.6 million, net of commissions and discounts and before expenses, through the Open Market Sale Agreement, the Convertible Debt Financing, the July 2020 private placement transaction, the ADDF award, and the Purchase Agreement. We also received $575,000 in proceeds from our $750,000 grant from the Alzheimer’s Association under its 2020 Part the Cloud Program. The remainder of this award is anticipated to be funded in 2021.

In addition, on May 8, 2020, the Company received a loan of $1.1 million from Five Star Bank (the “PPP Loan”) under the Paycheck Protection Program established as a part of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Company will need substantial additional capital to continue to support its ongoing operations. Financing strategies may include, but are not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding, collaborations, strategic alliances, or licensing arrangements with third parties. There can be no assurances that the Company will be able to secure additional financing, including by its agreement with Jefferies. There can also be no assurances that if financing is available, it will be sufficient to meet its needs or on favorable terms. As a result, taking into account the current economic uncertainty associated with COVID-19, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.

COVID-19 Pandemic

In order to mitigate the spread of COVID-19, governments have at times imposed unprecedented restrictions on business operations, travel, and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The Company has complied with state reopening guidance and has allowed research and development staff to begin working in the laboratory when necessary and using recommended health and safety precautions. The COVID-19 pandemic has impacted the expected timing of the Company’s clinical trials, the economy, the biotechnology industry, and the Company’s business. For example, the Company previously anticipated initiating a trial of pepinemab in Alzheimer’s disease in mid-2020, but the initial enrollment date has been delayed until the first half of 2021. In addition, to mitigate the impacts of the COVID-19 pandemic, including impacts on the Company’s ability to raise capital and to maintain its personnel, the Company applied for and received the PPP Loan. The Company may experience further disruptions as a result of the COVID-19 pandemic that could adversely impact its business, including disruption of research and clinical development activities, plans for release of data, manufacturing, supply, and interactions with regulators and other third parties, and difficulties in raising additional capital. The extent to which the COVID-19 pandemic may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

Note 2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiary in which the Company has a controlling financial interest and a variable interest entity (“VIE”) in which the Company is the primary beneficiary. As of September 30, 2020, and 2019, the Company’s accounts include Vaccinex Products, LP, a Delaware limited partnership (“Vaccinex Products”) and VX3 (DE) LP, a Delaware limited partnership (“VX3”). VX3 was established in October 2017 by a group of Canadian investors and was determined to be a VIE in which the Company is the primary beneficiary. The Company consolidates any VIE of which it is the primary beneficiary. The Company presents its noncontrolling interests as a separate component of stockholders’ equity (deficit). The Company presents the net loss of VX3 equal to the percentage ownership interest retained in such entity by the respective noncontrolling party (VX3), and as a separate component within its condensed consolidated statements of operations and comprehensive loss. The financial position of Vaccinex Products was not material as of September 30, 2020 and 2019, and there were no gains or losses for

Vaccinex Products for the nine months ended September 30, 2020 and 2019. All intercompany transactions and balances have been eliminated.

These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the "SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2020. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC.

These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 9, 2020.

Use of Estimates

These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.

Concentration of Credit Risk, Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.

Grant Revenue

From time to time, the Company receives certain grant award funding to support its continuing research and development efforts. The Company considers these grants to be operating revenue as they support the Company’s primary operating activities. We recognize revenue from these contracts as we perform services under these arrangements when the funding is received. Revenues and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as we have determined we control the arrangement as the primary obligor under the arrangements relative to the research and development services we perform. During the three and nine month periods ended September 30, 2020 the Company recorded grant revenue related to funds received from the ADDF of $575,000.

Deferred Offering Costs

The Company has incurred certain costs in connection with its securities offerings with Jefferies and Keystone. The Company capitalizes such deferred offering costs, which consist of direct, incremental legal, professional, accounting, and other third-party fees. The deferred offering costs will be offset against offering proceeds upon the completion of an offering. Should the offering be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Company’s condensed consolidated statement of operations and comprehensive loss. Accordingly, $713,000 of offering costs associated with the ATM Facility and Keystone were charged against paid in capital in the nine months ended September 30, 2020. There were no deferred offering costs on the condensed consolidated balance sheet at September 30, 2020.

Convertible Instruments

The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The accounting standards require companies to bifurcate embedded features from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company’s derivative instrument related to certain features embedded within the Debenture is discussed in Note 9. The derivative is accounted for as a derivative liability and remeasured to fair value as of each balance sheet date and the related remeasurement adjustments are recognized in the Company’s condensed consolidated statement of operations and comprehensive loss.

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under U.S. GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term. ASU 2016-02 is effective for the Company for annual periods beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, requiring the use of a modified retrospective transition approach applied at the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU No. 2018-11, Leases, Targeted Improvements to ASC 842, Leases, (“ASU 2018-11”), which contains certain amendments to ASU 2016-02 intended to provide relief in implementing the new standard. ASU 2018-11 provides registrants with an option to not restate comparative periods presented in the financial statements. The Company intends to elect this new transition approach using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods will be presented in accordance with the previous guidance in Accounting Standards Codification (“ASC”) 840, Leases.

The Company is currently evaluating the potential impact ASU 2016-02 may have on its financial position, results of operations, and related footnotes. The Company expects it will elect to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Company anticipates that the impact relating to the new lease standard will result in the Company’s operating lease of its corporate headquarters in Rochester, New York, being reflected on the consolidated balance sheet as an operating lease right to use asset and related lease liability.

In June 2016, the FASB issued ASU No. 2016-13, “Measurement of Credit Losses on Financial Instruments” to improve reporting requirements specific to loans, receivables, and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets. The standard is effective for interim and annual periods beginning after December 15, 2022 with early adoption permitted. Based on the composition of the Company’s financial assets, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial statements.

In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

Note 3. BALANCE SHEET COMPONENTS

Property and Equipment

Property and equipment consist of the following (in thousands):

	As of September 30, 2020			As of December 31, 2019
Leasehold improvements	$	3,174		$	3,161
Research equipment		3,499			3,442
Furniture and fixtures		350			350
Computer equipment		273			214
Property and equipment, gross		7,297			7,167
Less: accumulated depreciation and amortization		(6,809	)		(6,573	)
Property and equipment, net	$	488		$	594

Depreciation expense related to property and equipment was $74,000 and $64,000 for the three months ended September 30, 2020 and 2019, respectively and $237,000 and $181,000 for the nine months ended September 30, 2020 and 2019, respectively.

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	As of September 30, 2020		As of December 31, 2019

Accrued clinical trial cost	$	2,278	$	3,252
Accrued payroll and related benefits		420		262
Accrued consulting and legal		180		79
Accrued interest		94		-
Accrued other		21		77
Accrued expenses	$	2,993	$	3,670

Note 4.

FAIR VALUE MEASUREMENTS OF FINANCIAL MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Assets and liabilities recorded at fair value on a nonrecurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Financial instruments consist of cash, accounts receivable, accounts payable, accrued liabilities, and long-term debt. Cash, accounts receivable, accounts payable, accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Fair value measurement standards also apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its cash equivalents deposited in money market funds and derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis

The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):

	As of September 30, 2020
	Fair Value		Level 1		Level 2		Level 3
Financial Assets:
Cash equivalents:
Money market fund	$	626	$	626	$	-	$	-
Total Financial Assets	$	626	$	626	$	-	$	-

	As of December 31, 2019
	Fair Value		Level 1		Level 2		Level 3
Financial Assets:
Cash equivalents:
Money market fund	$	1,464	$	1,464	$	-	$	-
Total Financial Assets	$	1,464	$	1,464	$	-	$	-

The Company did not transfer any assets measured at fair value on a recurring basis to or from Level 1 and Level 2 during either of the nine months ended September 30, 2020 and 2019.

The Debenture, as discussed in Note 9, contains embedded derivative features that are required to be bifurcated and remeasured each reporting period. Each quarter, the change in the fair value of the embedded derivative features, if any, is recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The Company uses a binomial lattice valuation model to derive the value of the embedded derivative features, which initially valued the bifurcated embedded derivative at $65,000. The fair value of the derivative liability is $0 at September 30, 2020. Key inputs into this valuation model are the Company’s current stock price, risk-free interest rates, the stock dividend yield, the stock volatility, and the credit spread. The first three aforementioned inputs are based on observable market data and are considered Level 1 inputs while the last two aforementioned inputs are unobservable and thus require management’s judgment and are considered Level 3 inputs. This fair value measurement is considered a Level 3 measurement within the fair value hierarchy.

Note 5.

LICENSE AND SERVICES AGREEMENT

In November 2017, the Company entered into a license agreement (the “VX3 License Agreement”) with VX3, which was formed by a group of Canadian investors including the Company’s majority stockholder, FCMI Parent Co. (“FCMI Parent”). VX3 was created for the purpose of funding the Company’s research and development activities for pepinemab, the Company’s most advanced product candidate. Under the VX3 License Agreement, the Company granted VX3 the license to use, make, have made, sell, offer and import pepinemab for the treatment of Huntington’s disease in the U.S. and Canada and, in return, VX3 agreed to fund research and development activities with up to an aggregate of $32.0 million in milestone payments to the Company and to share any pepinemab profits and sublicensing revenue under the agreement in an amount based on a calculation set forth in the agreement. The Company also entered into a services agreement with VX3 (the “Services Agreement”), pursuant to which the Company will carry out development activities for pepinemab for the treatment of Huntington’s disease in the U.S. and Canada in exchange for services payments from VX3. The VX3 License Agreement expires upon the last to expire licensed patent and may be terminated by either party upon uncured material breach, the occurrence of certain transactions or financings, uncured failure of VX3 to make any payment due under the Services Agreement, or upon written notice after November 6, 2020. The Services Agreement may be terminated by either party upon an uncured material breach and is automatically terminated upon termination of the VX3 License Agreement. The VX3 License Agreement provides that upon termination, the Company will issue to VX3 or its designees the number of shares of the Company’s common stock equal to the lesser of (1) the aggregate of all payments made to VX3 by its partners divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of the Company’s common stock.

The Company has a variable interest in VX3 through FCMI Parent, which is majority owned and controlled by the Company’s chairman, and which controlled 90% of VX3’s voting interest as of September 30, 2020. VX3 does not have any business operations or generate any income or expenses and is primarily a funding mechanism specifically for the benefit of the Company, as its only activities consist of the receipt of funding and the contribution of such funding to the Company. Therefore, the Company determined that it is the primary beneficiary of VX3 and that the operating results of VX3 should be incorporated into the Company’s consolidated financial statements accordingly.

The Company entered into an exchange agreement on August 13, 2018 with VX3 and its partners, including FCMI Parent, that provides each VX3 partner with the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of the Company’s common stock. The exchange agreement also provides that FCMI Parent’s exercise of its option to exchange its VX3 partnership interests for shares of Company common stock would trigger the exchange of all VX3 partnership interests for shares of Company common stock. Further, under the exchange agreement, the Company will have a right to require the exchange of all partnership interests in VX3 for shares of Company common stock in any of the following circumstances:

•

the Company enters into a transaction such as a sale, merger or consolidation such that shares of Company common stock are or will be sold or exchanged for cash and/or marketable securities;

•

on or after August 13, 2023; or

•

either the Company or VX3 enters into a licensing, partnering or similar transaction with respect to one or more products and indications licensed to VX3 by the Company, and all amounts then due and owing to VX3 in connection with such transaction have been paid to VX3.

For the three and nine months ended September 30, 2020 and 2019, the Company did not receive any amounts from VX3 or record any related capital contributions from noncontrolling interests on the condensed financial statements. Noncontrolling equity interests do not participate in a proportionate share of the Company’s net losses for the three or nine months ended September 30, 2020 or 2019 pursuant to the aforementioned partnership, license, services and exchange agreements.

Note 6.

COLLABORATION AGREEMENTS

Surface Oncology, Inc.

In November 2017, the Company entered into a research collaboration and license option agreement with Surface Oncology, Inc. (“Surface”) to identify and select antibodies against two target antigens, using the Company’s proprietary technology as described in the agreement. The term for each research program is nine to twelve months (not exceeding twelve months unless extended by written agreement) including time necessary for any functional assessment conducted by Surface following the commencement of the research program. Surface will provide the Company material to carry out the research activities. During the research program term, the Company also grants Surface non-exclusive, worldwide, limited-purpose license for each target to use the Company’s research program materials for conducting the research work pursuant to the agreement. The Company received service fee payments of $4,000 and $123,000 for the three and nine months ended September 30, 2019, respectively. There were no service fee revenues for the three and nine months ended September 30, 2020. During the three and nine months ended September 30, 2019, the Company recorded $400,000 of revenue related to its agreement with Surface, of which $300,000 was due to the exercise by Surface of its product option and $100,000 was for an exclusive product license. During the three and nine months ended September 30, 2020 the Company received $50,000 for the annual maintenance fee of the exclusive product license. This agreement will expire upon the latest of the expiration of both research programs and all evaluation and testing periods.

Under the agreement, Surface may purchase exclusive options, exercisable by providing a written notice to the Company, to obtain (i) an exclusive product license to make, use, sell and import products incorporating antibodies targeting the first antigen and (ii) an exclusive research tool license to use antibodies targeting the second antigen to perform research. Surface purchased the first option and exercised the second option and the Company entered into an exclusive research tool license agreement with Surface in the third quarter of 2019.

Note 7.

COMMITMENTS AND CONTINGENCIES

Sublicense Termination Payments

In 2006, the Company licensed certain technology to EUSA Pharma SAS (“EUSA”), and in 2008, this technology was sublicensed by EUSA to Glaxo Group Limited (“GSK”) for development. GSK terminated its sub-license with EUSA in March 2010 and ownership of the technology reverted back to the Company. The Company may be required to pay EUSA up to $25.5 million plus ongoing royalty payments of 1% of net sales upon the occurrence of certain events involving the previously licensed technology, including a Phase 3 clinical trial, Food and Drug Administration acceptance and approval and product sales. The Company is not planning any further commercialization efforts related to the previously licensed technology, and therefore does not anticipate any of the above described amounts will be paid.

Operating Lease

The Company leases its facilities from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with a director of the Company, under non-cancellable operating leases. The lease agreement requires monthly rental payments of $14,000 through October 31, 2020. The Company entered into a lease extension in August 2020, which requires monthly rental payments of $14,511 commencing November 2020 continuing through October 2022. The Company is responsible for all maintenance, utilities, insurance and taxes related to the facility.

As of September 30, 2020, the future minimum payments for the operating lease are $43,022 in 2020, $174,132 in 2021, and $145,110 in 2022.

Rent expense incurred under the operating lease was $42,000 and $126,000 for each of the three and nine months ended September 30, 2020 and 2019, respectively.

Contingencies

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of September 30, 2020, and December 31, 2019, the Company was not involved in any material legal proceedings.

Note 8.

LONG-TERM DEBT

On May 8, 2020, the Company received the PPP Loan in the amount of $1,133,600. The PPP Loan matures on May 8, 2022, with no principal payments required prior to the maturity date, and bears interest at an annual rate of 1.0%, with interest payments commencing on November 8, 2020, less the amount of any potential forgiveness. The PPP Loan may be repaid at any time prior to maturity without incurring prepayment penalties. Pursuant to the CARES Act, all or a portion of the PPP Loan may be forgiven if the PPP Loan is used for qualifying expenses as described in the CARES Act, subject to certain conditions. The Company intends to seek forgiveness for this loan, but until such forgiveness is granted the loan has been recorded as long-term debt and related interest has been accrued accordingly. As of September 30, 2020, the Company has reflected accrued interest and interest expense of $5,000 within its condensed consolidated balance sheet and condensed statement of operations and comprehensive loss, respectively.

Note 9. CONVERTIBLE DEBENTURE

The senior secured convertible debt comprises the following (in thousands):

	As of September 30, 2020			As of December 31, 2019
Senior secured convertible debenture	$	8,531		$	-
Unamortized original issuance discount and debt issuance costs		(641	)		-
Total convertible debt	$	7,890		$	-

On July 30, 2020, the Company consummated the Convertible Debt Financing pursuant to which the Company issued the Debenture in the principal amount of $8,640,000 for a purchase price of $8,000,000, which reflects an original issue discount of approximately 8%. The closing of the sale of the Debenture occurred on August 3, 2020.

The Debenture will mature on the August 3, 2021. The Debenture accrues interest at 7% per year and is convertible into shares of common stock at the holder’s option, at a conversion price of $9.4125 per share, subject to certain customary adjustments (“Optional Conversion”). Should a holder elect to convert prior to maturity, the holder is entitled to a cash payment for interest that would have been earned by the holder through the original maturity of the Debenture (the “Interest Make-Whole”).

Subject to the satisfaction of certain conditions, at any time, the Company may elect to redeem all or any portion of the Debenture for an amount equal to 115% of the outstanding principal balance being redeemed plus all accrued unpaid interest on the amount being redeemed and an amount due under the Interest Make-Whole (the “Optional Redemption”).

The Debenture also provides that in connection with future capital raising transactions (subject to certain exceptions), the Company must offer to use 20% of the funds raised to redeem amounts outstanding under the Debenture (“Mandatory Redemption”). Any redemption in this circumstance will be at the election of the holder. Consistent with the Optional Conversion or Optional Redemption provisions, the Mandatory Redemption is subject to the Interest Make-Whole. During the three and nine month periods ended September 30, 2020, the Company made payments under the Mandatory Redemption provision totaling $116,329 consisting of $108,719 for principal repayments and $7,610 for accrued and make-whole interest.

The Debenture contains customary representations and warranties and affirmative and restrictive covenants, including limitations on indebtedness, liens, dispositions of assets, organizational document amendments, change of control transactions, stock repurchases, indebtedness repayments, dividends, affiliate transactions and certain other matters. The Company’s obligations under the Debenture can be accelerated upon the occurrence of certain customary events of default and are secured under a security agreement by a lien on substantially all of the Company’s assets, subject to certain exceptions. In the event of default and acceleration of the Company’s obligations, the Company would be required to pay the outstanding principal balance of the Debenture plus all accrued unpaid interest and amounts due under the Interest Make-Whole, subject to alternate payment in the event that the event of default prevents the holder from converting the Debenture or disposing of the shares issuable thereunder, and all other amounts due in respect of the Debenture.

If the Company, at any time while this Debenture is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any common stock equivalents, (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price will be multiplied by a fraction, the numerator of which will be the number of shares of common stock outstanding immediately before such event, and the denominator of which will be the number of shares of common stock outstanding immediately after such event.

In addition to the adjustments above, if the Company grants, issues, or sells any common stock equivalents or rights to purchase stock, warrants, securities, or other property pro rata to the holders of any class of shares of common stock (the “Purchase Rights”), then upon subsequent conversion of the Debenture, the holder will be entitled to acquire the aggregate Purchase Rights which the holder could have acquired if the holder had held the number of shares of common stock acquirable upon complete conversion of the Debenture immediately before such grant, issuance or sale of Purchase Rights.

The Company evaluated the Debenture and determined that the Interest Make-Whole feature and Optional Redemption meet the definition of an embedded derivative liability measured at fair value. On the issuance date, August 3, 2020, the fair value of the bifurcated embedded derivative liability was $65,000.

The Company incurred $50,000 in fees paid to 3i in connection with the issuance of the Debenture. These costs were primarily allocated to the debt component and recognized as additional debt discount. The Company amortizes the debt discount, including the initial value of the derivative liability of $65,000, allocated fees of $50,000 and the original issuance discount of $640,000, over the term of the Debenture using the effective interest method. The annual effective interest rate is 16.54%. Total interest expense under the Senior Secured Convertible Debenture for the three and nine months ended September 30, 2020 was $210,923, prior to impact of change in fair value of derivative liability.

The fair value of the derivative liability as of September 30, 2020 was $0. The Company recorded the change in the fair value of $65,000 as a reduction to interest expense in its condensed consolidated statement of operations and comprehensive loss.

Note 10. COMMON STOCK RESERVED FOR ISSUANCE

Common stock has been reserved for the following potential future issuances:

	As of September 30, 2020		As of December 31, 2019
Shares underlying outstanding stock options		891,748		579,731
Shares available for future stock option grants		208,395		230,952
Exchange of Vaccinex Products, LP units		1,154,935		1,173,500
Conversion of VX3 units		1,318,797		1,318,797
Total shares of common stock reserved		3,573,875		3,302,980

During the nine months ended September 30, 2020 and 2019, 18,565 and 4,455 units, respectively, of Vaccinex Products, LP were exchanged for shares of the Company’s common stock at par value of $0.0001 per share.

Note 11.

STOCK-BASED COMPENSATION

2011 Employee Equity Plan

In connection with the adoption of the Company’s 2018 Omnibus Incentive Plan (the “2018 Plan”) in August 2018, the Company ceased granting stock options under the Company’s 2011 Employee Equity Plan (the “2011 Plan”). However, the 2011 Plan will continue to govern the terms and conditions of the outstanding stock options previously granted thereunder. Any shares of stock related to awards outstanding under the 2011 Plan that terminate by expiration, forfeiture, cancellation, or otherwise without the issuances of such shares will become available for grant under the 2018 Plan. Stock options granted under the 2011 Plan expire in five or ten years from the date of grant.

2018 Omnibus Incentive Plan

In August 2018, the Company’s board of directors adopted, and its stockholders approved, the 2018 Plan, which allows for the granting of stock, stock options, and stock appreciation rights awards to employees, advisors and consultants. Stock options granted under the 2018 Plan may be either incentive stock options or non-statutory stock options. Incentive stock options may be granted to employees, advisors and consultants at exercise prices of no less than the fair value of the common stock on the grant date. If at the time of grant, the optionee owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price must be at least 110% of the fair value of the common stock on the grant date as determined by the board of directors. Non-statutory stock options may be granted to employees, advisors and consultants at exercise prices of less than the fair market value of a share of common stock on the date the non-statutory stock option is granted but shall under no circumstances be less than adequate consideration as determined by the board of directors for such a share. The vesting period of stock option grants is determined by the board of directors, ranging from zero to eight years. Stock options granted under the 2018 Plan expire in five or ten years from the date of grant.

The Company initially reserved 425,000 shares of common stock for issuance, subject to certain adjustments, pursuant to awards under the 2018 Plan. Any shares of common stock related to awards outstanding under the 2011 Plan as of the effective date of the 2018 Plan, which thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares, will be added to, and included in, the number of shares of common stock available for grant under the 2018 Plan. In addition, effective January 1, 2020 and continuing until the expiration of the 2018 Plan, the number of shares of common stock available for issuance under the 2018 Plan will automatically increase annually by 2% of the total number of issued and outstanding shares of the Company’s common stock as of December 31^st of the immediately preceding year or such lesser number as the Company’s board of directors may decide, which may be zero. Accordingly, on January 1, 2020, 297,743 additional shares of common stock became available for issuance under the 2018 Plan.

A summary of the Company’s stock option activity and related information is as follows:

	Stock Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Balance as of December 31, 2019		579,731		$	8.04		7.0	$	120
Granted		324,300			4.50
Exercised		(3,783	)		5.11			$	3
Canceled		(8,500	)		8.10
Balance as of September 30, 2020		891,748		$	6.77		7.3	$	-
Exercisable as of September 30, 2020		569,724		$	7.75		6.5	$	-

The weighted-average grant date fair value of stock options granted to employees and directors for the nine months ended September 30, 2020 and 2019 was $2.73 per share and $3.35 per share, respectively. The aggregate grant date fair value of stock options that vested during the nine months ended September 30, 2020 and 2019 was $719,632 and $105,061, respectively.

The intrinsic value of stock options vested and exercisable and expected to vest and become exercisable is calculated based on the difference between the exercise price and the fair value of the Company’s common stock as of September 30, 2020 and December 31, 2019. The intrinsic value of exercised stock options is the difference between the fair value of the underlying common stock and the exercise price as of the exercise date.

As of September 30, 2020 and December 31, 2019, total unrecognized compensation cost related to stock options granted to employees was $926,591 and $627,129, respectively, which is expected to be recognized over a weighted-average period of 2.96 and 2.39 years, respectively.

The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

	Nine Months Ended September 30,
	2020			2019
Expected term (in years)		6.3			6.0
Expected volatility		75	%		75	%
Risk-free interest rate		0.9	%		2.5	%
Expected dividend yield		-	%		-	%

In March 2020, the Company issued 20,000 shares of common stock as compensation for administrative fees incurred in connection with entering into a purchase agreement with Keystone. Pursuant to the terms of the Purchase Agreement, Keystone has agreed to purchase up to $5,000,000 of shares of the Company’s common stock. At the time of issuance, the fair market value of the shares was $4.00, and, as a result, $80,000 was included in general and administrative expenses for the nine months ended September 30, 2020.

Total stock-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development	$	37	$	26	$	96	$	72
General and administrative		54		111		565		237
Total stock-based compensation expense	$	91	$	137	$	661	$	309

Note 12.

INCOME TAXES

No provision for income taxes was recorded in either of the three months ended September 30, 2020 and 2019. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of September 30, 2020.

The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of September 30, 2020 and December 31, 2019, the Company had no unrecognized income tax benefits that would affect the Company’s effective tax rate if recognized.

In response to the COVID-19 pandemic, federal, state and local governments at various times enacted relief measures to provide aid and economic stimulus. These measures included deferring the due dates of tax payments or other changes to income and non-income-based tax laws. For the three and nine months ended September 30, 2020, there were no material tax impacts to the Company’s condensed consolidated financial statements as it relates to COVID-19 measures. The Company continues to monitor for additional developments and for guidance issued by the U.S. Treasury Department, the Internal Revenue Service and other governmental bodies.

Note 13.

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Options to purchase common stock		850,716		604,599		742,797		527,573
Contingently issuable common stock upon exchange of Vaccinex Products, LP units		1,163,141		1,198,111		1,170,047		1,199,906
Contingently issuable common stock upon exchange of VX3 units		1,318,797		1,318,797		1,318,797		1,318,797

Note 14.

SEGMENT AND GEOGRAPHIC INFORMATION

The Company’s chief operating decision maker, its Chief Executive Officer, reviews its operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity, the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, and there are no segment managers who are held accountable for operations or operating results. Accordingly, the Company operates in one reportable segment. As of September 30, 2020 and December 31, 2019, all long-lived assets are located in the United States.

Note 15.

RELATED PARTY TRANSACTIONS

As discussed in Note 7, the Company leases its facility from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with the Company’s chairman and major stockholder of the Company. Rent expense incurred under this operating lease was $42,000 and $126,000 for the three and nine months ended September 30, 2020 and 2019.

As discussed in Note 6, in November 2017, the Company entered into a research collaboration and license option agreement with Surface to identify and select antibodies against two target antigens, using the Company’s proprietary technology as described in the agreement. J. Jeffrey Goater, a member of the Company’s board of directors, served as the Chief Business Officer of Surface at that time, and currently serves as the Chief Executive Officer and a director of Surface. The Company received $4,000 and $123,000 in service fee payments for work conducted under the agreement for the three and nine months ended September 30, 2019, respectively. There were no service fee payments for work conducted under the agreement for the three and nine month periods ended September 30, 2020. During the three and nine months ended September 30, 2019, the Company recorded $400,000 of revenue related to its agreement with Surface, of which $300,000 was due to the exercise by Surface of its product option and $100,000 was for an exclusive product license. During the three and nine months ended September 30, 2020 the Company received $50,000 as an annual maintenance fee for the exclusive product license. This agreement will expire upon the latest of the expiration of both research programs and all evaluation and testing periods.

On January 21, 2020, the Company entered into a stock purchase agreement pursuant to which the Company issued and sold to certain investors 1,468,563 shares of its common stock at a purchase price of $5.09 per share for aggregate gross proceeds of $7.5 million (“the January 2020 Private Placement”). FCMI Parent Co., the Company’s majority stockholder, which is controlled by Albert D. Friedberg, the chairman of the Company’s board of directors, Vaccinex (Rochester) L.L.C., which is majority owned and controlled by Dr. Maurice Zauderer, the Company’s President, Chief Executive Officer, and a member of its board of directors, and Jacob Frieberg, a member of the Company’s board of directors, purchased 982,318, 98,231, and 39,292 shares of our common stock for aggregate purchase prices of $4,999,999, $499,996, and $199,996, respectively, in the January 2020 Private Placement. In connection with the January 2020 Private Placement, on January 23, 2020, the Company entered into a registration rights agreement with the investors pursuant to which the Company filed a registration statement on Form S-3 (File No. 333-236417), declared effective on March 11, 2020, to register the resale of the shares acquired by the investors in the January 2020 Private Placement.

On July 9, 2020, the Company entered into a stock purchase agreement (the “July 2020 Stock Purchase Agreement”) with Friedberg Global-Macro Hedge Fund, Ltd. (the “Investor”), pursuant to which the Company issued and sold to the Investor 1,126,760 shares (the “Shares”) of the Company’s common stock, at a purchase price of $3.55 per Share (the “Private Placement”), for gross proceeds of $4.0 million. Albert D. Friedberg, the Company’s chairman and beneficial owner of a majority of the Company’s outstanding common stock, controls Friedberg Mercantile Group, the investment manager of the Investor, which exercises voting and dispositive power over shares held directly by the Investor. The closing of the Private Placement occurred on July 10, 2020. The Company intends to use the net proceeds from the Private Placement to fund the ongoing development of pepinemab, the Company’s lead product candidate, and for working capital and general corporate purposes. Also, on July 10, 2020, the Company entered into a registration rights agreement with the Investor that affords the Investor certain resale registration rights with respect to the Shares.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this Quarterly Report on Form 10-Q, or this Report, to the “Company,” “we,” “our,” or “us” mean Vaccinex, Inc. and its subsidiaries except where the context otherwise requires You should read the following discussion and analysis of financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Report, as well as the audited financial statements, related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations and other disclosures included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, or the Annual Report.

Cautionary Note Regarding Forward-Looking Statements

The following discussion and other parts of this Report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements include, but are not limited to, statements about:

•

our ability to continue as a going concern;

•

the impacts of the COVID-19 pandemic on the expected timing and progress of our clinical trials, as well as other impacts of the COVID-19 pandemic on the economy, our industry, and our business, financial condition and results of operations, including our ability to raise capital;

•

the sufficiency of the financing arrangements we have entered into, that is intended to fund our payroll and certain other operations for a limited period of time and our ability to service our outstanding debt obligations;

•

our estimates regarding our expenses, future revenues, anticipated capital requirements and our needs for additional financing;

•

the implementation of our business model and strategic plans for our business and technology;

•

the timing and success of the commencement, progress and receipt of data from any of our preclinical and clinical trials;

•

our expectations regarding the potential safety, efficacy or clinical utility of our product candidates;

•

the expected results of any clinical trial and the impact on the likelihood or timing of any regulatory approval;

•

the difficulties in obtaining and maintaining regulatory approval of our product candidates;

•

the rate and degree of market acceptance of any of our product candidates;

•

the success of competing therapies and products that are or become available;

•

regulatory developments in the United States and foreign countries;

•

current and future legislation regarding the healthcare system;

•

the scope of protection we establish and maintain for intellectual property rights covering our technology;

•

developments relating to our competitors and our industry;

•

our failure to recruit or retain key scientific or management personnel or to retain our executive officers;

•

the performance of third parties, including collaborators, contract research organizations and third-party manufacturers;

•

the development of our commercialization capabilities, including the need to develop or obtain additional capabilities; and

•

our use of the proceeds from the offerings of our common stock.

Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the risk factors identified in the “Risk Factors” section of this Report, and in Part II, Item 1A of the Annual Report, as well as in our other filings with the Securities and Exchange Commission, or SEC. The forward-looking statements speak only as of the date they were made. Except as required by law, after the date of this Report, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise. We qualify all of our forward-looking statements by the foregoing cautionary statements.

Company Overview

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. We believe we are the leader in the field of semaphorin 4D, or SEMA4D, biology and that we are the only company targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the migration of immune and inflammatory cells to sites of injury, cancer, or infection. We are leveraging our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, pepinemab, an antibody that we believe utilizes novel mechanisms of action. We are focused on developing pepinemab for the treatment of non-small cell lung cancer, or NSCLC, Huntington’s disease, and Alzheimer’s disease. Additionally, third party investigators are studying pepinemab in clinical trials in osteosarcoma and melanoma as well as in “window of opportunity” studies in other indications. We have developed multiple proprietary platform technologies and are developing product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies. We employ our proprietary platform technologies, including through our work with our academic collaborators, to identify potential product candidates for sustained expansion of our internal product pipeline and to facilitate strategic development and commercial partnerships.

Our lead platform technologies include our SEMA4D antibody platform and our ActivMAb antibody discovery platform. In addition, we and our academic collaborators are using our Natural Killer T, or NKT, vaccine platform to discover product candidates that target and extend the activity of NKT cells. Our lead product candidate, pepinemab, is currently in clinical development for the treatment of NSCLC, osteosarcoma, and Huntington’s disease, through our efforts or through investigator-sponsored trials, or ISTs. Our additional product candidates VX5 and VX25 are in earlier stages of development and were selected using our ActivMAb and NKT vaccine platforms, respectively. We believe our multiple platform technologies position us well for continued pipeline expansion and partnership opportunities going forward.

We have generated a limited amount of service revenue from collaboration agreements but have not generated any revenue from product sales to date. We continue to incur significant development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since our inception. We reported a net loss of $8.8 million and $7.6 million for the three months ended September 30, 2020 and 2019, respectively, and a net loss of $22.4 and $25.5 million for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020, and December 31, 2019, we had cash and cash equivalents of $17.1 million and $2.8 million, respectively. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors, including as a result of the COVID-19 pandemic, that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues, if any.

Our recurring net losses and negative cash flows from operations raised substantial doubt regarding our ability to continue as a going concern within one year after the issuance of our consolidated financial statements for the year ended December 31, 2019. Until we can generate sufficient revenue from the commercialization of our product candidates, we expect to finance our operations through the public or private sale of equity, debt financings or other capital sources, such as government funding, collaborations, strategic alliances or licensing arrangements with third parties. For example, during the nine months ended September 30, 2020 we closed three private placements of shares of our common stock for aggregate gross proceeds of approximately $13.5 million, including $7.5 million and $4.0 million through a January 2020 private placement and a July 2020 private placement, respectively, and $2.0 million in September 2020 through an award from the Alzheimer’s Drug Discovery Foundation, or ADDF, in the form of an investment in our common stock. On March 27, 2020, we announced that we had (i) entered into an Open Market Sale Agreement with Jefferies LLC, or Jefferies, and filed a related prospectus supplement pursuant to which we were able to issue and sell up to $11.5 million of shares of our common stock from time to time through Jefferies as sales agent and (ii) entered into a Purchase Agreement with Keystone Capital Partners, LLC, or Keystone, pursuant to which Keystone agreed to purchase up to an aggregate of $5.0 million of shares of our common stock at our direction from time to time. In August 2020, we ceased use of the Purchase Agreement with Keystone, and in September 2020, we filed a replacement prospectus supplement related to the Open Market Sale Agreement pursuant to which we may sell up to $113 million of shares of our common stock through Jefferies. During the third quarter of 2020, 3,815,600 shares were sold through the Open Market Sale Agreement for proceeds of $12.3 million, net of commission, and 47,319 shares were sold through the Purchase Agreement with Keystone for proceeds of $300,000, net of discount. Through September 30, 2020, we received total proceeds, net of underwriting discounts and commissions, before expenses of approximately $15.0 million through the Open Market Sale Agreement and the Purchase Agreement with Keystone. On August 3, 2020, we closed the sale of our 7% Original Issue Discount Senior Secured Convertible Debenture due August 3, 2021, or the Debenture, for a purchase price of $8.0 million, or the Convertible Debt Financing. In addition, on May 8, 2020, we received a loan of approximately $1.1 million, or the PPP Loan, under the Paycheck Protection Program established as part of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, to provide loans to qualifying businesses to enable them to continue operations and keep their employees on payroll during the COVID-19 pandemic. For more information on the terms of the PPP Loan, see Note 8 to our unaudited condensed consolidated financial statements. In the third quarter, we raised total proceeds of approximately $26.6 million, net of commissions and discounts before expenses, through five financing transactions: our Open Market Sale Agreement with Jefferies, the Convertible Debt Financing, private placement transaction, the ADDF award, and our Purchase Agreement with Keystone. We also received $575,000 in proceeds from our $750,000 grant from the Alzheimer’s Association under its 2020 Part the Cloud Program and expect to receive the remainder of the amounts due under the grant by third quarter of 2021. Our cash and cash equivalents were $17.1 million and total current assets were $18.2 million at September 30, 2020, which the Company anticipates will be sufficient to fund our planned operations through the third quarter 2021. The Company plans to raise additional funds in the first half of 2021. There can be no assurances that we will be able to secure additional financing when needed, or if available, that it will be sufficient to meet our needs or on favorable terms.

In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel, and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts, which has had an adverse impact on our strategic plans, certain of our clinical trial operations, and our ability to raise additional capital necessary to continue as a going concern. We had previously anticipated initiating a trial of pepinemab in Alzheimer’s disease in mid-2020, but the initial enrollment date is now delayed until the first half of 2021. In addition, as discussed above, to mitigate the impacts of the COVID-19 pandemic, including impacts on the Company’s ability to raise capital and to maintain its personnel, the Company applied for and received the PPP Loan. We may experience further disruptions as a result of the COVID-19 pandemic that could adversely impact our business, including disruption of research and clinical development activities, plans for release of data, manufacturing, supply, and interactions with regulators and other third parties, and further difficulties in raising additional capital. The extent to which the COVID-19 pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

Financial Overview

Revenue

To date, we have not generated any revenue from product sales. During the nine months ended September 30, 2020 and 2019, we generated a limited amount of service revenue from our collaboration agreements, including with Surface Oncology, Inc. and Merck Sharp & Dohme Corp.

Our ability to generate revenue and become profitable depends on our ability to successfully obtain marketing approval of and commercialize our product candidates. We do not expect to generate product revenue in the foreseeable future as we continue our development of, and seek regulatory approvals for, our product candidates, and potentially commercialize approved products, if any.

Operating Expenses

Research and Development. Research and development expenses consist primarily of costs for our clinical trials and activities related to regulatory filings, employee compensation-related costs, supply expenses, equipment depreciation and amortization, consulting and other miscellaneous costs. The following table sets forth the components of our research and development expenses and the amount as a percentage of total research and development expenses for the periods indicated.

	Three Months Ended September 30,										Nine Months Ended September 30,
	2020					2019					2020					2019
	(in thousands)		%			(in thousands)		%			(in thousands)		%			(in thousands)		%
Clinical trial costs	$	5,215		71	%	$	4,840		74	%	$	11,175		65	%	$	16,138		75	%
Wages, benefits, and related costs		1,118		15	%		970		15	%		3,319		19	%		2,887		14	%
Preclinical supplies and equipment depreciation		489		7	%		479		7	%		1,415		8	%		1,435		7	%
Consulting, non-clinical trial services, and other		512		7	%		254		4	%		1,391		8	%		799		4	%
Total research and development expenses	$	7,334				$	6,543				$	17,300				$	21,259

We expense research and development costs as incurred. We record costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment. We do not allocate employee related costs, depreciation, rental and other indirect costs to specific research and development programs because these costs are deployed across multiple of our product programs under research and development.

Our current research and development activities primarily relate to clinical development in the following indications:

•

Head & Neck Squamous Cell Carcinoma (HNSCC). We are planning to evaluate pepinemab in combination with pembrolizumab in HNSCC in a Phase 1b/2 clinical trial. We recently completed a phase 2 study in NSCLC with pepinemab in combination with avelumab, and we announced near topline data for this trial at the virtual American Society of Clinical Oncology conference in late May 2020. This data suggested that immunotherapy naïve and PD-L1 negative or low patients achieved higher response rates with the combination than with the avelumab checkpoint inhibitor alone. This could provide a potentially important expansion of the opportunity for immunotherapy in cancer. HNSCC is a particularly attractive application of combination immunotherapy with pepinemab because of high levels of expression of SEMA4D that have been shown to induce myeloid suppressor cells in this indication. The combined benefit of increased infiltration and activity of cytotoxic CD8+ T cells and reduced immunosuppression may provide significantly enhanced benefit to patients.

•

Huntington’s Disease (HD). We are evaluating pepinemab for the treatment of HD in our Phase 2 SIGNAL trial. Enrollment in this trial, consisting of 265 subjects, was completed in December 2018 and topline data was reported in late September 2020. Although the study did not meet its prespecified primary endpoints, it provided important new information that is likely to influence the design of further studies. Trial data continues to be analyzed to determine a path forward in Huntington’s and other neurodegenerative disease indications. The Company is evaluating its development strategy in terms of business opportunity and near-term focus on Huntington’s or Alzheimer’s disease in the event that resources are limiting.

•

Alzheimer’s Disease. Given the current escalation in the COVID-19 pandemic, we are delaying plans to initiate a clinical trial of pepinemab in Alzheimer’s disease until 2021 with a study design that is based, in part, on knowledge gained from the SIGNAL trial in Huntington’s disease.

Results of Operations

The following table set forth our results of operations for the periods presented (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue	$	50		$	404		$	50		$	523
Grant revenue		575			-			575			-
Costs and expenses:
Cost of revenue		2			8			2			199
Research and development		7,334			6,543			17,300			21,259
General and administrative		1,872			1,531			5,565			4,741
Total costs and expenses		9,208			8,082			22,867			26,199
Loss from operations		(8,583	)		(7,678	)		(22,242	)		(25,676	)
Interest expense		(148	)		-			(150	)		-
Other expense, net		(23	)		36			(14	)		139
Loss before provision for income taxes		(8,754	)		(7,642	)		(22,406	)		(25,537	)
Provision for income taxes		-			-			-			-
Net loss		(8,754	)		(7,642	)		(22,406	)		(25,537	)
Net loss attributable to noncontrolling interests		-			-			-			-
Net loss attributable to Vaccinex, Inc.	$	(8,754	)	$	(7,642	)	$	(22,406	)	$	(25,537	)

Comparison of the Three Months Ended September 30, 2020 and 2019

Operating Expenses

	Three Months Ended September 30,
	2020		2019		$ Change		% Change
	(in thousands)
Research and development	$	7,334	$	6,543	$	791		12	%
General and administrative		1,872		1,531		341		22	%
Total operating expenses	$	9,206	$	8,074	$	1,132		14	%

Research and Development. Research and development expenses in the three months ended September 30, 2020 increased by $0.8 million, or 12%, compared to the three months ended September 30, 2019. This increase was primarily attributable to increased analytical costs incurred in conjunction with the closeout of the SIGNAL trial partially offset by decreased costs for the CLASSICAL-Lung study.

General and Administrative. General and administrative expenses in the three months ended September 30, 2020 increased by $0.3 million, or 22%, compared to the three months ended September 30, 2019. The increase was due to increased stock-based compensation as a result of new option awards to employees and board members, as well as increased directors and officers insurance costs.

Comparison of the Nine Months Ended September 30, 2020 and 2019

Operating Expenses

	Nine Months Ended September 30,
	2020		2019		$ Change			% Change
	(in thousands)
Research and development	$	17,300	$	21,259	$	(3,959	)		(19	)%
General and administrative		5,565		4,741		824			17	%
Total operating expenses	$	22,865	$	26,000	$	(3,135	)		(12	)%

Research and Development. Research and development expenses in the nine months ended September 30, 2020 decreased by $4.0 million, or 19%, compared to the nine months ended September 30, 2019. This decrease was primarily attributable to decreases in expenses in the CLASSICAL-Lung and SIGNAL studies, as patients have come off study.

General and Administrative. General and administrative expenses in the nine months ended September 30, 2020 increased by $0.8 million, or 17%, compared to the nine months ended September 30, 2019. The increase was due to increased stock-based compensation as a result of new option awards to employees and board members, as well as increased directors and officers insurance costs.

Liquidity and Capital Resources

To date, we have not generated any revenue from product sales. Since our inception in 2001, we have relied on public and private sales of equity and debt financing to fund our operations, in addition to capital contributions from noncontrolling interests and limited service revenue from collaboration agreements.

In July 2019, January 2020, and July 2020, we completed private placements of our common stock and received gross proceeds of $13.8 million, $7.5 million, and $4.0 million, respectively and in September 2020 we received gross proceeds of $2.0 million through an award from ADDF, in the form of an investment in our common stock. Additionally, on March 27, 2020, we announced that we had (i) entered into an Open Market Sale Agreement with Jefferies and filed a prospectus supplement pursuant to which we were able to issue and sell up to $11.5 million of shares of our common stock from time and (ii) entered into a Purchase Agreement with Keystone pursuant to which Keystone agreed to purchase up to an aggregate of $5.0 million of shares of our common stock from time to time. In August 2020, we ceased use of the Purchase Agreement with Keystone, and in September 2020, we filed a replacement prospectus supplement related to the Open Market Sale Agreement pursuant to which we may sell up to $113 million of shares of our common stock through Jefferies. During the third quarter of 2020, 3,815,600 shares were sold through the Open Market Sale Agreement for proceeds of $12.3 million, net of commission, and 47,319 shares were sold through the Purchase Agreement with Keystone for proceeds of $300,000, net of discount. On August 3, 2020, we closed the Convertible Debt Financing discussed below for gross proceeds of $8.0 million. In addition, on May 8, 2020, we received the PPP Loan in the amount of $1.1 million. In the third quarter, we raised total proceeds of approximately $26.6 million, net of commissions and discounts and before expenses, through our Open Market Sale Agreement with Jefferies, the Convertible Debt Financing, the July 2020 private placement transaction, the ADDF award, and our Purchase Agreement with Keystone. We also received $575,000 in proceeds from our $750,000 grant from the Alzheimer’s Association under its 2020 Part the Cloud Program.

In August 2020, we entered into a Securities Purchase Agreement, or the SPA, with 3i, LP, as collateral agent and purchaser, or 3i, or the Convertible Debt Financing. Pursuant to the SPA, on August 3, 2020, we issued our 7% Original Issue Discount Senior Secured Convertible Debenture, or the Debenture, in the principal amount of $8.64 million for a purchase price of $8.0 million, which reflects an original issue discount of approximately 8%. The Debenture will mature on August 3, 2021. The Debenture accrues interest at 7% per year and is convertible into shares of our common stock at a conversion price of $9.4125 per share, subject to certain customary adjustments. Subject to the satisfaction of certain conditions, at any time, we may elect to redeem all or any portion of the Debenture for an amount equal to 115% of the outstanding principal balance being redeemed plus all accrued and unpaid interest on the amount being redeemed that would have accrued if the Debenture were held through the maturity date. Our obligations under the Debenture can be accelerated upon the occurrence of certain customary events of default and are secured under a Security Agreement by a lien on substantially all of our assets, subject to certain exceptions.

Operating Capital Requirements

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party research services and amounts due to vendors for research supplies. As of September 30, 2020 and December 31, 2019, our principal source of liquidity was cash and cash equivalents in the amount of $17.1 million and $2.8 million, respectively.

Since our inception in 2001, we have incurred significant net losses and negative cash flows from operations. For the three months ended September 30, 2020 and 2019, we reported a net loss of $8.8 million and $7.6 million, respectively, and $22.4 and $25.5 million for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020 and December 31, 2019, we had an accumulated deficit of $271.0 million and $248.6 million, respectively. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates. We are subject to risks associated with the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors, including as a result of the COVID-19 pandemic, that may adversely affect our business.

Until we can generate a sufficient amount of revenue from the commercialization of our product candidates, we expect to finance our operations through the public or private sale of equity, debt financings, or other capital sources, such as government funding, collaborations, strategic alliances or licensing arrangements with third parties. We intend to use the net proceeds from our recent private placement, the agreements with Jefferies and Keystone, the Convertible Debt Financing, and the funding we received and expect to receive in 2020 from the Alzheimer’s Association and the ADDF to fund the ongoing development of pepinemab and for working capital and general corporate purposes. We have used the funds from the PPP Loan as required for loan forgiveness-eligible purposes under the CARES Act, including payroll, benefits, rent and utilities.

Financing strategies we may pursue include, but are not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding, collaborations, strategic alliances or licensing arrangements with third parties. There can be no assurances additional capital will be available to secure additional financing, or if available, that it will be sufficient to meet our needs on favorable terms. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates. In addition, the Debenture also provides that in connection with future capital raising transactions (subject to certain exceptions), at the election of the holder we must use 20% of the funds raised to redeem amounts outstanding under the Debenture. If we raise additional funds through the public or private sale of equity or debt financings, it could result in dilution to our existing stockholders or increased fixed payment obligations and these securities may have rights senior to those of

our common stock and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.

Cash Flows

The following table summarizes our cash flows for the periods presented:

	Nine Months Ended September 30,
	2020			2019
	(in thousands)
Cash used in operating activities	$	(22,265	)	$	(24,912	)
Cash provided by (used in) investing activities		(291	)		14,073
Cash provided by financing activities		36,872			13,800

Operating Activities. We have historically experienced negative cash flows as we have developed our product candidates and continued to expand our business. Our net cash used in operating activities primarily results from our net loss adjusted for non-cash expenses and changes in working capital components as we have continued our research and development, and is influenced by the timing of cash payments for research related expenses. Our primary uses of cash from operating activities are compensation and related-expenses, employee-related expenditures, third-party research services and amounts due to vendors for research supplies. Our cash flows from operating activities will continue to be affected principally by the extent to which we increase spending on personnel, research and development and other operating activities as our business grows.

During the nine months ended September 30, 2020, operating activities used $22.7 million in cash, primarily as a result of our net loss of $22.4 million.

During the nine months ended September 30, 2019, operating activities used $24.9 million in cash, primarily as a result of our net loss of $25.5 million.

Investing Activities. Cash used in investing activities during the nine months ended September 30, 2020 resulted from purchases of property and equipment. Cash provided by investing activities during the nine months ended September 30, 2019 resulted from sales and maturities of marketable securities.

Financing Activities. During the nine months ended September 30, 2020, financing activities provided $37.3 million, of which $11.4 million was attributable to the private placement of common stock, $17.0 million, net of underwriting commissions and discounts was due to the issuance of the Company’s common stock pursuant to the Open Market Sale Agreement and Purchase Agreement with Keystone, $7.8 million due to the issuance of Convertible Debt, and $1.1 million was from long-term debt. During the nine months ended September 30, 2019, financing activities provided $13.8 million attributable to the private placement of common stock.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

JOBS Act Accounting Election

We are an “emerging growth company” within the meaning of the Jumpstart Our Business Startups Act or the JOBS Act. Section 107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. We have elected to use this extended transition period and, as a result, our condensed consolidated financial statements may not be comparable to companies that comply with public company effective dates of such accounting standards.

Critical Accounting Policies and Estimates

Our unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates.

There have been no material changes to our critical accounting policies and significant judgments as compared to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

Impact of Recent Accounting Pronouncements

For a discussion on the impact of recent accounting pronouncements on our business, see Note 2 to our unaudited condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, we are not required to provide the information required by this item.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), evaluated the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of September 30, 2020, the end of the period covered by this Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2020, our disclosure controls and procedures were effective.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended September 30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Most of our employees are working remotely due to the COVID-19 pandemic. However, we have not experienced any changes to our internal control arising from the COVID-19 pandemic that have materially affected or that are reasonably likely to materially affect our internal control over financial reporting. We are continually monitoring and assessing the COVID-19 pandemic and the impact it may have on our operations, including our internal control.

Part II - OTHER INFORMATION

Item 1A. Risk Factors

An investment in our stock involves a high degree of risk. You should carefully consider the risks set forth in this section, and in Part I, Item 1A of the Annual Report, and all of the other information set forth in this Report, the Annual Report, and in the other reports we file with the SEC. If any of the risks contained in those reports actually occur, our business, results of operation, financial condition, and liquidity could be harmed, the value of our securities could decline and you could lose all or part of your investment. Other than the addition of the text below, there have been no material changes from risk factors disclosed in the Annual Report. See the discussion of the Company’s risk factors under Part I, Item 1A. of the Annual Report.

We will require additional capital to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, if at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates and have identified conditions that raise substantial doubt about our ability to continue as a going concern.

Our recurring net losses and negative cash flows from operations raise substantial doubt about our ability to continue as a going concern within one year after the issuance of our consolidated financial statements as of and for the year ended December 31, 2019, as discussed in Note 1 to our consolidated financial statements as of and for the year ended December 31, 2019 included in our Annual Report. Our independent registered public accounting firm also noted this in their report issued on our consolidated financial statements for the years ended December 31, 2019, and 2018. Our cash and cash equivalents were $17.1 million and total current assets were $18.2 million at September 30, 2020, which we anticipate will be sufficient to fund our planned operations through the third quarter of 2021. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity or debt financing, attain further operating efficiencies, reduce expenditures, and, ultimately, to generate revenue. For the foreseeable future, we will have to raise additional working capital to fund our operations. However, no assurance can be given that additional financing will be available, or, if available, will be on terms acceptable to us. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts to advance the clinical development of our product candidates. Given our projected operating requirements and our existing cash and cash equivalents and marketable securities, we obtained approximately $26.6 million, net of commissions and discounts and before expenses, in total proceeds through several financing transactions described elsewhere in this Report. We also received $575,000 in proceeds from our $750,000 grant from the Alzheimer’s Association under its 2020 Part the Cloud Program.

Even with the arrangements described above, we will need to complete additional financing transactions in order to continue operations. These arrangements may also not be sufficient in the near-term. Given, among other things, the current economic uncertainty associated with the COVID-19 pandemic, and our recent stock price performance, our arrangement with Jefferies and other financing strategies we may pursue may not be sufficient to fund our operations in the near term. There can be no assurances that we will be able to secure additional financing, or if available, that it will be sufficient to meet our needs or on favorable terms.

On May 8, 2020, we received the PPP Loan for approximately $1.1 million under the Paycheck Protection Program. However, the PPP Loan was only sufficient to fund our payroll and other eligible expenses for a limited period of time.

Circumstances may also cause us to consume capital even more rapidly than we currently anticipate. For example, as we move our lead product candidate through clinical trials and submit Investigational New Drug applications for new indications or other product candidates, we may have adverse results requiring us to find new product candidates or our development plans and anticipated clinical trial design may need to be altered.

Additional fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize future product candidates. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue our operations and the development or commercialization of one or more of our product candidates or the range of indications for which they are developed. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders, and/or increased fixed payment obligations. Furthermore, these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.

Our future capital requirements will depend on many factors, including, among others:

•

the scope, rate of progress, results and costs of our clinical trials, preclinical studies and other research and development activities;

•

the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates we may develop or in-license;

•

the number and characteristics of product candidates that we develop or in-license, if any;

•

the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

•

the effect of competing technological efforts and market developments;

•

our ability to establish collaborative arrangements to the extent necessary;

•

the economic and other terms, timing and success of any collaboration, licensing, distribution or other arrangements into which we may enter in the future;

•

revenues received from any product candidates that are approved; and

•

payments received under any current or future strategic partnerships.

If a lack of available capital prevents us from expanding our operations or otherwise capitalizing on our business opportunities, our business, financial condition and results of operations could be materially adversely affected. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue our operations and the development of one or more of our product candidates or cease operations.

We may not continue to pursue our clinical trial evaluating pepinemab for the treatment of Huntington’s Disease.

In late September 2020, we received topline data from our Phase 2 SIGNAL trial evaluating pepinemab for the treatment of Huntington’s Disease. Th trial did not meet its prespecified primary endpoints. Although the study results did provide clear and useful information for how to modify the study design for potential future success, the Company needs to evaluate the business opportunity and resources required in relation to other opportunities in Alzheimer’ disease and cancer. The Phase 2 SIGNAL trial evaluating pepinemab for the treatment of Huntington’s Disease was our most advanced clinical trial and based on the Phase 2 results we may not continue to pursue clinical development for this indication. If we cease to pursue the Huntington’s Disease indication, we may pursue clinical development of our other indications for pepinemab, which require significant additional development resources. Pursuing these other indications will take a significant amount of time and capital to pursue and may not ultimately be successful. This may require that we seek an early partnership or license selected assets to advance our business and continue as a going concern.

We may not be able to pay our indebtedness at maturity.

On May 8, 2020, we received the PPP Loan for approximately $1.1 million under the Paycheck Protection Program. On August 3, 2020, we issued the Debenture, which has a principal amount of $8.64 million, an interest rate of 7% per annum and matures on August 3, 2021. Our ability to make payments on our indebtedness depends on our future performance and capital raising activities, which are subject to economic, financial, competitive and other factors beyond our control.

While all or a portion of the PPP Loan may be forgiven if the PPP Loan is used for qualifying expenses as described in the CARES Act, if we seek forgiveness there is no assurance that we will be able to obtain forgiveness, notwithstanding that we believe we have used the PPP Loan for qualifying expenses. The U.S. Department of the Treasury, Small Business Administration and members of Congress have indicated an intention to provide strong oversight of loans granted under the Paycheck Protection Program. If we are audited or reviewed or our records are subpoenaed by the government as a result of entering into the PPP Loan, it could divert management’s time and attention and we could incur legal and reputational costs, and an adverse finding could lead to the requirement to return the PPP Loan, which could reduce our liquidity, or could subject us to fines and penalties.

While the holder of the Debenture may seek to convert the Debenture into shares of our common stock, there is no assurance that the holder will seek to do so, including because the conversion price for the Debenture is currently $9.4125 per share, and our stock price is currently trading below that level. Furthermore, the Debenture s secured under a Security Agreement by a lien on substantially all of the Company’s assets, subject to certain exceptions, and if we default, the holder will have rights to those assets. In addition, the Debenture also provides that in connection with future capital raising transactions (subject to certain exceptions), at the election of the holder we must use 20% of the funds raised to redeem amounts outstanding under the Debenture, which will further limit the use of proceeds we may obtain from future capital raising transactions.

Our business is not expected to generate cash flow from operations in the future sufficient to pay our debt at maturity. Accordingly, we expect to have to raise additional capital in the future, either through restructuring debt, or obtaining additional equity capital, or pursuing other alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. Furthermore, the existence of our indebtedness, and the terms associated with it, particularly our recently issued Debenture, could more generally make it difficult for us to raise additional capital.

The COVID-19 pandemic has adversely impacted and will continue to adversely impact our business, including our clinical development plans and our ability to raise capital.

Since December 2019, the COVID-19 pandemic has spread to multiple countries, including the United States, and has caused significant disruptions around the world. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel, and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts, which has had an adverse impact our strategic plans, certain of our clinical trial operations, and our ability to raise additional capital necessary to continue as a going concern. We had previously anticipated beginning enrollment in mid-2020 in our study of pepinemab in Alzheimer’s Disease, but the initial enrollment date is now delayed until the first half of 2021. In addition, to mitigate the impact of the COVID-19 pandemic including impacts on the Company’s ability to raise capital and to maintain its personnel, the Company applied for and received the PPP Loan.

We may experience further disruptions as a result of the COVID-19 pandemic that could severely impact our business, including:

•

interruption of key manufacturing, research and clinical development activities due to limitations on work and travel imposed or recommended by federal or state governments, employers and others;

•

delays or difficulties in clinical trial site operations, including difficulties in recruiting clinical site investigators and clinical site staff and difficulties in enrolling patients or meeting protocol-specified procedures, including difficulties in adhering to protocol-mandated visits, treating patients, and testing in active trials;

•

interruption of key business activities due to illness and/or quarantine of key individuals and delays associated with recruiting, hiring and training new temporary or permanent replacements for such key individuals, both internally and at our third-party service providers;

•

delays in research and clinical trial sites receiving the supplies and materials needed to conduct preclinical studies and clinical trials, due to work stoppages, travel and shipping interruptions or restrictions or other reasons;

•

further difficulties in raising additional capital needed to avoid furloughs and layoffs and pursue the development of our programs due to the slowing of our economy and near term and/or long-term negative effects of the pandemic on the financial, banking and capital markets, including as a result of ongoing impacts on our stock price;

•

changes in local regulations as part of a response to the COVID-19 pandemic that may require us to change the ways in which research, including clinical development, is conducted, which may result in unexpected costs; and

•

delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources, travel restrictions or forced furlough of government employees.

The COVID-19 pandemic and its impacts continue to rapidly evolve. The extent to which the COVID-19 pandemic will further impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the virus and resolve its impacts.

Item 6. Exhibits

INDEX TO EXHIBITS

Exhibit No.		Description

4.1		7% Original Issue Discount Senior Convertible Debenture due August 3, 2021 (incorporated by reference herein from Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020).

10.1		Stock Purchase Agreement by and between the Company and Friedberg Global-Macro Hedge Fund, Ltd., dated as of July 9, 2020 (incorporated by reference herein from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 10, 2020).

10.2		Registration Rights Agreement by and between the Company and Friedberg Global-Macro Hedge Fund, Ltd., dated as of July 10, 2020 (incorporated by reference herein from Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on July 10, 2020).

10.3		Securities Purchase Agreement, dated July 30, 2020, by and among the Company and the Purchaser (incorporated by reference herein from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 31, 2020).

10.4		Registration Rights Agreement, dated August 3, 2020, by and among the Company and 3i, LP (incorporated by reference herein from Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020).

10.5		Security Agreement, dated July 31, 2020, by and between the Company and 3i, LP, as Collateral Agent (incorporated by reference herein from Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020).

31.1*		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

101*		The following items from this Quarterly Report on Form 10-Q formatted in Extensible Business Reporting Language: (i) Condensed Consolidated Balance Sheets (Unaudited), (ii) Condensed Consolidated Statements of Operations (Unaudited), (iii) Consolidated Statements of Stockholders’ Deficit (Unaudited), (iv) Condensed Consolidated Statements of Cash Flows (Unaudited), and (v) Notes to Condensed Consolidated Financial Statements (Unaudited)

*	Filed or furnished herewith, as applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Vaccinex, Inc.
		(Registrant)

November 13, 2020	By:	/s/ Maurice Zauderer
		Maurice Zauderer, Ph.D.
		President & Chief Executive Officer
		(Principal Executive Officer)

November 13, 2020	By:	/s/ Scott E. Royer
		Scott E. Royer, CFA, MBA
		Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 vcnx-ex311_79.htm EX-31.1 vcnx-ex311_79.htm

Exhibit 31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Maurice Zauderer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the three months ended September 30, 2020 of Vaccinex, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Dated: November 13, 2020	By:	/s/ Maurice Zauderer
		Maurice Zauderer, Ph.D.
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 vcnx-ex312_80.htm EX-31.2 vcnx-ex312_80.htm

Exhibit 31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott E. Royer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the three months ended September 30, 2020 of Vaccinex, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Dated: November 13, 2020	By:	/s/ Scott E. Royer
		Scott E. Royer
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 vcnx-ex321_81.htm EX-32.1 vcnx-ex321_81.htm

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Vaccinex, Inc., (the "Company") on Form 10-Q for the three months ended September 30, 2020 (the "Report"), I, Maurice Zauderer, Ph.D., President and Chief Executive Officer of the Company and Scott E. Royer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: November 13, 2020	By:	/s/ Maurice Zauderer
		Maurice Zauderer, Ph.D.
		President and Chief Executive Officer


Dated: November 13, 2020	By:	/s/ Scott E. Royer
		Scott E. Royer
		Chief Financial Officer

EX-101.INS 5 vcnx-20200930.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure vcnx:TargetAntigen vcnx:BusinessActivity vcnx:SegmentManager vcnx:Segment 0001205922 2020-01-01 2020-09-30 0001205922 2020-11-10 0001205922 2020-09-30 0001205922 2019-12-31 0001205922 2020-07-01 2020-09-30 0001205922 2019-07-01 2019-09-30 0001205922 2019-01-01 2019-09-30 0001205922 us-gaap:CommonStockMember 2018-12-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001205922 us-gaap:TreasuryStockMember 2018-12-31 0001205922 us-gaap:RetainedEarningsMember 2018-12-31 0001205922 us-gaap:ParentMember 2018-12-31 0001205922 us-gaap:NoncontrollingInterestMember 2018-12-31 0001205922 2018-12-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001205922 us-gaap:ParentMember 2019-01-01 2019-03-31 0001205922 2019-01-01 2019-03-31 0001205922 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001205922 us-gaap:CommonStockMember 2019-03-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001205922 us-gaap:TreasuryStockMember 2019-03-31 0001205922 us-gaap:RetainedEarningsMember 2019-03-31 0001205922 us-gaap:ParentMember 2019-03-31 0001205922 us-gaap:NoncontrollingInterestMember 2019-03-31 0001205922 2019-03-31 0001205922 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001205922 us-gaap:ParentMember 2019-04-01 2019-06-30 0001205922 2019-04-01 2019-06-30 0001205922 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001205922 us-gaap:CommonStockMember 2019-06-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001205922 us-gaap:TreasuryStockMember 2019-06-30 0001205922 us-gaap:RetainedEarningsMember 2019-06-30 0001205922 us-gaap:ParentMember 2019-06-30 0001205922 us-gaap:NoncontrollingInterestMember 2019-06-30 0001205922 2019-06-30 0001205922 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001205922 us-gaap:ParentMember 2019-07-01 2019-09-30 0001205922 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001205922 us-gaap:CommonStockMember 2019-09-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001205922 us-gaap:TreasuryStockMember 2019-09-30 0001205922 us-gaap:RetainedEarningsMember 2019-09-30 0001205922 us-gaap:ParentMember 2019-09-30 0001205922 us-gaap:NoncontrollingInterestMember 2019-09-30 0001205922 2019-09-30 0001205922 us-gaap:CommonStockMember 2019-12-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001205922 us-gaap:TreasuryStockMember 2019-12-31 0001205922 us-gaap:RetainedEarningsMember 2019-12-31 0001205922 us-gaap:ParentMember 2019-12-31 0001205922 us-gaap:NoncontrollingInterestMember 2019-12-31 0001205922 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001205922 us-gaap:ParentMember 2020-01-01 2020-03-31 0001205922 2020-01-01 2020-03-31 0001205922 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001205922 us-gaap:CommonStockMember 2020-03-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001205922 us-gaap:TreasuryStockMember 2020-03-31 0001205922 us-gaap:RetainedEarningsMember 2020-03-31 0001205922 us-gaap:ParentMember 2020-03-31 0001205922 us-gaap:NoncontrollingInterestMember 2020-03-31 0001205922 2020-03-31 0001205922 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001205922 us-gaap:ParentMember 2020-04-01 2020-06-30 0001205922 2020-04-01 2020-06-30 0001205922 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001205922 us-gaap:CommonStockMember 2020-06-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001205922 us-gaap:TreasuryStockMember 2020-06-30 0001205922 us-gaap:RetainedEarningsMember 2020-06-30 0001205922 us-gaap:ParentMember 2020-06-30 0001205922 us-gaap:NoncontrollingInterestMember 2020-06-30 0001205922 2020-06-30 0001205922 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001205922 us-gaap:ParentMember 2020-07-01 2020-09-30 0001205922 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001205922 us-gaap:CommonStockMember 2020-09-30 0001205922 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001205922 us-gaap:TreasuryStockMember 2020-09-30 0001205922 us-gaap:RetainedEarningsMember 2020-09-30 0001205922 us-gaap:ParentMember 2020-09-30 0001205922 us-gaap:NoncontrollingInterestMember 2020-09-30 0001205922 2019-07-01 2019-07-31 0001205922 2020-01-01 2020-01-31 0001205922 2020-07-01 2020-07-31 0001205922 2020-09-01 2020-09-30 0001205922 2020-03-27 2020-03-27 0001205922 vcnx:KeystoneCapitalPartnersLLCMember vcnx:StockPurchaseAgreementMember 2020-01-01 2020-09-30 0001205922 srt:MaximumMember 2020-01-01 2020-09-30 0001205922 vcnx:SecuritiesPurchaseAgreementMember 2020-07-01 2020-09-30 0001205922 vcnx:AlzheimersAssociationMember 2020-01-01 2020-09-30 0001205922 vcnx:OpenMarketSaleAgreementMember us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001205922 vcnx:KeystoneCapitalPartnersLLCMember vcnx:StockPurchaseAgreementMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001205922 vcnx:OpenMarketSaleAgreementMember us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001205922 vcnx:KeystoneCapitalPartnersLLCMember vcnx:StockPurchaseAgreementMember us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001205922 vcnx:OpenMarketSaleAgreementMember 2020-04-01 2020-06-30 0001205922 vcnx:KeystoneCapitalPartnersLLCMember vcnx:StockPurchaseAgreementMember 2020-04-01 2020-06-30 0001205922 vcnx:OpenMarketSaleAgreementMember 2020-07-01 2020-09-30 0001205922 vcnx:SecuritiesPurchaseAgreementMember 2020-08-03 0001205922 vcnx:SecuritiesPurchaseAgreementMember 2020-08-03 2020-08-03 0001205922 vcnx:PaycheckProtectionProgramMember vcnx:FiveStarBankMember 2020-05-07 2020-05-08 0001205922 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-01-01 2020-09-30 0001205922 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-01-01 2019-09-30 0001205922 vcnx:AlzheimersDrugDiscoveryFoundationMember 2020-07-01 2020-09-30 0001205922 vcnx:AlzheimersDrugDiscoveryFoundationMember 2020-01-01 2020-09-30 0001205922 vcnx:KeystoneCapitalPartnersLLCMember us-gaap:AdditionalPaidInCapitalMember vcnx:AtTheMarketFacilityMember 2020-09-30 0001205922 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001205922 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001205922 vcnx:ResearchEquipmentMember 2020-09-30 0001205922 vcnx:ResearchEquipmentMember 2019-12-31 0001205922 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001205922 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001205922 us-gaap:ComputerEquipmentMember 2020-09-30 0001205922 us-gaap:ComputerEquipmentMember 2019-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-09-30 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-09-30 0001205922 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001205922 2020-08-03 0001205922 vcnx:VXThreeLicenseAgreementMember 2017-11-01 2017-11-30 0001205922 vcnx:VXThreeLicenseAgreementMember 2020-01-01 2020-09-30 0001205922 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-07-01 2020-09-30 0001205922 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-07-01 2019-09-30 0001205922 vcnx:SurfaceOncologyIncMember 2017-11-01 2017-11-30 0001205922 vcnx:SurfaceOncologyIncMember srt:MinimumMember 2017-11-01 2017-11-30 0001205922 vcnx:SurfaceOncologyIncMember srt:MaximumMember 2017-11-01 2017-11-30 0001205922 vcnx:SurfaceOncologyIncMember 2019-07-01 2019-09-30 0001205922 vcnx:SurfaceOncologyIncMember 2019-01-01 2019-09-30 0001205922 vcnx:SurfaceOncologyIncMember 2020-07-01 2020-09-30 0001205922 vcnx:SurfaceOncologyIncMember 2020-01-01 2020-09-30 0001205922 vcnx:SurfaceOncologyIncMember vcnx:ExerciseOfProductOptionMember 2019-07-01 2019-09-30 0001205922 vcnx:SurfaceOncologyIncMember vcnx:ExclusiveProductLicenseMember 2019-07-01 2019-09-30 0001205922 vcnx:SurfaceOncologyIncMember vcnx:ExerciseOfProductOptionMember 2019-01-01 2019-09-30 0001205922 vcnx:SurfaceOncologyIncMember vcnx:ExclusiveProductLicenseMember 2019-01-01 2019-09-30 0001205922 vcnx:SurfaceOncologyIncMember vcnx:ExclusiveProductLicenseMember 2020-07-01 2020-09-30 0001205922 vcnx:SurfaceOncologyIncMember vcnx:ExclusiveProductLicenseMember 2020-01-01 2020-09-30 0001205922 us-gaap:ContractTerminationMember 2020-01-01 2020-09-30 0001205922 srt:ScenarioForecastMember 2020-11-01 2022-10-31 0001205922 vcnx:PaycheckProtectionProgramMember 2020-05-07 2020-05-08 0001205922 vcnx:PaycheckProtectionProgramMember 2020-05-08 0001205922 vcnx:PaycheckProtectionProgramMember 2020-09-30 0001205922 vcnx:PaycheckProtectionProgramMember 2020-01-01 2020-09-30 0001205922 us-gaap:ConvertibleDebtMember 2020-09-30 0001205922 us-gaap:ConvertibleDebtMember 2020-07-30 0001205922 us-gaap:ConvertibleDebtMember 2020-07-30 2020-07-30 0001205922 us-gaap:ConvertibleDebtMember 2020-08-03 2020-08-03 0001205922 us-gaap:ConvertibleDebtMember 2020-08-03 0001205922 vcnx:PrincipalRepaymentsMember us-gaap:ConvertibleDebtMember 2020-09-30 0001205922 vcnx:AccruedAndMakeWholeInterestMember us-gaap:ConvertibleDebtMember 2020-09-30 0001205922 vcnx:InterestMakeWholeFeatureMember us-gaap:ConvertibleDebtMember 2020-08-03 0001205922 vcnx:CollateralAgentAndPurchaserMember us-gaap:ConvertibleDebtMember 2020-08-03 2020-08-03 0001205922 us-gaap:ConvertibleDebtMember vcnx:EffectiveInterestMethodMember 2020-08-03 0001205922 us-gaap:ConvertibleDebtMember vcnx:EffectiveInterestMethodMember 2020-08-03 2020-08-03 0001205922 us-gaap:ConvertibleDebtMember 2020-07-01 2020-09-30 0001205922 us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0001205922 vcnx:SharesUnderlyingOutstandingStockOptionsMember 2020-09-30 0001205922 vcnx:SharesUnderlyingOutstandingStockOptionsMember 2019-12-31 0001205922 vcnx:SharesAvailableForFutureStockOptionGrantsMember 2020-09-30 0001205922 vcnx:SharesAvailableForFutureStockOptionGrantsMember 2019-12-31 0001205922 vcnx:ExchangeOfVaccinexProductsLPUnitsMember 2020-09-30 0001205922 vcnx:ExchangeOfVaccinexProductsLPUnitsMember 2019-12-31 0001205922 vcnx:ConversionOfVX3UnitsMember 2020-09-30 0001205922 vcnx:ConversionOfVX3UnitsMember 2019-12-31 0001205922 vcnx:VaccinexProductsLPInterestsMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001205922 vcnx:VaccinexProductsLPInterestsMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001205922 srt:MinimumMember vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2020-01-01 2020-09-30 0001205922 srt:MinimumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandElevenEmployeeEquityPlanMember 2020-01-01 2020-09-30 0001205922 srt:MinimumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2020-01-01 2020-09-30 0001205922 srt:MaximumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandElevenEmployeeEquityPlanMember 2020-01-01 2020-09-30 0001205922 srt:MaximumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2020-01-01 2020-09-30 0001205922 vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2020-09-30 0001205922 vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2020-01-01 2020-09-30 0001205922 vcnx:TwoThousandElevenEmployeeEquityPlanMember 2020-01-01 2020-01-31 0001205922 2019-01-01 2019-12-31 0001205922 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001205922 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001205922 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001205922 us-gaap:CommonStockMember vcnx:KeystoneCapitalPartnersLLCMember 2020-03-01 2020-03-31 0001205922 us-gaap:CommonStockMember vcnx:KeystoneCapitalPartnersLLCMember vcnx:StockPurchaseAgreementMember srt:MaximumMember 2020-03-01 2020-03-31 0001205922 vcnx:KeystoneCapitalPartnersLLCMember 2020-03-31 0001205922 vcnx:KeystoneCapitalPartnersLLCMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001205922 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001205922 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001205922 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001205922 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001205922 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001205922 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001205922 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001205922 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001205922 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001205922 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001205922 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001205922 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001205922 vcnx:VaccinexProductsLPUnitsMember 2020-07-01 2020-09-30 0001205922 vcnx:VaccinexProductsLPUnitsMember 2019-07-01 2019-09-30 0001205922 vcnx:VaccinexProductsLPUnitsMember 2020-01-01 2020-09-30 0001205922 vcnx:VaccinexProductsLPUnitsMember 2019-01-01 2019-09-30 0001205922 vcnx:VX3DELPUnitsMember 2020-07-01 2020-09-30 0001205922 vcnx:VX3DELPUnitsMember 2019-07-01 2019-09-30 0001205922 vcnx:VX3DELPUnitsMember 2020-01-01 2020-09-30 0001205922 vcnx:VX3DELPUnitsMember 2019-01-01 2019-09-30 0001205922 country:US 2020-01-01 2020-09-30 0001205922 country:US 2019-01-01 2019-12-31 0001205922 vcnx:StockPurchaseAgreementMember 2020-01-21 2020-01-21 0001205922 vcnx:StockPurchaseAgreementMember us-gaap:CommonStockMember 2020-01-21 2020-01-21 0001205922 vcnx:StockPurchaseAgreementMember us-gaap:CommonStockMember 2020-01-21 0001205922 srt:PresidentMember 2020-01-21 0001205922 srt:ChiefExecutiveOfficerMember 2020-01-21 0001205922 srt:BoardOfDirectorsChairmanMember 2020-01-21 0001205922 srt:PresidentMember 2020-01-21 2020-01-21 0001205922 srt:ChiefExecutiveOfficerMember 2020-01-21 2020-01-21 0001205922 srt:BoardOfDirectorsChairmanMember 2020-01-21 2020-01-21 0001205922 vcnx:JulyTwoThousandTwentyStockPurchaseAgreementMember us-gaap:InvestorMember 2020-07-09 2020-07-09 0001205922 vcnx:JulyTwoThousandTwentyStockPurchaseAgreementMember us-gaap:CommonStockMember us-gaap:InvestorMember 2020-07-09 2020-07-09 0001205922 vcnx:JulyTwoThousandTwentyStockPurchaseAgreementMember us-gaap:CommonStockMember us-gaap:InvestorMember 2020-07-09 10-Q false 2020-09-30 2020 Q3 Yes VCNX Vaccinex, Inc. 0001205922 --12-31 Non-accelerated Filer true true false false 22385628 001-38624 16-1603202 1895 Mount Hope Avenue Rochester NY 14620 585 271-2700 Yes Common Stock, $0.0001 par value NASDAQ true false DE

17092000

2776000

443000

898000

702000

336000

18237000

4010000

488000

594000

18725000

4604000

2944000

3208000

2993000

3670000

7890000

13827000

6878000

1134000

14961000

6878000

3000

1000

250843000

222403000

11000

-271034000

-248630000

-20199000

-26237000

23963000

3764000

-2274000

18725000

4604000

0.0001

100000000

22380351

14887999

22379499

14887147

852

50000

404000

50000

523000

575000 575000

2000

8000

2000

199000

7334000

6543000

17300000

21259000

1872000

1531000

5565000

4741000

9208000

8082000

22867000

26199000

-8583000

-7678000

-22242000

-25676000

148000

150000

-23000

36000

-14000

139000

-8754000

-7642000

-22406000

-25537000

-8754000

-7642000

-22406000

-25537000

-8754000

-7642000

-22406000

-25537000

-8754000

-7642000

-22406000

-25537000

-0.44

-0.56

-1.27

-2.09

20074726

13759602

17587219

12246599

11476601

1000

208156000

852

-11000

-216767000

-8621000

23963000

15342000

60000

-9067000

11476601

1000

208216000

852

-11000

-225834000

-17628000

23963000

6335000

4455

113000

-8828000

11481056

1000

208329000

852

-11000

-234662000

-26343000

23963000

-2380000

3382332

13800000

136000

-7642000

14863388

1000

222265000

852

-11000

-242304000

-20049000

23963000

3914000

14887999

1000

222403000

852

-11000

-248630000

-26237000

23963000

1468563

1000

7475000

7476000

20000

204000

1025

4000

-7149000

16377587

2000

230086000

852

-11000

-255779000

-25702000

23963000

-1739000

642112000

2350000

54000

4125

366000

-6501000

17023824

2000

232748000

852

-11000

-262280000

-29541000

23963000

-5578000

5339329

1000

18648000

18649000

659000

14440

91000

2758

15000

-8754000

22380351

3000

250843000

852

-11000

-271034000

-20199000

23963000

237000

181000

113000

44000

661000

309000

-65000

-455000

449000

366000

-418000

-202000

21000

-692000

189000

-22265000

-24912000

14150000

291000

77000

-291000

14073000

11475000

13800000

17000000

8000000 108000

50000

1134000

598000

19000

36872000

13800000

14316000

2961000

2776000

5618000

17092000

8579000

161000

100000 15000

<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> Note 2.</td> <td valign="top">   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </td></tr></table></div> Basis of Presentation and Consolidation These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiary in which the Company has a controlling financial interest and a variable interest entity (“VIE”) in which the Company is the primary beneficiary. As of September 30, 2020, and 2019, the Company’s accounts include Vaccinex Products, LP, a Delaware limited partnership (“Vaccinex Products”) and VX3 (DE) LP, a Delaware limited partnership (“VX3”). VX3 was established in October 2017 by a group of Canadian investors and was determined to be a VIE in which the Company is the primary beneficiary. The Company consolidates any VIE of which it is the primary beneficiary. The Company presents its noncontrolling interests as a separate component of stockholders’ equity (deficit).  The Company presents the net loss of VX3 equal to the percentage ownership interest retained in such entity by the respective noncontrolling party (VX3), and as a separate component within its condensed consolidated statements of operations and comprehensive loss. The financial position of Vaccinex Products was not material as of September 30, 2020 and 2019, and there were no gains or losses for Vaccinex Products for the nine months ended September 30, 2020 and 2019. All intercompany transactions and balances have been eliminated. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the "SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2020. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 9, 2020.   Use of Estimates These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations. Grant Revenue From time to time, the Company receives certain grant award funding to support its continuing research and development efforts. The Company considers these grants to be operating revenue as they support the Company’s primary operating activities. We recognize revenue from these contracts as we perform services under these arrangements when the funding is received. Revenues and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as we have determined we control the arrangement as the primary obligor under the arrangements relative to the research and development services we perform.  During the three and nine month periods ended September 30, 2020 the Company recorded grant revenue related to funds received from the ADDF of $575,000. Deferred Offering Costs The Company has incurred certain costs in connection with its securities offerings with Jefferies and Keystone. The Company capitalizes such deferred offering costs, which consist of direct, incremental legal, professional, accounting, and other third-party fees. The deferred offering costs will be offset against offering proceeds upon the completion of an offering. Should the offering be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Company’s condensed consolidated statement of operations and comprehensive loss. Accordingly, $713,000 of offering costs associated with the ATM Facility and Keystone were charged against paid in capital in the nine months ended September 30, 2020. There were no deferred offering costs on the condensed consolidated balance sheet at September 30, 2020.          Convertible Instruments The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The accounting standards require companies to bifurcate embedded features from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company’s derivative instrument related to certain features embedded within the Debenture is discussed in Note 9. The derivative is accounted for as a derivative liability and remeasured to fair value as of each balance sheet date and the related remeasurement adjustments are recognized in the Company’s condensed consolidated statement of operations and comprehensive loss. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under U.S. GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term. ASU 2016-02 is effective for the Company for annual periods beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, requiring the use of a modified retrospective transition approach applied at the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU No. 2018-11, Leases, Targeted Improvements to ASC 842, Leases, (“ASU 2018-11”), which contains certain amendments to ASU 2016-02 intended to provide relief in implementing the new standard. ASU 2018-11 provides registrants with an option to not restate comparative periods presented in the financial statements. The Company intends to elect this new transition approach using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods will be presented in accordance with the previous guidance in Accounting Standards Codification (“ASC”) 840, Leases. The Company is currently evaluating the potential impact ASU 2016-02 may have on its financial position, results of operations, and related footnotes. The Company expects it will elect to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet.  The Company anticipates that the impact relating to the new lease standard will result in the Company’s operating lease of its corporate headquarters in Rochester, New York, being reflected on the consolidated balance sheet as an operating lease right to use asset and related lease liability.   In June 2016, the FASB issued ASU No. 2016-13, “Measurement of Credit Losses on Financial Instruments” to improve reporting requirements specific to loans, receivables, and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets. The standard is effective for interim and annual periods beginning after December 15, 2022 with early adoption permitted. Based on the composition of the Company’s financial assets, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial statements.   In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

Note 3.  BALANCE SHEET COMPONENTS Property and Equipment Property and equipment consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,499</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,442</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,297</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,167</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,809</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,573</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">594</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> Depreciation expense related to property and equipment was $74,000 and $64,000 for the three months ended September 30, 2020 and 2019, respectively and $237,000 and $181,000 for the nine months ended September 30, 2020 and 2019, respectively.   Accrued Expenses Accrued expenses consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,278</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,252</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">420</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting and legal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,993</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,670</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div>

<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> Note 4.</td> <td valign="top">   FAIR VALUE MEASUREMENTS OF FINANCIAL MEASUREMENTS </td></tr></table></div>   Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Assets and liabilities recorded at fair value on a nonrecurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Financial instruments consist of cash, accounts receivable, accounts payable, accrued liabilities, and long-term debt. Cash, accounts receivable, accounts payable, accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts.   Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards also apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its cash equivalents deposited in money market funds and derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market fund</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market fund</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> The Company did not transfer any assets measured at fair value on a recurring basis to or from Level 1 and Level 2 during either of the nine months ended September 30, 2020 and 2019.     The Debenture, as discussed in Note 9, contains embedded derivative features that are required to be bifurcated and remeasured each reporting period.  Each quarter, the change in the fair value of the embedded derivative features, if any, is recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The Company uses a binomial lattice valuation model to derive the value of the embedded derivative features, which initially valued the bifurcated embedded derivative at $65,000.  The fair value of the derivative liability is $0 at September 30, 2020.  Key inputs into this valuation model are the Company’s current stock price, risk-free interest rates, the stock dividend yield, the stock volatility, and the credit spread.  The first three aforementioned inputs are based on observable market data and are considered Level 1 inputs while the last two aforementioned inputs are unobservable and thus require management’s judgment and are considered Level 3 inputs.  This fair value measurement is considered a Level 3 measurement within the fair value hierarchy.

Note 9. CONVERTIBLE DEBENTURE The senior secured convertible debt comprises the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior secured convertible debenture</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized original issuance discount and debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total convertible debt</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,890</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   On July 30, 2020, the Company consummated the Convertible Debt Financing pursuant to which the Company issued the Debenture in the principal amount of $8,640,000 for a purchase price of $8,000,000, which reflects an original issue discount of approximately 8%. The closing of the sale of the Debenture occurred on August 3, 2020.   The Debenture will mature on the August 3, 2021. The Debenture accrues interest at 7% per year and is convertible into shares of common stock at the holder’s option, at a conversion price of $9.4125 per share, subject to certain customary adjustments (“Optional Conversion”).  Should a holder elect to convert prior to maturity, the holder is entitled to a cash payment for interest that would have been earned by the holder through the original maturity of the Debenture (the “Interest Make-Whole”).   Subject to the satisfaction of certain conditions, at any time, the Company may elect to redeem all or any portion of the Debenture for an amount equal to 115% of the outstanding principal balance being redeemed plus all accrued unpaid interest on the amount being redeemed  and an amount due under the Interest Make-Whole (the “Optional Redemption”).   The Debenture also provides that in connection with future capital raising transactions (subject to certain exceptions), the Company must offer to use 20% of the funds raised to redeem amounts outstanding under the Debenture (“Mandatory Redemption”). Any redemption in this circumstance will be at the election of the holder.   Consistent with the Optional Conversion or Optional Redemption provisions, the Mandatory Redemption is subject to the Interest Make-Whole.  During the three and nine month periods ended September 30, 2020, the Company made payments under the Mandatory Redemption provision totaling $116,329 consisting of $108,719 for principal repayments and $7,610 for accrued and make-whole interest.   The Debenture contains customary representations and warranties and affirmative and restrictive covenants, including limitations on indebtedness, liens, dispositions of assets, organizational document amendments, change of control transactions, stock repurchases, indebtedness repayments, dividends, affiliate transactions and certain other matters. The Company’s obligations under the Debenture can be accelerated upon the occurrence of certain customary events of default and are secured under a security agreement by a lien on substantially all of the Company’s assets, subject to certain exceptions.  In the event of default and acceleration of the Company’s obligations, the Company would be required to pay the outstanding principal balance of the Debenture plus all accrued unpaid interest and amounts due under the Interest Make-Whole, subject to alternate payment in the event that the event of default prevents the holder from converting the Debenture or disposing of the shares issuable thereunder, and all other amounts due in respect of the Debenture.   If the Company, at any time while this Debenture is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of common stock on shares of common stock or any common stock equivalents, (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of common stock into a smaller number of shares or (iv) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock of the Company, then the conversion price will be multiplied by a fraction, the numerator of which will be the number of shares of common stock outstanding immediately before such event, and the denominator of which will be the number of shares of common stock outstanding immediately after such event.   In addition to the adjustments above, if the Company grants, issues, or sells any common stock equivalents or rights to purchase stock, warrants, securities, or other property pro rata to the holders of any class of shares of common stock (the “Purchase Rights”), then upon subsequent conversion of the Debenture, the holder will be entitled to acquire the aggregate Purchase Rights which the holder could have acquired if the holder had held the number of shares of common stock acquirable upon complete conversion of the Debenture immediately before such grant, issuance or sale of Purchase Rights.   The Company evaluated the Debenture and determined that the Interest Make-Whole feature and Optional Redemption meet the definition of an embedded derivative liability measured at fair value. On the issuance date, August 3, 2020, the fair value of the bifurcated embedded derivative liability was $65,000.     The Company incurred $50,000 in fees paid to 3i in connection with the issuance of the Debenture. These costs were primarily allocated to the debt component and recognized as additional debt discount. The Company amortizes the debt discount, including the initial value of the derivative liability of $65,000, allocated fees of $50,000 and the original issuance discount of $640,000, over the term of the Debenture using the effective interest method. The annual effective interest rate is 16.54%. Total interest expense under the Senior Secured Convertible Debenture for the three and nine months ended September 30, 2020 was $210,923, prior to impact of change in fair value of derivative liability.   The fair value of the derivative liability as of September 30, 2020 was $0. The Company recorded the change in the fair value of $65,000 as a reduction to interest expense in its condensed consolidated statement of operations and comprehensive loss.

Note 10.  COMMON STOCK RESERVED FOR ISSUANCE Common stock has been reserved for the following potential future issuances:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares underlying outstanding stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">891,748</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,731</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,952</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of Vaccinex Products, LP units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,154,935</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,173,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of VX3 units</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,573,875</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,302,980</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   During the nine months ended September 30, 2020 and 2019, 18,565 and 4,455 units, respectively, of Vaccinex Products, LP were exchanged for shares of the Company’s common stock at par value of $0.0001 per share.</div>

<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> Note 11.  </td> <td valign="top"> STOCK-BASED COMPENSATION </td></tr></table></div> 2011 Employee Equity Plan In connection with the adoption of the Company’s 2018 Omnibus Incentive Plan (the “2018 Plan”) in August 2018, the Company ceased granting stock options under the Company’s 2011 Employee Equity Plan (the “2011 Plan”). However, the 2011 Plan will continue to govern the terms and conditions of the outstanding stock options previously granted thereunder. Any shares of stock related to awards outstanding under the 2011 Plan that terminate by expiration, forfeiture, cancellation, or otherwise without the issuances of such shares will become available for grant under the 2018 Plan. Stock options granted under the 2011 Plan expire in five or ten years from the date of grant. 2018 Omnibus Incentive Plan In August 2018, the Company’s board of directors adopted, and its stockholders approved, the 2018 Plan, which allows for the granting of stock, stock options, and stock appreciation rights awards to employees, advisors and consultants. Stock options granted under the 2018 Plan may be either incentive stock options or non-statutory stock options. Incentive stock options may be granted to employees, advisors and consultants at exercise prices of no less than the fair value of the common stock on the grant date. If at the time of grant, the optionee owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price must be at least 110% of the fair value of the common stock on the grant date as determined by the board of directors. Non-statutory stock options may be granted to employees, advisors and consultants at exercise prices of less than the fair market value of a share of common stock on the date the non-statutory stock option is granted but shall under no circumstances be less than adequate consideration as determined by the board of directors for such a share. The vesting period of stock option grants is determined by the board of directors, ranging from zero to eight years. Stock options granted under the 2018 Plan expire in five or ten years from the date of grant. The Company initially reserved 425,000 shares of common stock for issuance, subject to certain adjustments, pursuant to awards under the 2018 Plan. Any shares of common stock related to awards outstanding under the 2011 Plan as of the effective date of the 2018 Plan, which thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares, will be added to, and included in, the number of shares of common stock available for grant under the 2018 Plan. In addition, effective January 1, 2020 and continuing until the expiration of the 2018 Plan, the number of shares of common stock available for issuance under the 2018 Plan will automatically increase annually by 2% of the total number of issued and outstanding shares of the Company’s common stock as of December 31st of the immediately preceding year or such lesser number as the Company’s board of directors may decide, which may be zero. Accordingly, on January 1, 2020, 297,743 additional shares of common stock became available for issuance under the 2018 Plan. A summary of the Company’s stock option activity and related information is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,731</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,300</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,783</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of September 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">891,748</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569,724</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.75</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> The weighted-average grant date fair value of stock options granted to employees and directors for the nine months ended September 30, 2020 and 2019 was $2.73 per share and $3.35 per share, respectively. The aggregate grant date fair value of stock options that vested during the nine months ended September 30, 2020 and 2019 was $719,632 and $105,061, respectively. The intrinsic value of stock options vested and exercisable and expected to vest and become exercisable is calculated based on the difference between the exercise price and the fair value of the Company’s common stock as of September 30, 2020 and December 31, 2019. The intrinsic value of exercised stock options is the difference between the fair value of the underlying common stock and the exercise price as of the exercise date. As of September 30, 2020 and December 31, 2019, total unrecognized compensation cost related to stock options granted to employees was $926,591 and $627,129, respectively, which is expected to be recognized over a weighted-average period of 2.96 and 2.39 years, respectively. The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>  </div> In March 2020, the Company issued 20,000 shares of common stock as compensation for administrative fees incurred in connection with entering into a purchase agreement with Keystone. Pursuant to the terms of the Purchase Agreement, Keystone has agreed to purchase up to $5,000,000 of shares of the Company’s common stock. At the time of issuance, the fair market value of the shares was $4.00, and, as a result, $80,000 was included in general and administrative expenses for the nine months ended September 30, 2020.   Total stock-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">565</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> Note 13.  </td> <td valign="top"> NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS </td></tr></table></div>   The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850,716</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604,599</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527,573</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Vaccinex Products, LP units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,163,141</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198,111</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,047</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,199,906</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   VX3 units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div>

Use of Estimates These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.

Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.

Grant Revenue From time to time, the Company receives certain grant award funding to support its continuing research and development efforts. The Company considers these grants to be operating revenue as they support the Company’s primary operating activities. We recognize revenue from these contracts as we perform services under these arrangements when the funding is received. Revenues and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as we have determined we control the arrangement as the primary obligor under the arrangements relative to the research and development services we perform.  During the three and nine month periods ended September 30, 2020 the Company recorded grant revenue related to funds received from the ADDF of $575,000.

Convertible Instruments The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The accounting standards require companies to bifurcate embedded features from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company’s derivative instrument related to certain features embedded within the Debenture is discussed in Note 9. The derivative is accounted for as a derivative liability and remeasured to fair value as of each balance sheet date and the related remeasurement adjustments are recognized in the Company’s condensed consolidated statement of operations and comprehensive loss.

Recent Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under U.S. GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term. ASU 2016-02 is effective for the Company for annual periods beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, requiring the use of a modified retrospective transition approach applied at the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU No. 2018-11, Leases, Targeted Improvements to ASC 842, Leases, (“ASU 2018-11”), which contains certain amendments to ASU 2016-02 intended to provide relief in implementing the new standard. ASU 2018-11 provides registrants with an option to not restate comparative periods presented in the financial statements. The Company intends to elect this new transition approach using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods will be presented in accordance with the previous guidance in Accounting Standards Codification (“ASC”) 840, Leases. The Company is currently evaluating the potential impact ASU 2016-02 may have on its financial position, results of operations, and related footnotes. The Company expects it will elect to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet.  The Company anticipates that the impact relating to the new lease standard will result in the Company’s operating lease of its corporate headquarters in Rochester, New York, being reflected on the consolidated balance sheet as an operating lease right to use asset and related lease liability.   In June 2016, the FASB issued ASU No. 2016-13, “Measurement of Credit Losses on Financial Instruments” to improve reporting requirements specific to loans, receivables, and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets. The standard is effective for interim and annual periods beginning after December 15, 2022 with early adoption permitted. Based on the composition of the Company’s financial assets, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial statements.   In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

Property and equipment consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,499</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,442</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,297</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,167</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,809</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,573</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">594</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Accrued expenses consist of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,278</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,252</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">420</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting and legal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,993</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,670</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market fund</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">626</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market fund</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The senior secured convertible debt comprises the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior secured convertible debenture</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,531</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized original issuance discount and debt issuance costs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total convertible debt</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,890</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Common stock has been reserved for the following potential future issuances:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares underlying outstanding stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">891,748</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,731</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,952</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of Vaccinex Products, LP units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,154,935</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,173,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of VX3 units</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,573,875</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,302,980</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of the Company’s stock option activity and related information is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,731</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.04</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324,300</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,783</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of September 30, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">891,748</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of September 30, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569,724</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.75</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

Total stock-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">565</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">850,716</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604,599</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">527,573</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Vaccinex Products, LP units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,163,141</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198,111</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,170,047</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,199,906</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   VX3 units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

13800000

7500000

4000000

2000000

11500000

5000000

113000000

26600000

750000

3815600

47319

317688

324424

1200000

12300000

575000000

300000

0.07

8640000

8000000 0.08

2021-08-03

9.4125

1100

575000 575000

713000

3174000

3161000

3499000

3442000

350000

273000

214000

7297000

7167000

6809000

6573000

74000

64000

2278000 3252000

420000

262000

180000

79000

94000

21000

77000

626000

1464000

65000

32000000 the Company will issue to VX3 or its designees the number of shares of the Company’s common stock equal to the lesser of (1) the aggregate of all payments made to VX3 by its partners divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of the Company’s common stock. 18.20

0.90

2 P9M P12M

4000

123000

400000

300000

100000

300000

100000

50000

25500000

0.01 14000 14511

43022

174132

145110

42000

126000

42000

126000

1133600

2022-05-08

0.010

2020-11-08

5000

8531000

641000

7890000

8640000

8000000 0.08

2021-08-03

0.07

9.4125

1.15

0.20

116329

108719

7610

65000

50000

65000

50000 640000

0.1654

210923

65000

891748

579731

208395

230952

1154935

1173500

1318797

3573875

3302980

18565

4455

0.0001

0.10 1.10

P5Y

P10Y

425000

0.02

297743

579731

324300

3783

8500

891748

569724

8.04

4.50

5.11

8.10

6.77

7.75

P7Y

P7Y3M18D

P6Y6M

120000

3000

2.73

3.35

719632

105061

926591

627129

P2Y11M15D

P2Y4M20D

P6Y3M18D

P6Y

0.75

0.009

0.025

20000

5000000

4.00

80000

37000

26000

96000

72000

54000

111000

565000

237000

91000

137000

661000

309000

850716

604599

742797

527573

1163141

1198111

1170047

1199906

1318797

1 0

2020-01-21

1468563

5.09

7500000

982318

98231

39292

4999999

499996

199996

2020-07-09

1126760

3.55

4000000

EX-101.SCH 6 vcnx-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Company and Nature of Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Balance Sheet Components link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements of Financial Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - License and Services Agreement link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Long-term Debt link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Convertible Debenture link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Common Stock Reserved For Issuance link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Segment and Geographical Information link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Balance Sheet Components (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Fair Value Measurements of Financial Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Convertible Debenture (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Common Stock Reserved For Issuance (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Company and Nature of Business - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Balance Sheet Components - Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Balance Sheet Components - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Fair Value Measurements of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value Measurements of Financial Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - License and Services Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Collaboration Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Long-term Debt - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Convertible Debenture - Schedule of Senior Secured Convertible Debt (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Convertible Debenture - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Common Stock Reserved For Issuance - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Segment and Geographic Information - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Related Party Transactions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 vcnx-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vcnx-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vcnx-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Current Reporting Status Entity Current Reporting Status Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Incorporation, State or Country Code Entity Incorporation State Country Code Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Senior secured convertible debt, net Convertible Debt Total current liabilities Liabilities Current Long-term debt Long Term Debt Noncurrent TOTAL LIABILITIES Liabilities Commitments and contingencies (Note 7) Commitments And Contingencies Stockholders’ equity (deficit): Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract] Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of September 30, 2020, and December 31, 2019; 22,380,351 and 14,887,999 shares issued as of September 30, 2020 and December 31, 2019, respectively; 22,379,499 and 14,887,147 shares outstanding as of September 30, 2020 and December 31, 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Treasury stock, at cost; 852 shares of common stock as of September 30, 2020 and December 31, 2019, respectively Treasury Stock Value Accumulated deficit Retained Earnings Accumulated Deficit Total Vaccinex, Inc. stockholders’ deficit Stockholders Equity Noncontrolling interests Minority Interest TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) Stockholders Equity Including Portion Attributable To Noncontrolling Interest TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Treasury stock, common shares Treasury Stock Common Shares Grant revenue. Income Statement [Abstract] Revenue Revenue From Contract With Customer Excluding Assessed Tax Grant revenue Grant Revenue Costs and expenses: Costs And Expenses [Abstract] Cost of revenue Cost Of Revenue Research and development Research And Development Expense General and administrative General And Administrative Expense Total costs and expenses Costs And Expenses Loss from operations Operating Income Loss Interest expense Interest Expense Other income (expense), net Other Nonoperating Income Expense Loss before provision for income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Income Tax Expense Benefit Net loss Profit Loss Net loss attributable to noncontrolling interests Net Income Loss Attributable To Noncontrolling Interest Net loss attributable to Vaccinex, Inc. common stockholders Net Income Loss Comprehensive loss Comprehensive Income Net Of Tax Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Adjustments to additional paid in capital share based compensation requisite service period recognition shares. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Treasury Stock Treasury Stock [Member] Accumulated Deficit Retained Earnings [Member] Total Vaccinex,Inc. Stockholders' Deficit Parent [Member] Noncontrolling Interests Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Balance Balance, Shares Shares Outstanding Issuance of common shares Stock Issued During Period Value New Issues Issuance of common shares, Shares Stock Issued During Period Shares New Issues Common shares issuance costs Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Exchange of Vaccinex Products LP Units for common shares, Shares Stock Issued During Period Shares Conversion Of Units Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation, Shares Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Shares Exercise of stock options Stock Issued During Period Value Stock Options Exercised Exercise of stock options, Shares Stock Issued During Period Shares Stock Options Exercised Net loss Balance Balance, Shares Proceeds from issuance of convertible debt net of discount. Redemption of convertible debt. Offering costs in accounts payable. Offering costs in accrued expenses. Statement Of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Debt related charges included in interest expense Interest Expense Debt Net amortization of premiums and discounts on marketable securities Accretion Amortization Of Discounts And Premiums Investments Stock-based compensation Share Based Compensation Change in fair value of derivative liability Increase Decrease In Derivative Liabilities Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Sales of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Purchase of property and equipment Payments To Acquire Property Plant And Equipment Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from private offering of common stock Proceeds From Issuance Of Private Placement Proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Proceeds from issuance of convertible debt, net of discount Proceeds From Issuance Of Convertible Debt Net Of Discount Redemption of convertible debt Redemption Of Convertible Debt Payments of convertible debt issuance costs Payments Of Debt Issuance Costs Proceeds from long-term debt Proceeds From Issuance Of Long Term Debt Payments of common stock issuance costs Payments Of Stock Issuance Costs Proceeds from exercise of stock options Proceeds From Stock Options Exercised Net cash provided by financing activities Net Cash Provided By Used In Financing Activities NET INCREASE IN CASH AND CASH EQUIVALENTS Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CASH AND CASH EQUIVALENTS–Beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CASH AND CASH EQUIVALENTS–End of period SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing And Financing Items [Abstract] Purchase of property and equipment in accounts payable Capital Expenditures Incurred But Not Yet Paid Offering costs in accounts payable Offering Costs In Accounts Payable Offering costs in accrued expenses Offering Costs In Accrued Expenses Organization Consolidation And Presentation Of Financial Statements [Abstract] Company and Nature of Business Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements of Financial Measurements Fair Value Disclosures [Text Block] License and services agreement. Research And Development [Abstract] License and Services Agreement License And Services Agreement [Text Block] Collaboration agreements. Collaboration Agreements [Abstract] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Debt Instruments [Abstract] Long-term Debt Long Term Debt [Text Block] Debt Disclosure [Abstract] Convertible Debenture Debt Disclosure [Text Block] Common stock reserved for issuance. Equity [Abstract] Common Stock Reserved For Issuance Common Stock Reserved For Issuance [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Segment Reporting [Abstract] Segment and Geographic Information Segment Reporting Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Basis of presentation and consolidation. Basis of Presentation and Consolidation Basis Of Presentation And Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Concentration of Credit Risk, Other Risks and Uncertainties Concentration Risk Credit Risk Grant revenue. Grant Revenue Grant Revenue Policy [Text Block] Deferred Offering Costs Deferred Charges Policy [Text Block] Convertible instruments. Convertible Instruments Convertible Instruments Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Property and Equipment Property Plant And Equipment [Text Block] Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block] Schedule of Senior Secured Convertible Debt Convertible Debt Table [Text Block] Common stock reserved for future issuance. Common Stock Reserved for Potential Future Issuances Common Stock Reserved For Future Issuance Table [Text Block] Summary of Stock Option Activity and Related Information Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations and Comprehensive Loss Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Organization consolidation and presentation of financial statements. Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Open market sale agreement. EX-101.PRE 10 vcnx-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2020	Nov. 10, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Trading Symbol	VCNX
Entity Registrant Name	Vaccinex, Inc.
Entity Central Index Key	0001205922
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		22,385,628
Entity File Number	001-38624
Entity Tax Identification Number	16-1603202
Entity Address, Address Line One	1895 Mount Hope Avenue
Entity Address, City or Town	Rochester
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14620
City Area Code	585
Local Phone Number	271-2700
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 17,092	$ 2,776
Accounts receivable	443	898
Prepaid expenses and other current assets	702	336
Total current assets	18,237	4,010
Property and equipment, net	488	594
TOTAL ASSETS	18,725	4,604
Current liabilities:
Accounts payable	2,944	3,208
Accrued expenses	2,993	3,670
Senior secured convertible debt, net	7,890
Total current liabilities	13,827	6,878
Long-term debt	1,134
TOTAL LIABILITIES	14,961	6,878
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of September 30, 2020, and December 31, 2019; 22,380,351 and 14,887,999 shares issued as of September 30, 2020 and December 31, 2019, respectively; 22,379,499 and 14,887,147 shares outstanding as of September 30, 2020 and December 31, 2019, respectively	3	1
Additional paid-in capital	250,843	222,403
Treasury stock, at cost; 852 shares of common stock as of September 30, 2020 and December 31, 2019, respectively	(11)	(11)
Accumulated deficit	(271,034)	(248,630)
Total Vaccinex, Inc. stockholders’ deficit	(20,199)	(26,237)
Noncontrolling interests	23,963	23,963
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	3,764	(2,274)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 18,725	$ 4,604

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	22,380,351	14,887,999
Common stock, shares outstanding	22,379,499	14,887,147
Treasury stock, common shares	852	852

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 50,000	$ 404,000	$ 50,000	$ 523,000
Grant revenue	575,000		575,000
Costs and expenses:
Cost of revenue	2,000	8,000	2,000	199,000
Research and development	7,334,000	6,543,000	17,300,000	21,259,000
General and administrative	1,872,000	1,531,000	5,565,000	4,741,000
Total costs and expenses	9,208,000	8,082,000	22,867,000	26,199,000
Loss from operations	(8,583,000)	(7,678,000)	(22,242,000)	(25,676,000)
Interest expense	(148,000)		(150,000)
Other income (expense), net	(23,000)	36,000	(14,000)	139,000
Loss before provision for income taxes	(8,754,000)	(7,642,000)	(22,406,000)	(25,537,000)
Provision for income taxes	0	0	0	0
Net loss	(8,754,000)	(7,642,000)	(22,406,000)	(25,537,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(8,754,000)	(7,642,000)	(22,406,000)	(25,537,000)
Comprehensive loss	$ (8,754,000)	$ (7,642,000)	$ (22,406,000)	$ (25,537,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (0.44)	$ (0.56)	$ (1.27)	$ (2.09)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	20,074,726	13,759,602	17,587,219	12,246,599

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total Vaccinex,Inc. Stockholders' Deficit	Noncontrolling Interests
Balance at Dec. 31, 2018	$ 15,342,000	$ 1,000	$ 208,156,000	$ (11,000)	$ (216,767,000)	$ (8,621,000)	$ 23,963,000
Balance, Shares at Dec. 31, 2018		11,476,601		852
Stock-based compensation	60,000		60,000			60,000
Net loss	(9,067,000)				(9,067,000)	(9,067,000)
Balance at Mar. 31, 2019	6,335,000	$ 1,000	208,216,000	$ (11,000)	(225,834,000)	(17,628,000)	23,963,000
Balance, Shares at Mar. 31, 2019		11,476,601		852
Balance at Dec. 31, 2018	15,342,000	$ 1,000	208,156,000	$ (11,000)	(216,767,000)	(8,621,000)	23,963,000
Balance, Shares at Dec. 31, 2018		11,476,601		852
Net loss	(25,537,000)
Balance at Sep. 30, 2019	3,914,000	$ 1,000	222,265,000	$ (11,000)	(242,304,000)	(20,049,000)	23,963,000
Balance, Shares at Sep. 30, 2019		14,863,388		852
Balance at Mar. 31, 2019	6,335,000	$ 1,000	208,216,000	$ (11,000)	(225,834,000)	(17,628,000)	23,963,000
Balance, Shares at Mar. 31, 2019		11,476,601		852
Exchange of Vaccinex Products LP Units for common shares, Shares		4,455
Stock-based compensation	113,000		113,000			113,000
Net loss	(8,828,000)				(8,828,000)	(8,828,000)
Balance at Jun. 30, 2019	(2,380,000)	$ 1,000	208,329,000	$ (11,000)	(234,662,000)	(26,343,000)	23,963,000
Balance, Shares at Jun. 30, 2019		11,481,056		852
Issuance of common shares	13,800,000		13,800,000			13,800,000
Issuance of common shares, Shares		3,382,332
Stock-based compensation	136,000		136,000			136,000
Net loss	(7,642,000)				(7,642,000)	(7,642,000)
Balance at Sep. 30, 2019	3,914,000	$ 1,000	222,265,000	$ (11,000)	(242,304,000)	(20,049,000)	23,963,000
Balance, Shares at Sep. 30, 2019		14,863,388		852
Balance at Dec. 31, 2019	(2,274,000)	$ 1,000	222,403,000	$ (11,000)	(248,630,000)	(26,237,000)	23,963,000
Balance, Shares at Dec. 31, 2019		14,887,999		852
Issuance of common shares	7,476,000	$ 1,000	7,475,000			7,476,000
Issuance of common shares, Shares		1,468,563
Stock-based compensation	204,000		204,000			204,000
Stock-based compensation, Shares		20,000
Exercise of stock options	4,000		4,000			4,000
Exercise of stock options, Shares		1,025
Net loss	(7,149,000)				(7,149,000)	(7,149,000)
Balance at Mar. 31, 2020	(1,739,000)	$ 2,000	230,086,000	$ (11,000)	(255,779,000)	(25,702,000)	23,963,000
Balance, Shares at Mar. 31, 2020		16,377,587		852
Balance at Dec. 31, 2019	$ (2,274,000)	$ 1,000	222,403,000	$ (11,000)	(248,630,000)	(26,237,000)	23,963,000
Balance, Shares at Dec. 31, 2019		14,887,999		852
Exercise of stock options, Shares	3,783
Net loss	$ (22,406,000)
Balance at Sep. 30, 2020	3,764,000	$ 3,000	250,843,000	$ (11,000)	(271,034,000)	(20,199,000)	23,963,000
Balance, Shares at Sep. 30, 2020		22,380,351		852
Balance at Mar. 31, 2020	(1,739,000)	$ 2,000	230,086,000	$ (11,000)	(255,779,000)	(25,702,000)	23,963,000
Balance, Shares at Mar. 31, 2020		16,377,587		852
Issuance of common shares	2,350,000	$ 642,112,000	2,350,000			2,350,000
Common shares issuance costs	(54,000)		(54,000)			(54,000)
Exchange of Vaccinex Products LP Units for common shares, Shares		4,125
Stock-based compensation	366,000		366,000			366,000
Net loss	(6,501,000)				(6,501,000)	(6,501,000)
Balance at Jun. 30, 2020	(5,578,000)	$ 2,000	232,748,000	$ (11,000)	(262,280,000)	(29,541,000)	23,963,000
Balance, Shares at Jun. 30, 2020		17,023,824		852
Issuance of common shares	18,649,000	$ 1,000	18,648,000			18,649,000
Issuance of common shares, Shares		5,339,329
Common shares issuance costs	(659,000)		(659,000)			(659,000)
Exchange of Vaccinex Products LP Units for common shares, Shares		14,440
Stock-based compensation	91,000		91,000			91,000
Exercise of stock options	15,000		15,000			15,000
Exercise of stock options, Shares		2,758
Net loss	(8,754,000)				(8,754,000)	(8,754,000)
Balance at Sep. 30, 2020	$ 3,764,000	$ 3,000	$ 250,843,000	$ (11,000)	$ (271,034,000)	$ (20,199,000)	$ 23,963,000
Balance, Shares at Sep. 30, 2020		22,380,351		852

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (22,406,000)	$ (25,537,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	237,000	181,000
Debt related charges included in interest expense	113,000
Net amortization of premiums and discounts on marketable securities		(44,000)
Stock-based compensation	661,000	309,000
Change in fair value of derivative liability	(65,000)
Changes in operating assets and liabilities:
Accounts receivable	455,000	(449,000)
Prepaid expenses and other current assets	(366,000)	418,000
Accounts payable	(202,000)	21,000
Accrued expenses	(692,000)	189,000
Net cash used in operating activities	(22,265,000)	(24,912,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales of marketable securities		14,150,000
Purchase of property and equipment	(291,000)	(77,000)
Net cash (used in) provided by investing activities	(291,000)	14,073,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from private offering of common stock	11,475,000	13,800,000
Proceeds from issuance of common stock	17,000,000
Proceeds from issuance of convertible debt, net of discount	8,000,000
Redemption of convertible debt	(108,000)
Payments of convertible debt issuance costs	(50,000)
Proceeds from long-term debt	1,134,000
Payments of common stock issuance costs	(598,000)
Proceeds from exercise of stock options	19,000
Net cash provided by financing activities	36,872,000	13,800,000
NET INCREASE IN CASH AND CASH EQUIVALENTS	14,316,000	2,961,000
CASH AND CASH EQUIVALENTS–Beginning of period	2,776,000	5,618,000
CASH AND CASH EQUIVALENTS–End of period	17,092,000	$ 8,579,000
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Purchase of property and equipment in accounts payable	(161,000)
Offering costs in accounts payable	100,000
Offering costs in accrued expenses	$ 15,000

XML 17 R7.htm IDEA: XBRL DOCUMENT

Company and Nature of Business

9 Months Ended

Sep. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Company and Nature of Business

Note 1.

COMPANY AND NATURE OF BUSINESS

Going Concern

To date, the Company has relied on public and private sales of equity and debt financing to fund its operations, in addition to capital contributions from noncontrolling interests and a limited amount of service revenue from collaboration agreements. In July 2019, January 2020, and July 2020, we completed private placements of our common stock and received gross proceeds of $13.8 million, $7.5 million, and $4.0 million, respectively and in September 2020 we received gross proceeds of $2.0 million through an award from the Alzheimer’s Drug Discovery Foundation (“ADDF”), in the form of an investment in our common stock. Additionally, on March 27, 2020, we announced that we had (i) entered into an open market sale agreement (the “Open Market Sale Agreement” or “ATM”) with Jefferies, LLC (“Jefferies”) and filed a prospectus supplement pursuant to which we were able to issue and sell up to $11.5 million of shares of our common stock from time and (ii) entered into a purchase agreement (the “Purchase Agreement”) with Keystone Capital Partners, LLC (“Keystone”) pursuant to which Keystone agreed to purchase up to an aggregate of $5.0 million of shares of our common stock from time to time. During the second quarter of 2020, 317,688 shares were sold through the Open Market Sale Agreement for proceeds of $1.2 million, net of commission, and 324,424 shares were sold through the Purchase Agreement with Keystone for proceeds of $1.2 million, net of discount. In August 2020, we ceased use of the Purchase Agreement with Keystone, and in September 2020, we filed a replacement prospectus supplement related to the Open Market Sale Agreement pursuant to which we may sell up to $113 million of shares of our common stock through Jefferies. During the third quarter of 2020, 3,815,600 shares were sold through the Open Market Sale Agreement for proceeds of $12.3 million, net of commission, and 47,319 shares were sold through the Purchase Agreement for proceeds of $300,000, net of discount. In August 2020, we entered into a Securities Purchase Agreement (the “SPA”), with 3i, LP, (“3i”) as collateral agent and purchaser (the “Convertible Debt Financing”). Pursuant to the SPA, on August 3, 2020, we issued a 7% Original Issue Discount Senior Secured Convertible Debenture (“Senior Secured Convertible Debenture” or “the Debenture”), in the principal amount of $8.64 million for a purchase price of $8.0 million, which reflects an original issue discount of approximately 8%. The Debenture will mature on August 3, 2021. The Debenture accrues interest at 7% per year and is convertible into shares of our common stock at a conversion price of $9.4125 per share, subject to certain customary adjustments. In the third quarter of 2020, we raised total proceeds of approximately $26.6 million, net of commissions and discounts and before expenses, through the Open Market Sale Agreement, the Convertible Debt Financing, the July 2020 private placement transaction, the ADDF award, and the Purchase Agreement. We also received $575,000 in proceeds from our $750,000 grant from the Alzheimer’s Association under its 2020 Part the Cloud Program. The remainder of this award is anticipated to be funded in 2021.

COVID-19 Pandemic

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

Use of Estimates

Concentration of Credit Risk, Other Risks and Uncertainties

Grant Revenue

Deferred Offering Costs

Convertible Instruments

Recent Accounting Pronouncements Not Yet Adopted

XML 19 R9.htm IDEA: XBRL DOCUMENT

Balance Sheet Components

9 Months Ended

Sep. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Note 3. BALANCE SHEET COMPONENTS

Property and Equipment

Property and equipment consist of the following (in thousands):

	As of September 30, 2020			As of December 31, 2019
Leasehold improvements	$	3,174		$	3,161
Research equipment		3,499			3,442
Furniture and fixtures		350			350
Computer equipment		273			214
Property and equipment, gross		7,297			7,167
Less: accumulated depreciation and amortization		(6,809	)		(6,573	)
Property and equipment, net	$	488		$	594

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	As of September 30, 2020		As of December 31, 2019

Accrued clinical trial cost	$	2,278	$	3,252
Accrued payroll and related benefits		420		262
Accrued consulting and legal		180		79
Accrued interest		94		-
Accrued other		21		77
Accrued expenses	$	2,993	$	3,670

XML 20 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements of Financial Measurements

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements of Financial Measurements

Note 4.

FAIR VALUE MEASUREMENTS OF FINANCIAL MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):

	As of September 30, 2020
	Fair Value		Level 1		Level 2		Level 3
Financial Assets:
Cash equivalents:
Money market fund	$	626	$	626	$	-	$	-
Total Financial Assets	$	626	$	626	$	-	$	-

	As of December 31, 2019
	Fair Value		Level 1		Level 2		Level 3
Financial Assets:
Cash equivalents:
Money market fund	$	1,464	$	1,464	$	-	$	-
Total Financial Assets	$	1,464	$	1,464	$	-	$	-

The Company did not transfer any assets measured at fair value on a recurring basis to or from Level 1 and Level 2 during either of the nine months ended September 30, 2020 and 2019.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

License and Services Agreement

9 Months Ended

Sep. 30, 2020

Research And Development [Abstract]

License and Services Agreement

Note 5.

LICENSE AND SERVICES AGREEMENT

•

the Company enters into a transaction such as a sale, merger or consolidation such that shares of Company common stock are or will be sold or exchanged for cash and/or marketable securities;

•

on or after August 13, 2023; or

•

XML 22 R12.htm IDEA: XBRL DOCUMENT

Collaboration Agreements

9 Months Ended

Sep. 30, 2020

Collaboration Agreements [Abstract]

Collaboration Agreements

Note 6.

COLLABORATION AGREEMENTS

Surface Oncology, Inc.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 7.

COMMITMENTS AND CONTINGENCIES

Sublicense Termination Payments

Operating Lease

As of September 30, 2020, the future minimum payments for the operating lease are $43,022 in 2020, $174,132 in 2021, and $145,110 in 2022.

Rent expense incurred under the operating lease was $42,000 and $126,000 for each of the three and nine months ended September 30, 2020 and 2019, respectively.

Contingencies

XML 24 R14.htm IDEA: XBRL DOCUMENT

Long-term Debt

9 Months Ended

Sep. 30, 2020

Debt Instruments [Abstract]

Long-term Debt

Note 8.

LONG-TERM DEBT

XML 25 R15.htm IDEA: XBRL DOCUMENT

Convertible Debenture

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Convertible Debenture

Note 9. CONVERTIBLE DEBENTURE

The senior secured convertible debt comprises the following (in thousands):

	As of September 30, 2020			As of December 31, 2019
Senior secured convertible debenture	$	8,531		$	-
Unamortized original issuance discount and debt issuance costs		(641	)		-
Total convertible debt	$	7,890		$	-

XML 26 R16.htm IDEA: XBRL DOCUMENT

Common Stock Reserved For Issuance

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Common Stock Reserved For Issuance

Note 10. COMMON STOCK RESERVED FOR ISSUANCE

Common stock has been reserved for the following potential future issuances:

	As of September 30, 2020		As of December 31, 2019
Shares underlying outstanding stock options		891,748		579,731
Shares available for future stock option grants		208,395		230,952
Exchange of Vaccinex Products, LP units		1,154,935		1,173,500
Conversion of VX3 units		1,318,797		1,318,797
Total shares of common stock reserved		3,573,875		3,302,980

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

Note 11.

STOCK-BASED COMPENSATION

2011 Employee Equity Plan

2018 Omnibus Incentive Plan

A summary of the Company’s stock option activity and related information is as follows:

	Stock Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Balance as of December 31, 2019		579,731		$	8.04		7.0	$	120
Granted		324,300			4.50
Exercised		(3,783	)		5.11			$	3
Canceled		(8,500	)		8.10
Balance as of September 30, 2020		891,748		$	6.77		7.3	$	-
Exercisable as of September 30, 2020		569,724		$	7.75		6.5	$	-

The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

	Nine Months Ended September 30,
	2020			2019
Expected term (in years)		6.3			6.0
Expected volatility		75	%		75	%
Risk-free interest rate		0.9	%		2.5	%
Expected dividend yield		-	%		-	%

Total stock-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development	$	37	$	26	$	96	$	72
General and administrative		54		111		565		237
Total stock-based compensation expense	$	91	$	137	$	661	$	309

XML 28 R18.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

Note 12.

INCOME TAXES

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders

Note 13.

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Options to purchase common stock		850,716		604,599		742,797		527,573
Contingently issuable common stock upon exchange of Vaccinex Products, LP units		1,163,141		1,198,111		1,170,047		1,199,906
Contingently issuable common stock upon exchange of VX3 units		1,318,797		1,318,797		1,318,797		1,318,797

XML 30 R20.htm IDEA: XBRL DOCUMENT

Segment and Geographical Information

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Segment and Geographic Information

Note 14.

SEGMENT AND GEOGRAPHIC INFORMATION

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 31 R21.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions

Note 15.

RELATED PARTY TRANSACTIONS

XML 32 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiary in which the Company has a controlling financial interest and a variable interest entity (“VIE”) in which the Company is the primary beneficiary. As of September 30, 2020, and 2019, the Company’s accounts include Vaccinex Products, LP, a Delaware limited partnership (“Vaccinex Products”) and VX3 (DE) LP, a Delaware limited partnership (“VX3”). VX3 was established in October 2017 by a group of Canadian investors and was determined to be a VIE in which the Company is the primary beneficiary. The Company consolidates any VIE of which it is the primary beneficiary. The Company presents its noncontrolling interests as a separate component of stockholders’ equity (deficit). The Company presents the net loss of VX3 equal to the percentage ownership interest retained in such entity by the respective noncontrolling party (VX3), and as a separate component within its condensed consolidated statements of operations and comprehensive loss. The financial position of Vaccinex Products was not material as of September 30, 2020 and 2019, and there were no gains or losses for Vaccinex Products for the nine months ended September 30, 2020 and 2019. All intercompany transactions and balances have been eliminated. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and following the requirements of the Securities and Exchange Commission (the "SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2020. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 9, 2020.
Use of Estimates	Use of Estimates These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.
Grant Revenue	Grant Revenue From time to time, the Company receives certain grant award funding to support its continuing research and development efforts. The Company considers these grants to be operating revenue as they support the Company’s primary operating activities. We recognize revenue from these contracts as we perform services under these arrangements when the funding is received. Revenues and related expenses are presented gross in the consolidated statements of operations and comprehensive loss as we have determined we control the arrangement as the primary obligor under the arrangements relative to the research and development services we perform. During the three and nine month periods ended September 30, 2020 the Company recorded grant revenue related to funds received from the ADDF of $575,000.
Deferred Offering Costs	Deferred Offering Costs The Company has incurred certain costs in connection with its securities offerings with Jefferies and Keystone. The Company capitalizes such deferred offering costs, which consist of direct, incremental legal, professional, accounting, and other third-party fees. The deferred offering costs will be offset against offering proceeds upon the completion of an offering. Should the offering be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Company’s condensed consolidated statement of operations and comprehensive loss. Accordingly, $713,000 of offering costs associated with the ATM Facility and Keystone were charged against paid in capital in the nine months ended September 30, 2020. There were no deferred offering costs on the condensed consolidated balance sheet at September 30, 2020.
Convertible Instruments	Convertible Instruments The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The accounting standards require companies to bifurcate embedded features from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company’s derivative instrument related to certain features embedded within the Debenture is discussed in Note 9. The derivative is accounted for as a derivative liability and remeasured to fair value as of each balance sheet date and the related remeasurement adjustments are recognized in the Company’s condensed consolidated statement of operations and comprehensive loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), in order to improve comparability among organizations by recognizing lease assets and liabilities in the consolidated balance sheets for those leases previously classified as operating leases under U.S. GAAP. The update requires a lessee to recognize in its consolidated balance sheet a liability to make lease payments and also a right-of-use asset representing its right to use the underlying asset for the lease term. ASU 2016-02 is effective for the Company for annual periods beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021, requiring the use of a modified retrospective transition approach applied at the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU No. 2018-11, Leases, Targeted Improvements to ASC 842, Leases, (“ASU 2018-11”), which contains certain amendments to ASU 2016-02 intended to provide relief in implementing the new standard. ASU 2018-11 provides registrants with an option to not restate comparative periods presented in the financial statements. The Company intends to elect this new transition approach using a cumulative-effect adjustment on the effective date of the standard, for which comparative periods will be presented in accordance with the previous guidance in Accounting Standards Codification (“ASC”) 840, Leases. The Company is currently evaluating the potential impact ASU 2016-02 may have on its financial position, results of operations, and related footnotes. The Company expects it will elect to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Company anticipates that the impact relating to the new lease standard will result in the Company’s operating lease of its corporate headquarters in Rochester, New York, being reflected on the consolidated balance sheet as an operating lease right to use asset and related lease liability. In June 2016, the FASB issued ASU No. 2016-13, “Measurement of Credit Losses on Financial Instruments” to improve reporting requirements specific to loans, receivables, and other financial instruments. The new standard requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. The new standard also requires enhanced disclosure of credit risk associated with financial assets. The standard is effective for interim and annual periods beginning after December 15, 2022 with early adoption permitted. Based on the composition of the Company’s financial assets, current market conditions and historical credit loss activity, the adoption of this standard is not expected to have a material impact on the Company’s condensed consolidated financial statements. In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its condensed consolidated financial statements.

XML 33 R23.htm IDEA: XBRL DOCUMENT

Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Property and Equipment

Property and equipment consist of the following (in thousands):

	As of September 30, 2020			As of December 31, 2019
Leasehold improvements	$	3,174		$	3,161
Research equipment		3,499			3,442
Furniture and fixtures		350			350
Computer equipment		273			214
Property and equipment, gross		7,297			7,167
Less: accumulated depreciation and amortization		(6,809	)		(6,573	)
Property and equipment, net	$	488		$	594

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	As of September 30, 2020		As of December 31, 2019

Accrued clinical trial cost	$	2,278	$	3,252
Accrued payroll and related benefits		420		262
Accrued consulting and legal		180		79
Accrued interest		94		-
Accrued other		21		77
Accrued expenses	$	2,993	$	3,670

XML 34 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements of Financial Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy

The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):

	As of September 30, 2020
	Fair Value		Level 1		Level 2		Level 3
Financial Assets:
Cash equivalents:
Money market fund	$	626	$	626	$	-	$	-
Total Financial Assets	$	626	$	626	$	-	$	-

	As of December 31, 2019
	Fair Value		Level 1		Level 2		Level 3
Financial Assets:
Cash equivalents:
Money market fund	$	1,464	$	1,464	$	-	$	-
Total Financial Assets	$	1,464	$	1,464	$	-	$	-

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

Convertible Debenture (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Schedule of Senior Secured Convertible Debt

The senior secured convertible debt comprises the following (in thousands):

	As of September 30, 2020			As of December 31, 2019
Senior secured convertible debenture	$	8,531		$	-
Unamortized original issuance discount and debt issuance costs		(641	)		-
Total convertible debt	$	7,890		$	-

XML 36 R26.htm IDEA: XBRL DOCUMENT

Common Stock Reserved For Issuance (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Common Stock Reserved for Potential Future Issuances

Common stock has been reserved for the following potential future issuances:

	As of September 30, 2020		As of December 31, 2019
Shares underlying outstanding stock options		891,748		579,731
Shares available for future stock option grants		208,395		230,952
Exchange of Vaccinex Products, LP units		1,154,935		1,173,500
Conversion of VX3 units		1,318,797		1,318,797
Total shares of common stock reserved		3,573,875		3,302,980

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity and Related Information

A summary of the Company’s stock option activity and related information is as follows:

	Stock Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (in thousands)
Balance as of December 31, 2019		579,731		$	8.04		7.0	$	120
Granted		324,300			4.50
Exercised		(3,783	)		5.11			$	3
Canceled		(8,500	)		8.10
Balance as of September 30, 2020		891,748		$	6.77		7.3	$	-
Exercisable as of September 30, 2020		569,724		$	7.75		6.5	$	-

Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions

The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

	Nine Months Ended September 30,
	2020			2019
Expected term (in years)		6.3			6.0
Expected volatility		75	%		75	%
Risk-free interest rate		0.9	%		2.5	%
Expected dividend yield		-	%		-	%

Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations and Comprehensive Loss

Total stock-based compensation expense recognized in the condensed consolidated statements of operations and comprehensive loss is as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development	$	37	$	26	$	96	$	72
General and administrative		54		111		565		237
Total stock-based compensation expense	$	91	$	137	$	661	$	309

XML 38 R28.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Options to purchase common stock		850,716		604,599		742,797		527,573
Contingently issuable common stock upon exchange of Vaccinex Products, LP units		1,163,141		1,198,111		1,170,047		1,199,906
Contingently issuable common stock upon exchange of VX3 units		1,318,797		1,318,797		1,318,797		1,318,797

XML 39 R29.htm IDEA: XBRL DOCUMENT

Company and Nature of Business - Additional Information (Details) - USD ($)					1 Months Ended					3 Months Ended		9 Months Ended
	Aug. 03, 2020	May 08, 2020	Mar. 27, 2020	Jan. 21, 2020	Sep. 30, 2020	Jul. 31, 2020	Mar. 31, 2020	Jan. 31, 2020	Jul. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Cash flow from operations												$ (22,265,000)	$ (24,912,000)
Accumulated deficit					$ 271,034,000					$ 271,034,000		271,034,000		$ 248,630,000
Proceeds from private offering of common stock					$ 2,000,000	$ 4,000,000		$ 7,500,000	$ 13,800,000			11,475,000	$ 13,800,000
Proceeds from capital contribution			$ 11,500,000
PPP Loan
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument interest rate		1.00%
Debenture maturity date		May 08, 2022
Amount of loan received		$ 1,133,600
PPP Loan \| Five Star Bank
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Amount of loan received		$ 1,100
Alzheimers Association
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Sale of stock, consideration received												750,000
Proceeds from the sale of shares												575,000,000
Open Market Sale Agreement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from the sale of shares										$ 12,300,000	$ 1,200,000
Open Market Sale Agreement \| Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock sold										3,815,600	317,688
Securities Purchase Agreement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Sale of stock, consideration received										$ 26,600,000
Debt instrument interest rate	7.00%
Debt instrument principal amount	$ 8,640,000
Purchase price of convertible debentures	$ 8,000,000
Debt instrument, discount rate	8.00%
Debenture maturity date	Aug. 03, 2021
Common stock conversion price	$ 9.4125
Stock Purchase Agreement \| Keystone Capital Partners, LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock purchase program number of shares agree to purchase												5,000,000
Proceeds from the sale of shares											$ 1,200,000	$ 300,000
Stock Purchase Agreement \| Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock sold				1,468,563
Stock Purchase Agreement \| Common Stock \| Keystone Capital Partners, LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common stock sold											324,424	47,319
Maximum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Sale of stock, consideration received												$ 113,000,000
Maximum \| Stock Purchase Agreement \| Common Stock \| Keystone Capital Partners, LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from the sale of shares							$ 5,000,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Summary Of Significant Accounting Policies [Line Items]
Grant revenue	$ 575,000	$ 575,000
Deferred offering costs	0	0
ADDF
Summary Of Significant Accounting Policies [Line Items]
Grant revenue	575,000	575,000
Keystone Capital Partners, LLC \| ATM Facility \| Additional Paid-in Capital
Summary Of Significant Accounting Policies [Line Items]
Deferred offering costs	$ 713,000	713,000
Vaccinex Products
Summary Of Significant Accounting Policies [Line Items]
Gain or loss from VIE		$ 0	$ 0

XML 41 R31.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 7,297	$ 7,167
Less: accumulated depreciation and amortization	(6,809)	(6,573)
Property and equipment, net	488	594
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,174	3,161
Research Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,499	3,442
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	350	350
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 273	$ 214

XML 42 R32.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Property Plant And Equipment [Abstract]
Depreciation	$ 74,000	$ 64,000	$ 237,000	$ 181,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued clinical trial cost	$ 2,278	$ 3,252
Accrued payroll and related benefits	420	262
Accrued consulting and legal	180	79
Accrued interest	94
Accrued other	21	77
Accrued expenses	$ 2,993	$ 3,670

XML 44 R34.htm IDEA: XBRL DOCUMENT

Fair Value Measurements of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) - Fair Value Measurements Recurring - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Financial Assets:
Total Financial Assets	$ 626	$ 1,464
Money Market Funds
Financial Assets:
Cash equivalents, Fair value disclosure	626	1,464
Level 1
Financial Assets:
Total Financial Assets	626	1,464
Level 1 \| Money Market Funds
Financial Assets:
Cash equivalents, Fair value disclosure	$ 626	$ 1,464

XML 45 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements of Financial Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2020	Aug. 03, 2020	Sep. 30, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Embedded derivative liability	$ 0	$ 65,000
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets, level 1 to level 2 transfers, amount	0		$ 0
Financial assets, level 2 to level 1 transfers, amount	$ 0		$ 0

XML 46 R36.htm IDEA: XBRL DOCUMENT

License and Services Agreement - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 27, 2020	Nov. 30, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
License And Services Agreement [Line Items]
Proceeds from capital contribution	$ 11,500,000
VX3 License Agreement
License And Services Agreement [Line Items]
Research and development, milestone payments to company		$ 32,000,000
Terms of license agreement upon termination					the Company will issue to VX3 or its designees the number of shares of the Company’s common stock equal to the lesser of (1) the aggregate of all payments made to VX3 by its partners divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of the Company’s common stock.
Base amount to determine issuance of common stock upon termination		$ 18.20
VX3
License And Services Agreement [Line Items]
Percentage of voting interest					90.00%
Proceeds from capital contribution			$ 0	$ 0	$ 0	$ 0

XML 47 R37.htm IDEA: XBRL DOCUMENT

Collaboration Agreements - Additional Information (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 30, 2017 TargetAntigen	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue		$ 50,000	$ 404,000	$ 50,000	$ 523,000
Surface Oncology, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of target antigens against which antibodies are to be identified and selected \| TargetAntigen	2
Service fee payments/revenue		0	4,000	0	123,000
Revenue			400,000		400,000
Surface Oncology, Inc. \| Exercise of Product Option
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue			300,000		300,000
Surface Oncology, Inc. \| Exclusive Product License
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue			$ 100,000		$ 100,000
Annual maintenance fee		$ 50,000		$ 50,000
Surface Oncology, Inc. \| Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Term of research program	9 months
Surface Oncology, Inc. \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Term of research program	12 months

XML 48 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		24 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Oct. 31, 2022
Commitments And Contingencies [Line Items]
Royalty payments, percent of net sales			1.00%
Monthly rental payments	$ 14,000		$ 14,000
Future minimum operating leases payment in 2020	43,022		43,022
Future minimum operating leases payment in 2021	174,132		174,132
Future minimum operating leases payment in 2022	145,110		145,110
Rent expense incurred under operating lease	$ 42,000	$ 42,000	126,000	$ 126,000
Scenario Forecast
Commitments And Contingencies [Line Items]
Monthly rental payments					$ 14,511
Contract Termination
Commitments And Contingencies [Line Items]
Termination payment			$ 25,500,000

XML 49 R39.htm IDEA: XBRL DOCUMENT

Long-term Debt - Additional Information (Details) - USD ($)		9 Months Ended
	May 08, 2020	Sep. 30, 2020
Debt Instrument [Line Items]
Interest expense		$ 113,000
PPP Loan
Debt Instrument [Line Items]
Amount of loan received	$ 1,133,600
Maturity date	May 08, 2022
Annual interest rate	1.00%
Payments commencement date	Nov. 08, 2020
Accrued interest		5,000
Interest expense		$ 5,000

XML 50 R40.htm IDEA: XBRL DOCUMENT

Convertible Debenture - Schedule of Senior Secured Convertible Debt (Details) - Senior Secured Convertible Debenture $ in Thousands	Sep. 30, 2020 USD ($)
Debt Instrument [Line Items]
Senior secured convertible debenture	$ 8,531
Unamortized original issuance discount and debt issuance costs	(641)
Total convertible debt	$ 7,890

XML 51 R41.htm IDEA: XBRL DOCUMENT

Convertible Debenture - Additional Information (Details) - USD ($)			3 Months Ended	9 Months Ended
	Aug. 03, 2020	Jul. 30, 2020	Sep. 30, 2020	Sep. 30, 2020
Short Term Debt [Line Items]
Embedded derivative liability	$ 65,000		$ 0	$ 0
Interest expense				113,000
Senior Secured Convertible Debenture
Short Term Debt [Line Items]
Debt instrument principal amount		$ 8,640,000
Purchase price of convertible debentures		$ 8,000,000
Debt instrument, discount rate		8.00%
Debenture maturity date	Aug. 03, 2021
Debt instrument interest rate	7.00%
Common stock conversion price	$ 9.4125
Debenture redemption percentage	115.00%
Percentage of funds used to redeem outstanding debentures	20.00%
Payments under mandatory redemption provision			116,329	116,329
Embedded derivative liability			0	0
Annual effective interest rate	16.54%
Interest expense			210,923	210,923
Change in fair value of derivative liability				65,000
Senior Secured Convertible Debenture \| 3i
Short Term Debt [Line Items]
Fees paid in connection with issuance of debentures	$ 50,000
Senior Secured Convertible Debenture \| Effective Interest Method
Short Term Debt [Line Items]
Embedded derivative liability	65,000
Fees paid in connection with issuance of debentures	50,000
Original issuance discount	640,000
Senior Secured Convertible Debenture \| Interest Make-Whole Feature
Short Term Debt [Line Items]
Embedded derivative liability	$ 65,000
Senior Secured Convertible Debenture \| Principal Repayments
Short Term Debt [Line Items]
Payments under mandatory redemption provision			108,719	108,719
Senior Secured Convertible Debenture \| Accrued and Make-whole Interest
Short Term Debt [Line Items]
Payments under mandatory redemption provision			$ 7,610	$ 7,610

XML 52 R42.htm IDEA: XBRL DOCUMENT

Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) - shares	Sep. 30, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Total shares of common stock reserved	3,573,875	3,302,980
Shares Underlying Outstanding Stock Options
Class Of Stock [Line Items]
Total shares of common stock reserved	891,748	579,731
Shares Available For Future Stock Option Grants
Class Of Stock [Line Items]
Total shares of common stock reserved	208,395	230,952
Exchange of Vaccinex Products, LP Units
Class Of Stock [Line Items]
Total shares of common stock reserved	1,154,935	1,173,500
Conversion of VX3 Units
Class Of Stock [Line Items]
Total shares of common stock reserved	1,318,797	1,318,797

XML 53 R43.htm IDEA: XBRL DOCUMENT

Common Stock Reserved For Issuance - Additional Information (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Class Of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Vaccinex Products, LP Interests \| Common Stock
Class Of Stock [Line Items]
Limited partnership interests exchanged	18,565	4,455

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	Mar. 31, 2020	Jan. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total shares of common stock reserved			3,573,875			3,573,875		3,302,980
Weighted-average grant date fair value of stock options granted to employees and directors						$ 2.73	$ 3.35
Options granted						324,300
Aggregate grant date fair value of stock options vested						$ 719,632	$ 105,061
Total unrecognized compensation cost related to stock options granted to employees			$ 926,591			$ 926,591		$ 627,129
Common stock, par value			$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Stock based compensation expense			$ 91,000		$ 137,000	$ 661,000	$ 309,000
General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense			$ 54,000		$ 111,000	565,000	$ 237,000
Keystone Capital Partners, LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, par value	$ 4.00
Keystone Capital Partners, LLC \| General and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense						80,000
Keystone Capital Partners, LLC \| Stock Purchase Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issued under purchase agreement				$ 1,200,000		$ 300,000
Common Stock \| Keystone Capital Partners, LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issued for administrative fees	20,000
Maximum \| Common Stock \| Keystone Capital Partners, LLC \| Stock Purchase Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issued under purchase agreement	$ 5,000,000
2011 Employee Equity Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares of common stock		297,743
2018 Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total shares of common stock reserved			425,000			425,000
Percentage of total shares of common stock reserved						2.00%
2018 Omnibus Incentive Plan \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of voting power of all classes of stock to be owned by optionee to determine the exercise price						10.00%
Exercise price as a percentage of fair value of common stock on grant date if optionee owns stock representing more than 10 percent of voting power of all classes of stock						110.00%
Employee Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost related to stock options granted to employees, weighted-average recognition period						2 years 11 months 15 days		2 years 4 months 20 days
Employee Stock Options \| 2011 Employee Equity Plan \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, expiration year						5 years
Employee Stock Options \| 2011 Employee Equity Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, expiration year						10 years
Employee Stock Options \| 2018 Omnibus Incentive Plan \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, expiration year						5 years
Employee Stock Options \| 2018 Omnibus Incentive Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, expiration year						10 years

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options, Balance \| shares	579,731
Stock Options, Granted \| shares	324,300
Stock Options, Exercised \| shares	(3,783)
Stock Options, Cancelled \| shares	(8,500)
Stock Options, Balance \| shares	891,748	579,731
Stock Options, Exercisable \| shares	569,724
Weighted-Average Exercise Price, Balance \| $ / shares	$ 8.04
Weighted-Average Exercise Price, Granted \| $ / shares	4.50
Weighted-Average Exercise Price, Exercised \| $ / shares	5.11
Weighted-Average Exercise Price, Canceled \| $ / shares	8.10
Weighted-Average Exercise Price, Balance \| $ / shares	6.77	$ 8.04
Weighted-Average Exercise Price, Exercisable \| $ / shares	$ 7.75
Weighted-Average Remaining Contractual Life (Years), Balance	7 years 3 months 18 days	7 years
Weighted-Average Remaining Contractual Life (Years), Exercisable	6 years 6 months
Aggregate Intrinsic Value, Balance \| $	$ 120
Aggregate Intrinsic Value, Exercised \| $	$ 3
Aggregate Intrinsic Value, Balance \| $		$ 120

XML 56 R46.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) - Employee Stock Options	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 3 months 18 days	6 years
Expected volatility	75.00%	75.00%
Risk-free interest rate	0.90%	2.50%

XML 57 R47.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 91	$ 137	$ 661	$ 309
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	37	26	96	72
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 54	$ 111	$ 565	$ 237

XML 58 R48.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0	$ 0	$ 0
Unrecognized tax benefits that would impact effective tax rate	$ 0		$ 0		$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 59 R49.htm IDEA: XBRL DOCUMENT

Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average common stock equivalents excluded from calculation of diluted net loss per share	850,716	604,599	742,797	527,573
Vaccinex Products, LP Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average common stock equivalents excluded from calculation of diluted net loss per share	1,163,141	1,198,111	1,170,047	1,199,906
VX3 Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average common stock equivalents excluded from calculation of diluted net loss per share	1,318,797	1,318,797	1,318,797	1,318,797

XML 60 R50.htm IDEA: XBRL DOCUMENT

Segment and Geographic Information - Additional Information (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2020 BusinessActivity SegmentManager Segment	Dec. 31, 2019 Segment
Segment Reporting Information [Line Items]
Number of business activity \| BusinessActivity	1
Number of segment managers held accountable for operations or operating results \| SegmentManager	0
United States
Segment Reporting Information [Line Items]
Number of reportable segments \| Segment	1	1

XML 61 R51.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Details)			1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 09, 2020 USD ($) $ / shares shares	Jan. 21, 2020 USD ($) $ / shares shares	Nov. 30, 2017 TargetAntigen	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Dec. 31, 2019 shares
Related Party Transaction [Line Items]
Rent expense incurred under operating lease				$ 42,000	$ 42,000	$ 126,000	$ 126,000
Revenue				$ 50,000	404,000	50,000	523,000
Gross proceeds from issuance of common stock						$ 17,000,000
Common stock, shares issued \| shares				22,380,351		22,380,351		14,887,999
Dr. Maurice Zauderer
Related Party Transaction [Line Items]
Gross proceeds from issuance of common stock		$ 4,999,999
Common stock, shares issued \| shares		982,318
Chief Executive Officer
Related Party Transaction [Line Items]
Gross proceeds from issuance of common stock		$ 499,996
Common stock, shares issued \| shares		98,231
Jacob Frieberg
Related Party Transaction [Line Items]
Gross proceeds from issuance of common stock		$ 199,996
Common stock, shares issued \| shares		39,292
Stock Purchase Agreement
Related Party Transaction [Line Items]
Sale of stock, transaction date		Jan. 21, 2020
Stock Purchase Agreement \| Common Stock
Related Party Transaction [Line Items]
Aggregate number of shares issued \| shares		1,468,563
Shares issued, price per share \| $ / shares		$ 5.09
Gross proceeds from issuance of common stock		$ 7,500,000
July 2020 Stock Purchase Agreement \| Friedberg Global-Macro Hedge Fund, Ltd
Related Party Transaction [Line Items]
Sale of stock, transaction date	Jul. 09, 2020
July 2020 Stock Purchase Agreement \| Common Stock \| Friedberg Global-Macro Hedge Fund, Ltd
Related Party Transaction [Line Items]
Aggregate number of shares issued \| shares	1,126,760
Shares issued, price per share \| $ / shares	$ 3.55
Gross proceeds from issuance of common stock	$ 4,000,000
Surface Oncology, Inc.
Related Party Transaction [Line Items]
Number of target antigens against which antibodies are to be identified and selected \| TargetAntigen			2
Service fee payment received				$ 0	4,000	$ 0	123,000
Revenue					400,000		400,000
Surface Oncology, Inc. \| Exercise of Product Option
Related Party Transaction [Line Items]
Revenue					300,000		300,000
Surface Oncology, Inc. \| Exclusive Product License
Related Party Transaction [Line Items]
Revenue					$ 100,000		$ 100,000
Annual maintenance fee				$ 50,000		$ 50,000

EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
%NN\Z>^%R".;]L6UR&C-MQ M%7):A@S?"3EB=RJWJ6&W>0+)L7\;X=48PQW&:7@RX R*%NL&87 B7K?F MW'7QNN_$NQ$FELJL-+#[Q3'K1Y#=L+ ^Z)YCJB\;MAK=(/ Z[6BP-M!3[RS M;F,P['KG7M3JD'?7NZ9U)'T:-B)T.,>(G> 5 %2OK1!4$O:&HTYCT!MBC'YK M,$ $7;QM[I:BNGO?-^HC^K"'#H/6(,( $?F>T&)4:S$ZJ1#'GMW0!G_F0E=[ MBR!NLT*J+<"11+&ZC169$\9W0XF;2HZ=9!:G"MM&9=6D?-/'.Y4 M3:;LCKY MN]Q/#$JS#/J6KD^BIC/KPA0\ABL?#R4#>@W^^ GUO71T$J*S(#KK'1W8T3E4 MO&$;W'&H*:T<)?Z*5&G;+"I2V9X45519#?1ALZ/(*XI\3_'"^Q,I'+7(XS1[ M+LU.J;:&!!9T[FV[(6^JB8?BO8&ZP5UJB06+(>BN)3>7D4YKFYT$A5 MH*YQ=RS3R,X+6B/\&K;(IHZ08,$G@.6^%2 35.,G^K$3PNK7PNJ?%-:3LEC+ M[QXTA" WU )BM U3'@^ @P'DGF MN+&^ZFP7WE-*V3RAG8]K:W_WB&7#=9PZ2 FL<5 K"#&UN %>PCY>1G09A-X7 MR)&"=+8\P8%$T&E(DY47];P.-L:H'WDA.GYL)RDT-=..6ZK?=XTU&+TEN_;! ME).!7KI9SF#456[+@:=^6X^+DW)*VIN7L^8=UTL\09B$!;H&V$A]ILOYK7RP MJG STUQ9G,#<;8HC+V@RP.\+I>SN@1:HA^CQ_U!+ P04 " #0.VU1T-@5 MV#$# *!P &0 'AL+W=O-85N!8"2L9%F2?ALCT_M"B@R5AE=W]E2_G@6&BK!00=HEO&X3 MQB\DG,)'69E"PTV5878:'U#Q/8/XP. Z/@NXP?H"AJ$/<1B'9_"&O2)#AS=\ M >^&J8I7NV-%?BZWVBAJH%]G\$<]_LCACU[ _^X:!;,WRP=4U/4]&02) K6<**B;01S/6RS.$M%PVAP#,?D&FX*_ )WK,,EI7A;YPO M-3_@&DS*P/S!@'8.T9: = SQBL$,B:(?+C$X4:D(F9R)I+,F"2#*ZW99G=N")CN?5X*Y0 MB"<-!]0N!LLM9:">&7PBHN?.;4_1(YH>69]K6[BV5Z-N5%K03#A18' Y#OTD MF@PFX<@?3Z>#9!3[R309C./$'R?#P8KRD8[$0SP!U[IQ-^U$Q*8FDX0K&/E9 MC;ZQ-*5:'V&M9-:D1OMPNX:FXD8/(C^:#/UH%%EK>NE'D;.2T ]'B=N;^M-P M\G]Y?PS[+,/HTO$X:SUW0X*C^52BVKDIK"ES4YEV5/6[_:!?MO/MKWO[E_C( MU(Z3^ )S"@TODK$'JIV\[<+(VDV[K30T.YU9T,\*E76@\UQ*&PO=V]R:W-H965T)$L%TD QVG7-$YCU.CV,.R! MD6E;B"X>125-L1^_HXM%.Y)HN<4&OR22?+[#C^?P?#RB??84RX=D)81"7\,@ M2LY[*Z76;_O]Q%N)D">G\5I$\,DBEB%7<"N7_60M!9_GH##H$\MR^B'WH][% M6?YL*B_.XE0%?B2F$B5I&'+Y?"F"^.F\AWN;!Y_]Y4IE#_H79VN^%#.AOJRG M$N[ZE9>Y'XHH\>,(2;$X[XWPVSLVS "YQ>^^>$JVKE$VE?LX?LANKN?G/2MC M) +AJYZ(<1S\X<_5ZKSG M]M!<+'@:J,_QTP=13LC._'EQD.1_T5-I:_60ER8J#DLP, C]J/C/OY:!V * MGV8 *0'D)8"U &@)H%T!K 2PK@"[!-A= 4X)<+H"!B5@T!7@E@"W*V!8 H9= M =C:9,[J#*F27%3'W#J8AR':QX](Q[-T2>N4BE0O$"7 M:0)V28+>H-%\[F>%S -T'15RE)7UZRNAN!\DOX+)E]D5>OWSKV=]!80RMWVO M'/RR&)RT##Y*EZ?(HB>(6,1J@(_-\%O^C"RW%7VU#RU/$1FTPM^9X1]Y!'#< M"G]OAL_$^A11JQ7^VY[1TP#@[:-_Z#!W _RZP]P-\(^=R>-A _SFQT(WV3=Z M9(3?_MCHGSK#&^=^9X9?":\M='VH_*K\257^)/='6_S=R26/_&]%38_C*(D# M?U[N]'//)\T((9/!30)J@$_3D!I^@:;I._#)1H18GF ME%B;(O%DA1;0MJ"%C$,$C9#,QT^:/&&$.+8E@6Y>=Q.2Y,E M&V*R;;G#EU5\F9'OR//2, T@'/.L+_$]7S7) :N-3P;8HJS&]*:SY6UA:>^W MO&OPR5R'6JVSMZO9V\;93V7L"3%/BF2MI?\(@8 M9"&D'RVSO<2+PQ!6#^QE MWD-38.PZ-3UG;Y)[\].H5[&#$Q&VKA\1F"0SC%&(%Q1[ PH"W M1D_ .]^\D1MN6):4.FVK$NN=#)-.ZQ+] POE461K1*)+'CV8IJ@W)4R/9:EB MO?/@/5O/ 7&O[P 8MP9=JS\VR_\H^+82?BAD@D9)$L.,ZW*TZUJ+'G:.)N): M^[!9_&8\R%^0\MWL)-/@Q)^7#8HI_K>E7[NV+;5D0$LH=@_8'-1*H&3#<<4A M1HUDW!H9N]PDV_AH_<1FQ;M;BPC!^\6#4"B/UF@I19X.4[NJ99!8Q[(JB-8_ M8M:_[\C!#6D00D(;^H])HZ4A5V2K^3=+9GNN0$3'1=\VJ_=MNZ-I"25'(Z%$ M2R@Q2^BG-+P7\F6?BH!;4QG?D'K+35UL._6D-1CB@>.Z+3G3BDO,BCL37K;[ M^R)!TU1Z*YYT+#$MO.1HA)=HX27_C?#>E'YWWB\LM&SVL8G)QMK3:D[WG"$VZ(36QUGI/S?IL6&\=FR6J%9P.CV5U,2WDS"SDAS5+[TIO.R=G MS'%MA[:8?[>@P/6=(Y+33+, MM PSLPR748DO=O('VM[[ SWZ5 ^_D M2VA-42 6@+1.![#B9?%#E^)&Q>O\._W[6*DXS"]7@L."R@S@\T4&PO=V]R:W-H M965TBO$G,0>0Z#E-J.A; M!V] 8_% 8"4J:Z1#>63L26_&4=]RM")(()2: JO;$D:0))I) MZ?A3D%JE3PVLKM?LUR9X%0AP!(/>IRM$-?6BDTO3#(-6H5/J*[[5'+UE"B<'$SS>B,6HRF941*3 M$%.)AF'(%E02.D,3EI"0@$"?T3"*B*X63M"8YN^.Y M47IN&,^- YZ_<.V(PQ+H O:]%SF\9>"Z32T'S7;3<532EM5T'S7;4M0B:DV*^4GCOO*W[G5&,2-75)IA+"ERLL&L>MMO6ZFVT>K5:'W 8JJ-G-.$L6H2[*K=9-PW2_>@.Z6Y:I'ND M1ZH!#3&.$B8$BCE+T#Y#)9O),O,5/+(I)IQ MS'*NYE;@VD ]CQF3ZXUV4$["@W]02P,$% @ T#MM40:!_M R P P@L M !D !X;"]W;W)K&ULM5;?3]LP$/Y7K(@'D(#$ M2=JTJ*T$[="0F%31L3U,>S#IM;%(XF [%/;7SW;2I#]"8!-]:6SGOKOOOIXO M-U@Q_B@B (E>DC@50RN2,KNP;1%&D!!QSC)(U9L%XPF1:LN7ML@XD+D!);'M M.D[73@A-K=' G$WY:,!R&=,4IAR)/$D(?[V"F*V&%K;6!W=T&4E]8(\&&5G" M#.1]-N5J9U=>YC2!5%"6(@Z+H76)+\8XT !C\8/"2FRLD4[E@;%'O;F9#RU' M,X(80JE=$/5XAC'$L?:D>#R53JTJI@9NKM?>KTWR*ID'(F#,XI]T+J.AU;/0 M'!8DC^4=6WV%,J&.]A>R6)A?M"IM'0N%N9 L*<&*04+3XDE>2B$V -A_ ^"6 M />C *\$>";1@IE):T(D&0TX6R&NK94WO3#:&+3*AJ;Z;YQ)KMY2A9.C*Q*3 M- 0T,S4S9DG&4DBE0&=HRE6Q><(M=QG0;XN!T^@5#! ML8;C_C;<5GI4HKB5**[QY[WAK\I\JL21Z'(K_U^WRAK=2$C$[Y987A7+,['\ M]V)IE6$=Y10M.1.-2A;NNL:=OJ3/H\#M!P/[>5.O!B/4PDS-5U4:TCI*2XD(H_21B7](\Y:.)>!.ALT#KK]IS^#ODFJT[@ M-;/O5.P[_Z5S"K*):6>/@]_K[?#L.AH-/%CS8^PJZ&Y^14O &([S;Q>V- 4M/M]$7])4H!@6"N6< M!TI^7@R,Q4:RS,Q<#TRJ"Z#&N&MM'?P%02P,$% M @ T#MM4&ULI57+;MLP$/P50N@A =KHF3@Q; &VY:(Y!#!BI#T4/=#2VB)"D0I)Q\G? M=TG)JAL_8+07B8^=&>YJ.1ILI'K6)8 A;Q47>NB5QM1]W]=Y"1755[(&@3M+ MJ2IJ<*I6OJX5T,*!*NY'07#C5Y0)+QVXM9E*!W)M.!,P4T2OJXJJ]S%PN1EZ MH;==>&2KTM@%/QW4= 5S,$_U3.',[U@*5H'03 JB8#GT1F%_FMAX%_"=P4;O MC(G-9"'ELYW<%T,OL <"#KFQ#!1?KS !SBT1'N.EY?0Z20O<'6_9O[K<,9<% MU3"1_ XC!J:#I3< M$&6CDD MG-R+IB/MI[W(P%#&]26&/,TSQQ)T=8BV=1A')PGG4%^1./A,HB *#IQGNL0UW4H&\:]I+@@!+]+K[;?:C;O:CLOVH*.[MA4WW MP\+;<#>L2=3?N7,5J)4S.TURN1:FJ72WVOGIR-G(A_5QV)^$!]8S]-_&+O_0 M-^;]0-6*"4TX+%$JN.JA):C&$)N)D;6[\0MIT#_F?/!] MG>904'TO2Q XLY&JH :[:NOK4@'-G*C@?A@$L5]0)KSIV(TMU70L=X8S 4M% M]*XHJ'I[!"[W$Z_G'0>>V#8W=L"?CDNZA168YW*IL.#VT:#)[0(,95S?H>'S:D%N;^[(#6&"_,SE3E.1Z;%OD,]&\=.: MY;%B"2^PK*"$U'PB81!&'3(YQ_+%Y"BO&?EO=%[N8]5:4H3-J4)G;_H@K\E M?:-KCKG.1%85@')-_LS6VBC\;9LPOH [:' 'UY55"HW'F8FM(^:PI;P+<]!" MZ W/,=LVR:B;,FXHXZLHF3"@H'O%XU;44;\[:M)$3:Z**DT.JBMDTEZ/WEDM MVB9)TDTU;*B&5U%!?;]T@0W;NW\TBL[0VD91G 1GN3XSL>+1[+,E'GAQE&!ES #]5P\"#US&Y64Y, DX0P)6(R<&_]Z[ >&8!$O M!-9R:XQ,*G/.7\WD9SIR/!,14$B4D<#ZL8(Q4&J4=!QOM:C3_*9W,'$L8<_J;I"H;.5<.2F&!2ZH>^?H.ZH0&1B_A5-I?M*ZQGH.24BJ>UV0= M04Y8]<3OM1%;!+_?0@AJ0O!=0J\F]&RB560VK0E6.(X$7R-AT%K-#*PWEJVS M(::EV\)YA*04@K"EQCS/ M)NCTY R=(*WXE/%28I;*R%7:#I.4F]2IWU:I!RVISZ"X0#WO' 5>X!V@C[OI M$T@TW3=T?[A+=W41FDH$324"J]=KJ\07\ZX[-'N-9L]J]ELTG[C2>E^5#UE5 MZ816QWSZJS@,PLA=;?NQC_'[8;\![438;R+L=T9XSQELT#T6KWK+FI9[A=P1 M'32B@Z-9&3::86>@8RPS!&\E66%J6O*\ZM65[=64R(1RTZZ'O*V$!YW>[F/: MO;UL0K[L#+GZ]/R.Y*\:I:NC&3IL-(='ZLWA-_S;Q[3[YWN?FZ/W'0?1'_1/ M?>IO[;[^T8SU/W<2/_A?O5HK=V\$!T 'W':W3B5S)=#F+0F3B,)"T[R+2UTM M49VRU43QPAY4'F;Z9@# O;[@7'U,S-G7W'7BOU!+ P04 " #0 M.VU1"$KU:*4" "]!P &0 'AL+W=O8\?OP?LR4:J)[T",.2YX$)/O94QY;GOZW0%!=4]68+ F5RJ M@AKLJJ6O2P4TYO]RNT=][*@ M&BXE_\$RLYIZGSR204XK;N[EYBLT^QG:?*GDVCW)IHD-/))6VLBB$2-!P43] MIL^-#SN"_N" (&P$X;&"J!%$QPH&C6#@G*FWXGQ(J*'Q1,D-438:L]F&,].I M+>%) H8RKD\QY&&>D),/IQ/?(*-=R4\;GHN:)SS ,X>R1Z+@C(1! M&+PAO^R6SZIECP3107ER].K]S_MR'XUMW0U;=T.7+WK?W9G6@.[-1$9N&%TP MCA:"WEJ;D>^"W$-:*<7$TD5]DT*U Q=4,TU^WF!^W2E>G&[ET]CQ9Q^CQ>K,AD'P&K7'.6@Y M!YV^OZ0KHH;W=\Y*>['= M4K5D0B-(CIJ@-T9O5'U9U!TC2W=\+J3!P]@U5WB_@K(!.)]+:;8=>R*W-W;\ M!U!+ P04 " #0.VU1KQP\!=(# !\# &0 'AL+W=O>Z5Q_/B(.232@$T^9)G7"V=5.OB MG>NJ*(68YE<\WD(G#TO&=X\8C2U)M-MS5HJ );$%_+!XDKMR6)68Y<,4$)Q+V M2^?:?W?G!P9@)3XQ.*C.,S&N[(1X,HO[>.EXQB+((-*&@N)7!6O(,L.$=GQN M2)U6IP%VGX_LM]9Y=&9'%:Q%]BN+=;ITY@Z)84_+3#^*PX_0.#0U?)'(E/U/ M#K5L.'-(5"HM\@:,%N2,U]_T2Q.(#L"?G $#2 X%S!N .-S 9,&,#D7,&T MT[\!YMX)P*P!S,[5$#: T":KCJY-S89JNEI(<2#22".;>;#YM6C,"..F%+=: MXEN&.+WZP"*L*R"4QV0+LL*E(M>)!,!ZT^1[AO\LJA$9 M>P;NASWPS3!\"\41WJO]_=EP_ZH'?OO?M-_]:^TNED!;!T%;!X'E&[]2!]?] M=?#[!Y0G]QIR]<> MG&K;6RU34YH>Y B H@5V4N1DX@63&-]18)KR7:E*;"^ M8JHY9Y;3M-AJY?M3S_PMW*K'FDEKS630FD^_C4GK_]'E 2^G+>_T*\1TUFJ; M#7KQ" JHC%)[E&.H\)8IC)ZWV#8RP$:"R@KZ;+84T0*CG1>4/_<=N]D_ CT. MO(% AZV)X:")OX#,%1%[DAV[3AN,LL"FHO$]X_1$_F^'R74*9%W[A#TTRPA3 MJ@3CJB+PN<1:15HCB8%5-<.%?VEW:((^)52#V:1H1AOSG,:M.;MG:TY!I>8@T2Y6 ML1ABL__&GX\"SV;Q(J@Y\64/^$MPSRF!=ZYQWVP!&K+\RKUI+ MKUYK 0/^^M[+;>I]A2/O=VYO?[B1@D2%&H=&$\I*:,83PCA&$$]\[Z4TS'?E MC3SOVR'37BX4/_C_>_RF(>WVGI>FTUS+KXK.-0FS_LAYUZX46A9VT=D+CW&8?4_QY -((X/N]$/JX,,-;^X-C]2=0 M2P,$% @ T#MM4;1RDSXI! #A( !D !X;"]W;W)K&ULS5C?;^(X$/Y7+'0/>])>$YL?+14@T0*Z2MMNU79W'T[W8)(! MK$ULSG:@E>Z//]L)"91@N-X]T(=B._.-Q_.-9VSWUD+^5 L C5[3A*M^8Z'U M\CH(5+2 E*H+L01NOLR$3*DV73D/U%("C1TH30(2AIT@I8PW!CTW]B@'/9'I MA'%XE$AE:4KEVPTD8MUOX,9FX(G-%]H.!(/>DL[A&?2WY:,TO:#4$K,4N&*" M(PFS?F.(KR>$6("3^,Y@K;;:R"YE*L1/V[F+^XW06@0)1-JJH.9G!;>0)%:3 ML>.O0FFCG-,"M]L;[1.W>+.8*55P*Y(?+-:+?N.J@6*8T2S13V+].Q0+:EM] MD4B4^X_6A6S80%&FM$@+L+$@93S_I:^%([8 Y/( @!0 \AZ #P":!:!Y*J!5 M %JG MH%H'TJH%, .L[WN;.&$82.A62.IZ'AD+;A[6,OX M?[%E\E]MV7%ZLPS9IE/;/!ZR*T!#*2F?%T$[Y#%Z$#PZ)(%>3%-1E]04^N.+ MT8SN-*3J3X]=K=*NEK.K=<"N)U@!SZ".^1S8<4";ZU>#=FC^>L%JF]E]J5;8 MVA,;GZ1L4B-%FMMB.VMLEVML>]?XG,D9C0!]M3X6\[?/)C5$%Q[G=4K%G;,B M];*TZ]*[X(F\SN:NRH5<^9D#N6*&N1D 6M(WY]I M'@[9JST#WH?KOD1-L!Y5,]F7P)Y [9;+[7YP,XZZM7;O;:"C8CMVX; JN.$' MMI")B?$KR(@IL,'V*$6<11I]7=JH]L0QWBKT^*QV&":59>2C7!7(;1::=60= ME]NUK:HUN/E1MJ(D4]91&ZZ^F.W%%?A<4I42W#HOLJH"@/T5P$=6>Z_FX%JR MCLKMVE;5$-SQVC;D/#.G57NATL IS]-=[3FS?C?T')$%28>7H*MZVH*YB!D'Q84 MBD3&=7X-*$?+QXNAN[*_&[_%UR-<,S[&UY/\::)2G[^4W)MSESFUH01F9JKP MXM*D(ID_/N0=+9;NLCP5VER]77,!- 9I!&PO=V]R:W-H965TLLSKH;.2NOUG>NJ9$5S MHF[$FG)XLQ R)QJ&A/AA!H_IT/&,(IK11!L7!/Y>Z81FF?$$.OZIG#HU MIP$>/N^\S^SB83$O1-&)R/YDJ5X-G5L'I71!BDP_B\UOM%J0%9B(3-E?M"EM M>Y&#DD)ID5=@4) S7OZ3MRH0!P!\#N!7 /\4$)X!!!4@N)8AK #AM0Q1!8A. M ?$90%P!8AO[,E@VTE.BR6@@Q09)8PW>S(/]7!8- 6;<9-9<2WC+ *='$Y'G M3$.J:(4(3]%$<,WXDO*$485^1?=IRDP*D P]\C*134)\G%)-6*8^@IS3]0T*O,_(]WRO1=#D:CCNM\7CY]@??HY]U@W_/=$ QY;=[XAE M4&=F8/T%5V3F?2,S__H"YNA1TUS]W4$6UF2A)0O/D#V++1\Z]$6UOJC3C\W3; NUG&O8BCN9;7NN=!1; M1^9<>1WAT/,@'UX/95^R.E(9URKC3I6S0A>2FC+%\B)'K:\/][9I/ID?X[L);IF?XKN'\G*P=U_>5;X2N61 )5W8YI[6;;_ MY4"+M6U77X2&YM<^KN#*1*4Q@/<+(?1N8 CJ2]CH7U!+ P04 " #0.VU1 MPY:H'KL" =" &0 'AL+W=OICV8Y )1$YO9#I2_W[43,C0E MWL.T%V([/N>>>W*OS>@@Y*O: FCR5N1F(''-^LA2R8 MQJG<^&HG@:465.1^2&GL%RSCWF1DUQ9R,A*ESC,."TE4611,'A\@%X>Q%WBG MA>=LL]5FP9^,=FP#2] ONX7$F=^PI%D!7&6"$PGKL7F/1F$W& MS6=<:HEO,\3IR:/@FVL-LB S6&ER3>[3-#,&LYS,>54FQNZ+&6B6Y>H2M[PL M9^3BP^7(URC T/A)'>RA"A9V!'MB1T*'5R2D(6U!3]WH)>QZ)*)M0N89"_7#01PU]9.G['?1SCK:"T@3>L.<4 MM"5<,<26P33 M%Z)$5K$F.>K%8R$!;.JTK;+B-JNBN,NKFT;!C5/!$].ES/21I$RW?:*'O\&/ M9'CU_MT[K,G08Q[C56N]@WH[Z.+NLU*$EE"VKC5>J14%(.SNAET-EAP M=FH&_]S<-47L#NV?G=WFXGQB&UL?91O;]HP$,:_BA7U12NM M30C0=E6(M!9-J[1)56FW%]->F.0@5AT?LR_0[=/O[(2,=< ;XC]WCW_WF'.V M0?OB*@ 2K[4V;A)51*N;.'9%!;5T%[@"PSL+M+4DGMIE[%869!F2:AVG27(9 MUU*9*,_"VH/-,VQ(*P,/5KBFKJ7]=0L:-Y-H$&T7'M6R(K\0Y]E*+F$&]+QZ ML#R+>Y52U6"<0B,L+";1A\'-[=C'AX"O"C9N9RQ\)7/$%S^Y+R=1XH% 0T%> M0?)G#7>@M1=BC)^=9M0?Z1-WQUOUCZ%VKF4N'=RA_J9*JB;1=21*6,A&TR-N M/D%73P L4+OP*S9=;!*)HG&$=9?,!+4R[5>^=C[L)*2# PEIEY &[O:@0#F5 M)//,XD98'\UJ?A!*#=D,IXR_E!E9WE6<1_D=FC584G,-8@IS,-18$.=BQK=? M-KR("S$#H]#RI^"]4KQ)(7$Z!9)*NS.?=S2VDS\1RHBG"ALG3>FRF+@0CQ,7 M'?1M"YT>@)[!ZD(,DW385IR=G_ZK$;$/O1=I[D0;9X0'94,R]<60; M_MN1^/Z9 \0]0>U^')$?]O+#(#\Z2!VL<9TUQ8XUY=::?5ZTJI=!U??8.K\> M#P=9O-[#,NI91D=9GHVLD0__S2!HU5(9J85RKI&F8!SE"FS8 ;X>ST9_MPIT MM/?&VO/&.Y3GEZ,#E..>Y^!6%L0 NDMD19ME,D!A([03.LF)&LZ\.P!UJZ MMHE(I$92=@+LQX^495&.9YE[S8=E5+9 MIUY/1BM(B>SR#)C^LN B)4H_BF5/9@)(7 BE20][WJ"7$LHZXXOBW4R,+WBN M$LI@)I#,TY2(YVM(^.:RXW=V+^[I #U-9L)_=2K4&*: I.4 M,R1@<=FY\C_=! ,C4*SXD\)&UGXC8\J<\T?S2H=41/0.,T"N!3 +P7Z1P2"4B X M5:!?"O1/%0A+@<+TWM;VPG%3HLCX0O -$F:U1C,_"N\7TMI?E)E$>5!"?Z5: M3HTGG*U!*#I/ $UA#DSE M!'=!7'U$22).B.;?/1Q/7]%!2AB?R@EWQ]F*+W M/W^XZ"FMAT'K1>6>U]L]\9$]K_)E%WG!&<(>]AK$)V[Q7_.DBP+OJ/C4+?X MF5/\YG^+][3OJP#@*@"XP N.X:VX4.@/$*GQOT)__:87H#L%J?S; 1]4\$$! MWS\"?Y/.(8XAUL4CZ)J8JD0))7.:4/7<%+HMW*" ,RRS'@]"S].6KNLN/ESU M8L6-:\6>)?W*DK[3DCNF0(!4")XT2TIH"MT6(:QMZOM!7?N]G<-JY]"Y\P,P MR@5Z@$C71HP:2\81JD&US> M,F%8P0^=5A28E$DE!#$T:#O'77HJ%)EY%1EEHMHI=G=Z! !X@L4U7P:[WPJFU0:':KD><=5 M.J]4.G^-=\Y03&5DW(($44VY-G'CC;J>]XLC:KYG"=IKTZQD9#O=.D1KUVWX W;W&9IU<=.I E/4]VP M= .-'LOT*H:;(N4:-=OB#6N9==[M^SAL3BS?,K#OIF ;0,T>D&9%(\U 1/JM MGL4:=7$C^G[8YB?+JKZ;5F>5(J8.%SF+)*&CZ3J7[.MIVX;O[AM7C.6Z2MZ_:5M)W%=[>"R8JPI7$;6A J MT)HD>5%K)\;]IH2O*[8_DNW/G;:Q8'<[.&6L0?^B@+JF7-LIL/\6TPVNS=%N MPK\%D"@C-#:>UH3/RJ/HAJH5HE+FA$6EWUT45NY2'S#"X^,%MET NSG[1&_? M5&56Y?874"L>NWQDR1[WWR0(EI:QFY9??=S A_3J2F[+KMC-KC\J&PX)U94- MEE2QFP-_%W1)S>&Z4F4W;S9J,3QTDF,,QY8_L9L_3TQ*FXKD$3Y^6W']_19( MR[D'6X;$YV]R!K94%[BI[O6G8*_E&+ROB&7!P#W?GNCP674VNX>LG'1_.6-QKZ+^>R]G7[%EB.#-Q#ZHDANHHBD>OOVL!M M66R*LMB5BLN9EDV#\$VB95DR<+/D]T=K<% GPX%_=_N@>%9<;,ZY4CPM?JZ :$/, OU]P;G:/9B[TNKV M??P?4$L#!!0 ( - [;5&=ZQUR&0, +@* 9 >&PO=V]R:W-H965T MV M+>(4"B+.V1*H.IDS7A"IMGQABR4'DAA0D=NNX_3M@F34&@W,MPD?#5@I\XS" MA"-1%@7A+U>0L_70PM;KAX=LD4K]P1X-EF0!4Y"/RPE7.[MA2;("J,@811SF M0^L27XRQKP$FXBF#M6BMD4YEQMBSWMPF0\O1BB"'6&H*HOY6,(8\UTQ*Q[^: MU&KNU,#V^I7]QB2ODID1 6.6_\H2F0ZMT$()S$F9RP>V_@YU0D9@S')A?M&Z MCG4L%)="LJ(&*P5%1JM_LJF-: %P[PC K0'N1P%>#?!,HI4RD]8UD60TX&R- MN(Y6;'IAO#%HE4U&=1FGDJO33.'D:,R*0KDYE2Q^1@\@@*\@05.O>( MNBDLSY'GG"'7<9T#\'$W_!IB!<<:CJ.W<%OYU)CE-F:YAL\[9E9.A$#W\]J) M/W?J'-U**,3?#G:O8?<,>^\(^T\FE8^558C-45RY+LQ=O';]D(<5K6]H];-= MC3P_\,+ ']BKMED'XCS'C4*GB7NCN]?H[G7JGE:*'VD"/'_)Z +=EU)(0A.] MKJRZ7^I'*SI<\IO;_!/4H-^P]T]3@_Z>MV&$@UZX4X+],#^( @\?KD#0J X^ M4H'+E7IO9):#>9KU@VS[C[YQ0F57%<+FQO $58@:]N@T58CV['6=T(MV'\*! M,,^)?/=P%;"S[:5.I^ZOFS@E= %:\Q.)8W6\01/.DC*6X@S=3=0CR3K]QZV^ MC4]0 ;QM==@]30UJWK:[&/N]R-NMPL' P/.=(_T(;QLI[NZD8T97P,VDH2OQ MVWO?]VVSP[U3^+YM;]@_D>_^OIT>#E5[V?7]_H\SE3XT*]T<-+,ZR._@-02P,$ M% @ T#MM49%'02"Y @ 1 < !D !X;"]W;W)K&ULM57?;]HP$/Y73M$>-JDC(2305H!48-.06@T5K7N8]N F!['J'YGM M )/VQ\]V0D8997W92V*?[_M\WYU]'FZE>M(%HH$=9T*/@L*8\CH,=58@)[HC M2Q1V9245)\9.U3K4I4*2>Q!G81Q%_9 3*H+QT-L6:CR4E6%4X$*!KC@GZN<$ MF=R.@FZP-]S3=6&<(1P/2[+&)9HOY4+96=BRY)2CT%0*4+@:!3?=Z]G ^7N' M!XI;?3 &I^11RB>C('(!(RT@:0")STPMQ>=A1@P9#Y7<@G+> MELT-?#(]VLJGPI5]:91=I19GQE/)N4W_TLCL">Y1H]I@#C:E,->Z(B)#> \W M>4Y=E0B#N:B/FJO9VQD:0IE^9UW>0 BZ( KU,#0V+L<>9DT,DSJ&^(48KN!. M"E-H^"!RS)_C0ZNG%17O14WBLX1++#O0BRX@CN+H1#S35\.[5R?@L_/P&686 MWCT%?Z:FUY:HY_EZ+Y6($:WA\ZHITK=;NPYS@UQ_/\.>M.R)9T_.'P#MN"^@ M) HVA%5XJHHUT< 3N7:R&4>=*(JZPW!SF-S7N2!99DT[ M6"B95YG1%W"[L*?6H#V:1L,O.#SQ9_+7;S?L_X?J#%KVP5DYMY138R^DK8L1 MJ'1!2Z"M&-QE!1'KXSM35ZLF3@_RV[U,^^E1L?[V2I(T/:I!>-!?.*JU[],: M,ED)4]_*UMH^!3>^ Q[9)]WK:=W1_]#4[\L=46LJ-#!<6='MJNF"9TR=BR7/ MX9>9D!G3\"KG7;64G,6%4I9V21#TNAE+\L[U9?'M25Y?BI5.DYP_2:166<;D M9L13L;[JX,[;AY^3^4*;#]WKRR6;\V>N?UT^27CK;JW$2<9SE8@<23Z[ZMS@ MBTD4&H5"XC\)7ZO:,S*AO CQU;Q,XJM.8#SB*9]J8X+!?Z_\EJ>IL01^_%D9 M[6S'-(KUYS?KGXO@(9@7IOBM2']+8KVXZ@PZ*.8SMDKUSV+]P*N (F-O*E)5 M_(O6E6S00=.5TB*KE,&#+,G+_]FW*A$U!;#C5B"5 ME7"(\HT$J!MATAK!3" MMB-$E4+45J%7*?3V%$COB$*_4NBW'6%0*0SV1S@6]+!2&!;3H<2O /^.:79] M*<4:22,-ULQ#,8,*;< \RN%0O=YS&.'_IU?GS;IC_WZPR;]28/_Q&.@"QAL@2!O0(R(U^(CD^>( MXC-$ A(X'+KUJ_^+Y5[U.[_Z,U^">G!4_;YA]%7N5?_<>G0\=('Y,>2,GR.8=.H]%H@^IR3VQ3?+Y9 M,QFCW[^ 2331/%-_>!P*MPZ%A4/A$8=^$1HH0)GA%!(S-!59!NXHPQS0[Q27 MK^X2+LU&A5G3=%^O:=2G@WYTV7VMH]M2;N*0HP$9#H*MW$Y\T3:^R!O?;T5# MY/$G]LHE-'@TASQK%#/-T8PE$KVR=,5-Y&7(8FG@4*48)%\+Q+-E*C8<\L/R M&,6)A%8NI')-Y=*702T(NCCA8#M2K.=C'PQXE>^D[%,-!%/2P.X[! M-HY!BSI8Y0"NF.?)?P'Z:;T^IT)IJ(>459.B>;:XBF9PX/N0]*(AWJN9=F*3 M0[$>Z6,R=&=BN,W$T)N)VQH#G*$EJY!TA5,:ZM<<",Z#(-CS\W,[L7$[L8=V M8I-&L9WDX, NJ0)O>HHU5;$$WYLA_)MY=N:I,KD#* YJI5?FR2&&:?] ;NR0 MZ_4.[3TXY&@P#(Z5/*XM*[$W!V.> YFF!1_>Q+!P3926S&QLT'V9!>5I39C8 M<F?S_\] "'*'3 ?RB&\2&LXTJNSN11+W+ ?VB/[$ZGW1S8)0/V MKQG^S3? #I#76[9,#&T^,:EA1J@S].7+K2_-MFOCZ$20MQT6^UML>UX<59;J MF0^/)-WV6>QOM/ZDH[_0!XO2-DH\.!%H;,?"_I;UCJ(<5R;K530(CA8'L?V! M^/M#(TZELT\K.5V P^@&UD]%SGS;3,O,!)\&.,22."&MZP8E2JU@R!7LJR5: MON6 N7-0;4[)(2V2(#CD18<@#3R06LXG?LZO(BB!^PN]F_Z(95@2G@B,EI&) M?R/U7&X1*P!G0B*V2S(S]YIW5-FM%QKQH&+YF/CY^)%]2[)5!H#\7_B\LP(M M3Y/^B4!G&9OX]S8?K, 1.=QH1(&OLBQQ$S]QDP!C=%_MF-#]GZM$;]!3RG+? M48NE8AJ"AOU^2-WIIY::J9^:(?T#]%.6 M)R\KA2;Y% (WE=P$0.VPZT1.NZAE5OH/G7?1PP.JD!RNNL?-6P*F?@)^ MXM( 9,ZPP&_]SCC&#:,0V"1_[\NTY6?JYV?/Y (.?H36 >SM&\E2+CT1RJ66 MA4ZR>=H*=; N?#.TA1-4Z94B5T)FA;H!:37.7CWLJF.EH 5X7O, M-9>9<5$O."QJP7@"I+V4R=2YMFUP#@=-(%L"IWX"O]_Q!3&%&%KNQ+Y[%K@S M3>&A=FB8S&S,D 6UGV/M.VJ80GLN@/;6<)_9WE[S]./4/K_:/\RGAA$"9#(IR$U^ I M01O.I$*P$,G*/_KA"";DQK66G;2T%;Z9(H'#U&Y*;3,-_;L0]P0"*CVZB&I% MLV'M+T4GLBD);4\,&S8EKFES9K;]B2Q],X X9X7?<%0BZ7/2-L+0WPC?!URY MN_$Y8/MC>"+],;3],?2WH \ U]3;FI&SW2ULZ&X>Y#ZTMHELVXA.9 \3V783 M^?NP7!ST46V 45^*GXO=(UE%UG"CDYD]Q-9"H_\NY\/0.5%A^W5[P^ZFN%>V]WV$+VZQX_L=OOCL^C[&%P_EO3H[ M;'G-[Y')>0(92/D,7 C.^] -9'ESKGS18EE%QP%G-I!.#WF1#Z M[<4,L+V_>/T_4$L#!!0 ( - [;5&]56(?*@0 !H0 9 >&PO=V]R M:W-H965T([35&F2'/^42JUJ3B78;)^T_Z*-E\:L$,=SFOX@B=C>6J$%$KQ& M^U3?&+GDM'- 2\H$? +07< M2P6\4L#3AA9DVJP[)-!DS.@!,#5::E,-[1LM+:TAN5K&I6#R+9%R8K(4-'Z\ MF4E')&!.,QD='&G_WH!EL;* KH$>!;[M])NI\CP11X#R!-SC% DI^R4O0DH- MN+K# I&47X,/P 9\BQCF@.3@(2>"?Y2=LOW'ENZY5,#'MI!F*!@[+I%G!;+; M@QR!KS076PX^YPE..N3G9GGH&A38TG^5$]V3$V>N4>,2[P; ?'=QFK7>X5AJA4HKC"[2^@+>JR+ T]-X?=,0'J>4[QD&W]8O8^"T MN'/*!0=+->-*1\H"'>56EGU_35=<,+D7_S:0#"N2H289FF*QC#(9)S.4HCS& MX%_0Z\%9H=#7"M6)]33Q@RCPX-A^Z@#Q*Q#_-2"_,I0K-YA _!:(YPX]Q^D& M&54@H]> ?'[&+";\#,JHA7+C!:'731)4),%K2.9J9=+T#$G0)@G]/I^$%4GX MLZ,D;'&$$0R&8052;,?V,%,P115O](8U1*O4S!RU8491X Z[8:!3G_>.$>>' M3FPXN9D^8283=1548,%(C)L.K0^;SD.ZF"=L>G7@>%'STP/;2$[P?;#UUCP# M6\P3-6"' [\'SZWQW/?A-3?L&4"W!>@/8$_HP?ILA][["(N-? F@UP(,!WU\ M]8D/S4?^SXO&80MO- B"_^WP"H= /9,7% M"X8@0F)4>L)D1YT0H3DC3C<; MAC?RIB9OX8(166+%X#M*]R^W3R=MH7C4""_H]N1G6"<\:,YX!IX7!V(G4=0B MZKFYN'7*<\TI[\W^F9>*S?ZQ&]57AME&%Z4JRSV['EY4 MS5\1VT@^D.*U%'7D3K< *PK1XD'0G:[E5E3(RE WM[)XQTP-D._7E(K3@YJ@ M^CM@\A]02P,$% @ T#MM4:U5R'79 @ D < !D !X;"]W;W)K&ULE55M3]LP$/XKITB30%J;-*7E16VEML"&-+2*"O@P M[8-)KHV%'6>V2^F_W]D)64%IQ+XD?KGG\3UW]MUHJ_2SR1 MO$J1FW&065M< MA*%),I3,=%6!.>VLE);,TE2O0U-H9*D'21'&430,)>-Y,!GYM86>C-3&"I[C M0H/92,GT;H9";<=!+WA;N./KS+J%<#(JV!J7:.^+A:996+.D7&)NN,I!XVH< M3'L7\Z&S]P8/'+=F;PQ.R9-2SVYRDXZ#R#F$ A/K&!C]7G".0C@B>VFP' $%> ^ .@=W( T*\ ?2^T],S+NF26349: M;4$[:V)S Q\;CR8U/'=97%I-NYQP=K*T*GGNS"@0*/"')-#S>>.0DMQ<&K" MI-(\*S7'!S2?T^FYS[[^(;Z,:82&G$XUI72-] @MS':P;[=@.[\\W3*=PJ\?1 DW M%J7YW>+02>W0B7?HY(!#5Z\%O5HZQ:*6<,1SV"'3YK@I=>U,PQ()?9!E"GMG MD+)=TR68?XJI1=V@5C?XG+H7)2C.@MM=D[!VDM-!-XJ^-,GX?]P[%<-:Q;"5 MZ(Z;Y\Y*T^OB.:4)C05-C[E)23M1U#UO%M(.B[N#9AWA7G&3J->^YAM(U":W MY1.M5^NV,O75],/ZC-I-V1W^T92]ZI;I-:=B(W!%E%'WE&*NR_I?3JPJ? E] M4I8*LA]FU#)1.P/:7REEWR;N@+H)3_X"4$L#!!0 ( - [;5%1CC<^2 , M !D+ 9 >&PO=V]R:W-H965TQ!;VKKN[2:!?W]FU,<9Q(M0*B9?$NS[G M[)R9L3W]+1 <,[2RY2JG I5K;,!-#0 MD-+$]ARG8Z6HR."! *E)2C^;6 "2:*5,([?A:A5GJF)U>MG]<_&/)JYIQ(F//D1ARH: M6.<6"6%)UXFZX=NO4!AJ:[V )]+\DFV!=2P2K*7B:4'&"-*8Y?_TL4A$A8 Z MS02O('AU0FL/P2\(_EM/:!6$UEM/:!<$8]W.O9O$3:FBP[[@6R(T&M7TA$INN:()V0N8/>IK(#<0 M\!6+_^#]F"&$A7I;@YGD21Q2A8N%PC_L+R4)7Y)O&0@C(@EEN:R 2'??!L@5 MEY(<3T'1.)$G&,?=8DJ.CT[(D=:_C?A:(DGV;87VM0D[**R.'JL^N>9, M19+,,,2P@3\]S.\=X-N8]C+WWG/NQ]Y!P05D9\1W/A'/\9R&>"9OIKN])CO_ M=_KLGT]_E0R_;$3?Z/G[]"(J@#3TV4@(RE:F>_M*T_[TY+JB&!7G[-[5AKMLQNOI%O1GVW+Z] MJ59V%^+ZW=>8Z2ZFTZGIS'8QOM,K,:]\MTO?[8.^;T "%4%D'LTI;/!;DNDL M'TAIIY3N?(P:=\N NN]4XURW74U\K7Z378C7J95X%]*K06:[D*[77.#STO3Y M0=-?@.'K-S'U'87X38FETJ_C#1S(:*\4[WV,$KO.RQ?.>:.ZM<=TVB34:=Z_?K93LAHE0:DOH#MW'..S_75O9,# M%T\R!U#HN:!,3IU,BP(KO14[5Y8"<&I!!74#SQNY M!2;,B2;V;"VB":\4)0S6 LFJ*+#X,P?*#U/'=XX'#V27*W/@1I,2[V #ZK%< M"[US6Y:4%, DX0P)R*;.S!^OAB;>!GPG<) G:V2<;#E_,IN[=.IXYD) (5&& M >N_/2R 4D.DK_&[X71:20,\71_95]:[]K+%$A:<_B"IRJ?.%P>ED.&*J@=^ M^ J-'WO!A%-I?]&ACAV%#DHJJ7C1@/4-"L+J?_SL+EOS_E0:+C?!7^1R["MH]#RA6?K M",5$)I3+2@#Z.=M*)73W^-4C,6@E!E9B\(;$6O ]L0U-%R8BM: RA=M5BS77 MR'*9[KJ/=)+WIZ][-B(^&['LBWAA&PO=V]R:W-H965T=J7.Y!-"1H#$ %4K35M4^K%2M0\FN2'6.'%J.S#S[VL[(0V08='V M95X@<WU0?VN25\ELL( Y MH]])(K.)-;)0 BFNJ/S,]N^@26B@]6)&A?E$^P;K6"BNA&1Y0U81Y*2HO_%3 M4X@.0>GT$[R&X)T2@A<(?D/PK]TA: C!M3L,&H))W:YS-X5;8(FG8\[VB&NT M4M,7IOJ&K>I%"FV4M>3J*5$\.?VHO/C A$ KX&B=80YH)B4GFTKB#04D&9JS M/%='NI8L?LP838 +=(.^FR. Y&:V ZXL=01#RY\5V6$*A11H^133*H$$I9SE M:(YI7%%L7,)2M""T4BJH)PXLT)<,GM$[G*!9(:GZP'CU4XJ6 MF!>DV'8]^N-!":/W$G+Q[X6P!FU8@XOYMDV%FZ:*ZZ82)GWH-!4<-55\W%1) MTU2%:BJJFZI4 9L.Z6N0.J2!"4F_5W;3T< )W>'8WG5]=PX;.L$@BHYABW-8 M&'AA%![#EN>P@1<.0K^%'=5OV-9O>+%^WW S=V>]84>I\W$]EN^ MGL4_8+XEA4 44K65&PO=V]R:W-H M965TMDE$27R/?)1IN*M5/>Z ##DL>1"S[S" MF.K"]W5:0$GUB:Q X,E&JI(:-%7NZTH!S5Q0R?TH",[\DC+A);';NU%)+&O# MF8 ;171=EE0]+8#+[8 F<6R!,XU>+ MZ764-G!_O4/_Z&K'6M94PU+R[RPSQB2##:VYN97;S]#6,[9XJ>3:_9)M MZQMX)*VUD64;C!F43#3_]+'582]@'!X)B-J Z$5 ="Q@U :,7*%-9JZL2VIH M$BNY)](%$3!HM9XK/7<7C)FGEJ5KJG FZU: MJR_K88Y+2)$CM!SA>2_*0>JCKHN[&0W^V.';(?.0A+'_T)/2 MN$MI_,J4=*M$V31*DP)XAOFELA:&KCD0U(7@"%1.&TV>+51-@<:/7V,9A_WN M*V+\5Q%!?Q%G71%G@T7<"68@(RM##>B!/DTZO,G_OQ33CFSZR@XH1^>D;INQ MIV>?D-.!V]!\4T,>3;;^WOPK0>7N6=#$=;T9A=UN]_+,W<#UG]V;9^N:JISA MQ>"PP=#@9(*\JGD*&L/(RDW3M30XF]VRP-<3E'7 \XV49F=8@NX]3OX 4$L# M!!0 ( - [;5$1')?!8 8 $H? 9 >&PO=V]R:W-H965TC4>IM2(S3(=V21+P)*(LQ%[=L/4JWC& _5XJC$30,>Q3C,!G,IOFS6S:; MTHQ'84)N&4BS.,;LX9Q$='/#[Z&ZPV7#T:SZ1:OR9+P[]M;)NY&%8H? MQB1)0YH 1H+3P9GY?F'94B&7^#,DN[1V#>145I3^D#<+_W1@2(M(1#PN(;#X M=TO7C^A7^>3%9%8X)19TX R 3P*<1?PK MW=V0?1*,U_P:Z4-0; RU).XU)96!"'2?$?WY>.J"F@28<"+!7@H0JH M5$!/%&"7@E4J6(8E J30T=P2@7GJ4)7'-Q2PABEX!\Y\/Y37. *+I%A8,D'?S G'892^G8ZX,$$"C;QRN/-B.-@Q MW(?WV-1B!=(,928O?%M2+'E2<# $TGXLZUZ-^IG=# M@ R):DZ^8;8F_"SAX9HD+5B7>JPEV3YB519VVG5U,);IEE@M*->_T:*;WV+1 M0H\R)YY ,0N4-E-&(K>K!(=5@L,<%3TWP<$_'X4H6' 2I_]J!D+50"@?R.H< M*.& W(M=*"4@3+R,,3%LEOB$ ;$W,;%VDC6(B&#FMOPIP.T<7.Y0=S-+;%C& M='17SXR#I*Z;4B:T&V(WO6)[?K J/U@]?K@C2=8Z1ZLQX-AHSK&0&M?G:%C- M23;%6L!N6J0@ZISCN)KC6#O':T;3%&P9]0CQ4Q P&H,P33.<> 30 '@TCD6& M"?;V?K0MS7'3\Q/#,#KMLBN[;*U=%[5Q3TKZRPT3F?@?Z%S>EW;#2Q BQT!C M\XG3#Q5<- 5-RW$FKNNVSW!2S7"BG>&<#<$GG+%0./IOG(G%19AF\3H5K'-< MEG"K@=QC9LZ%VR0 -_]K=ZMIJ#K .$;J7)2P]4B[#D2FTV%0K3 Q]09M0A* MRWOB9;(>!E^"0 1=%VQ3[0GFD3<%4^T*IGY;>&G S1;*E_&V._RK:-K4\_0O M![Q)J7G .^Q1E&KJ.?4#]N@*7+&0K A;ZWROV-"TCQQF14NFGI=>'.9)(C%H M'#?@4-$3U-/3$D=Y8$O'\MI8OK"AS:4]B(^GF#]>O9(UN<[*6O$+?\G;(O1E M8BR;&;D_EF(ZB([L?,5=4,]=9VLQD;48#219O)(%=O",U(9-!C,MVQG;J#VY MH>(PJ.>P9=V&$T$'LDP1M7]AC#!*G4I;#2O0G7JU.C0ZMG:H:!#JJ\*7FR5A3K4+%FE#/FA^RZ"$_@ )-HLHMP9=[ KB.Z I'[SYACU%P0_PU 5?B M@'4"/G)?EU>*+.&1RT"H>!#V\."S^>.\!S'OK;@'T =2?(KT1>%!\:D3R>\( M%U(IUQT' \ M[K!*\3/2\_,+&><<-3L%ENY\C!1#HQZ&SEB A1%?$H]&=/UP A:)-]2EB*)9 M=.1J$RG>1'K>_%SE(,_[D@ 7CMI/WAZUU;:TC M>U]QL*7G8)WW6SJCK=[OE=NW39&XI:^5SY(DPQ&0GXDY2?+]2A!3:S.[616W M-*"O>\4*0T>U3WCR*_,G0<6"R$%$ J%G#"=BPJSX<%O<<+K-O^JM*.6QE9A M;T6QKVV!/CQ9SIS^^NG#<9RT&:$/6YJ'Z-YSI7./KH2OXD:O&3Q4 !IUG(DF MP976]><@:+(*.&DN90W"1 JI.-'&5670U I(WMA%G 63,)P'G%"!TUBT_);K M!F6R%3K!TP%"?OB6)SB:?\3(T]W('!+\>/[^5ROU]3ODQ[,/9V?AX\7U/G[N M A)%T=@3I96A^!YE=]!#]_#CZOY$[ZJ O41H74NQ6R@(F-^& 5H0E^(8P MNE34KBH(IVSMX8D%,LFD0MH_;T>AY.A50NM\_@_Y?]]+W MQK,"*6.#P GV0!K71&M0XM8X;K(#GX50;R_6M5%8*K*.)C.\7> &DV0I50YJ M2!/A#93&# HK1]&RLJ.6=6"#6DMNC)R24@KB-&Q6](:AS8"Q!WNU?Q8[W%TQ M.M70GJD83".H-SV-=RS_F,USCVG#5_&BFJZD_MJ:[0CGV\L"]PH*VCF_*P8! MA]BCP^RDKMGZ"Z.EX. W?W3"-":;=:B2BCZ9;/:J9 8 A=$*E*;9&/FM2+V M3F^N4U<-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B MM/XU@LD/['X 4$L#!!0 ( - [;5%C2Y1&7@0 'TB / >&PO=V]R M:V)O;VLN>&ULQ9I+;^,V$(#_"J%3>W!M271V-U@OD&R:U$":&I&1:T%+M$V$ M#X.DDLW^^@ZEN$LU\: 7KDZV7M2G$34?.=+G9V,?-\8\DF]*:K?(]MX?SJ=3 M5^^Y8NXW<^ :MFR-5>V%T; RK'@0_-G]V!X6R9-P8B.D\"^+K/LO>4:4T$*)[[Q99+.,N+UY_L-8 M\=UHSV156R/E(LO[#0_<>E&_65T%R#7;N&Z-9YM[!B"+[&PZ%=;[;HVN? M >,3AYW[I=:;:R$]MU?,\QMKVH/0N] ,7,4TNHPN#L??/HCG]O^$T6RWHN97 MIFX5U[Z/H^4R &JW%P>7$$/@GS-2-,#1D$LFF:XYB2 +!+(8$?+O(H(L M$I894!Z9?"(.'^X[YUG)B MMN2R=4)SYR+&#PCCA[2,5:L4LR\!K!([+> P%O)179L6\E$$^1&!_)@6\IAJ MNHQ.0EB-AB/B$'Y"Z#ZEI;MFPI(')EM._N3,P6T.![@0TFNA69S$9U@6GZ7% MO(7=X(GI>F/%[1,L.G*QL[S#C2E1UR27C91L8VRWY0=>?*MS3#-YU(_DGCMX0, GU\:2I7/MX"'&C)(G5DK'-[EDO?D4 MM.3>C!0QF^2)=;+4M5&5T/M6S,)D M96T9],!N"AC?[P)32)%8(>B09C" += )2V*3G!K4D%_6_^F6!>:2(K%+T-'- M,)J87(HQY/(:2O=K3(E9IAC3,L-@8I8I1K+,.UT3DTV16#9H8A]&$_-/D=@_ M^#1P4#_!_%.D]@^:-N,I=8GYITSLGY-I[?5_/Q.U#,0O/1:G%=%X@Q,0O-^R\? MCI\[-'P+,]/F#D[A8'W-9+VR)/ST;U_H/-1)MZV47V'=7_K6L.;X]<3QRX\O M_P!02P,$% @ T#MM4:&7ZI3) 0 H!X !H !X;"]?,ZF7V<^9H<>[B7R:VJ]5V M&5_;Y>M!QI?)U>CM8U[U;Q]2 MA=)!"D%:/L@@R,H'.01Y^: :@NKR05,(FI8/>H"@A_)!CQ#T6#[H"8*>R@?) M!&6<$"0-L";06I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!; M$&\AT%M1;R706U%O)=!;!Q_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MM@LX1 ;T.]C4!O0[V-0&]#O8U M;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O'VQV$^CMJ+<3 MZ.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H7:/>-8'>->I=_Z?>*9_W,=U[;FM\_G]2 MG2_WQOOCK\O;R<%+N.(7!E&ULS=G);L(P% 707T'95L1X@ X"-FVW M+8O^@)L$"*)+=M0^/LZ89!:T:B(2KV;1(GM=U]LZ6PR?MM9\KUM5=9^DBQ# ML ^,^6Q)E?:IL53'D;EQE0[QT2V8U=E*+XB)P6#$,E,'JD,_-#62Z?B)YGI= MAM[S-K[VA:DGB:/2)[W'_<0F:Y)H:\LBTR&.LTV=?TOI'Q+2N+*=XY>%]3=Q M0L+.)C0C/P<M.='.(.T_[*K\YORW0%QIDS9ZR/)^;H\KCCD32K^S86 M(A>*[D\$<;25W\?-:>=4_[+[+B]'\:MVO/PK+U=O\=?S_A4_\(^!$@?$J0/ M!=+'$*2/$4@?MR!]W('T<0_2!Q^@-((B*D&UL4$L! M A0#% @ T#MM4:N$"4GM *P( !$ ( !KP &1O M8U!R;W!S+V-O&UL4$L! A0#% @ T#MM49E&PO=V]R:W-H M965T&UL4$L! A0#% @ T#MM487F,R2G!0 (A0 !@ M ("!B@T 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ T#MM44&!9#V2"0 6#P !@ ("!XAL M 'AL+W=O[[ MA 8 -49 8 " @:HE !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ T#MM M41KN*YZ!$ 4BX !@ ("!43L 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ T#MM4; Q,JN*! YPH !D ("!FUT 'AL M+W=O#P &0 @(%<8@ >&PO=V]R:W-H965T LZP, &,( 9 " M@8)I !X;"]W;W)K&UL4$L! A0#% @ T#MM M40+QT'UO"@ #AP !D ("!I&T 'AL+W=O >&PO=V]R:W-H965T&UL4$L! A0#% @ T#MM49HRO"A>! 1 D M !D ("!%H4 'AL+W=O&PO=V]R:W-H965TV, !X;"]W;W)K&UL4$L! A0#% @ T#MM43J$(''H!P !!4 !D M ("!EY 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ T#MM4<@2U@.^ @ H08 !D ("!3JP 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ T#MM41Y@ MH]'2! 4 L !D ("!#;4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T#MM4551H$4N P %0L !D M ("!C,0 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ T#MM41B_%T:] @ D < !D ("! M",X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ T#MM4:\&PO=V]R:W-H965T&UL4$L! A0#% @ T#MM4<.6J!Z[ M @ '0@ !D ("!#N, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ T#MM49WK'7(9 P N H !D M ("!!>X 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ T#MM4;U58A\J! &A !D ("![OL M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MT#MM48?.?B>D @ X0< !D ("!W@8! 'AL+W=O&UL4$L! A0#% @ T#MM41$&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #0.VU1*+1H M$\,! ")'@ $P @ 'C( $ 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 .P [ !00 #7(@$ ! end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 226 298 1 false 56 0 false 8 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.vaccinex.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.vaccinex.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.vaccinex.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.vaccinex.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.vaccinex.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.vaccinex.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Company and Nature of Business Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCompanyAndNatureOfBusiness Company and Nature of Business Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Balance Sheet Components Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureBalanceSheetComponents Balance Sheet Components Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements of Financial Measurements Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsOfFinancialMeasurements Fair Value Measurements of Financial Measurements Notes 10 false false R11.htm 100100 - Disclosure - License and Services Agreement Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureLicenseAndServicesAgreement License and Services Agreement Notes 11 false false R12.htm 100110 - Disclosure - Collaboration Agreements Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCollaborationAgreements Collaboration Agreements Notes 12 false false R13.htm 100120 - Disclosure - Commitments and Contingencies Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 100130 - Disclosure - Long-term Debt Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureLongTermDebt Long-term Debt Notes 14 false false R15.htm 100140 - Disclosure - Convertible Debenture Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureConvertibleDebenture Convertible Debenture Notes 15 false false R16.htm 100150 - Disclosure - Common Stock Reserved For Issuance Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCommonStockReservedForIssuance Common Stock Reserved For Issuance Notes 16 false false R17.htm 100160 - Disclosure - Stock-Based Compensation Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 19 false false R20.htm 100190 - Disclosure - Segment and Geographical Information Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureSegmentAndGeographicalInformation Segment and Geographical Information Notes 20 false false R21.htm 100200 - Disclosure - Related Party Transactions Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 100210 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.vaccinex.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100220 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.vaccinex.com/20200930/taxonomy/role/DisclosureBalanceSheetComponents 23 false false R24.htm 100230 - Disclosure - Fair Value Measurements of Financial Measurements (Tables) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsOfFinancialMeasurementsTables Fair Value Measurements of Financial Measurements (Tables) Tables http://www.vaccinex.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsOfFinancialMeasurements 24 false false R25.htm 100240 - Disclosure - Convertible Debenture (Tables) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureConvertibleDebentureTables Convertible Debenture (Tables) Tables http://www.vaccinex.com/20200930/taxonomy/role/DisclosureConvertibleDebenture 25 false false R26.htm 100250 - Disclosure - Common Stock Reserved For Issuance (Tables) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCommonStockReservedForIssuanceTables Common Stock Reserved For Issuance (Tables) Tables http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCommonStockReservedForIssuance 26 false false R27.htm 100260 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.vaccinex.com/20200930/taxonomy/role/DisclosureStockBasedCompensation 27 false false R28.htm 100270 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://www.vaccinex.com/20200930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders 28 false false R29.htm 100280 - Disclosure - Company and Nature of Business - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails Company and Nature of Business - Additional Information (Details) Details 29 false false R30.htm 100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Balance Sheet Components - Property and Equipment (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails Balance Sheet Components - Property and Equipment (Details) Details 31 false false R32.htm 100310 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails Balance Sheet Components - Schedule of Accrued Expenses (Details) Details 33 false false R34.htm 100330 - Disclosure - Fair Value Measurements of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsOfFinancialMeasurementsSummaryOfFairValueOfFinancialAssetsByLevelWithinFairValueHierarchyDetails Fair Value Measurements of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) Details 34 false false R35.htm 100340 - Disclosure - Fair Value Measurements of Financial Measurements - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsOfFinancialMeasurementsAdditionalInformationDetails Fair Value Measurements of Financial Measurements - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - License and Services Agreement - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureLicenseAndServicesAgreementAdditionalInformationDetails License and Services Agreement - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Collaboration Agreements - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails Collaboration Agreements - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Long-term Debt - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureLongTermDebtAdditionalInformationDetails Long-term Debt - Additional Information (Details) Details 39 false false R40.htm 100390 - Disclosure - Convertible Debenture - Schedule of Senior Secured Convertible Debt (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureConvertibleDebentureScheduleOfSeniorSecuredConvertibleDebtDetails Convertible Debenture - Schedule of Senior Secured Convertible Debt (Details) Details 40 false false R41.htm 100400 - Disclosure - Convertible Debenture - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureConvertibleDebentureAdditionalInformationDetails Convertible Debenture - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCommonStockReservedForIssuanceCommonStockReservedForPotentialFutureIssuancesDetails Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) Details 42 false false R43.htm 100420 - Disclosure - Common Stock Reserved For Issuance - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureCommonStockReservedForIssuanceAdditionalInformationDetails Common Stock Reserved For Issuance - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 44 false false R45.htm 100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureStockBasedCompensationGrantDateFairValueOfEmployeeStockOptionsEstimatedUsingBlackScholesOptionPricingModelWithWeightedAverageAssumptionsDetails Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) Details 46 false false R47.htm 100460 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossDetails Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) Details 47 false false R48.htm 100470 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 48 false false R49.htm 100480 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersWeightedAverageCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareAsTheyHadAntiDilutiveEffectDetails Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) Details 49 false false R50.htm 100490 - Disclosure - Segment and Geographic Information - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetails Segment and Geographic Information - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.vaccinex.com/20200930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 51 false false All Reports Book All Reports vcnx-20200930.xml vcnx-20200930.xsd vcnx-20200930_cal.xml vcnx-20200930_def.xml vcnx-20200930_lab.xml vcnx-20200930_pre.xml http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 true true ZIP 67 0001564590-20-053729-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-053729-xbrl.zip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
/9OYMHD?3SV+.=JS'4ZT$-XX]AS'>\8/Q,9CUIGQQ'SC$;.X MZ2+?5[H#EJ+,WR+O.;X;8_[^Y4T+",HZTFIV2%8WWY20I@^17VV7:%_AX$FB7 M,$$K.ZG#0?X_O=_ZN=-JJ,&#>VRMH Q"]3@"IX["J@MFI+N4QB;57>V#ZBZ] MTQQN44R"E!NN59UCI@H6S%(&):6%Y58,=XBP>]W@)/E:?ZC;+7VD!L^2?-V_ M ['S.EJQ3W'\>:_+[S-F8M 6!,14>VN[VIP9?K!MMYH]-&WM%S=M/3)%@><#ETN@CBH?ART3,O0L:7#8T-DA@;NW@V]G89TRS4:6R(-1\ M(V3*1F_(\50%B1.59#5 ADR!#*Y6<]N34L1!BGF>E/@\9:%VHLQ2 V1(W4@G M<[>N*$0<5 _7D_*=E><[+?O)ABE:VMQFCJ5LZ(9<3U60.%%)5@-DR!90IS83 M\0^E/%6'I 8B[429I0;(D+(A9:,L("7=SAW7^L-/MZSGMWW]O66U_2[C^GEW MS'^R359<.O#<@2'X3]?C6V9ZCRXLQ+IAONW!LS (X3\(-F\9Y\V8;XC2AH8KAO;9!+YF/S'-\8) LP/L+B>J M%@;\WFPX\:( G@[>O=>R#7;XDI4G7;KB MD\Q3]5%26GR2>4KRE>0KF:P&"4%MO4P X.20.%$>(=52 Y!&I%H40Z0& M HW\&'6Q.5&N(653 Y &;551.E6VH3LDM83M-^8RWW!XELVPIK9K!R&63'C: MMF[^*9S;4PE 94X*K9*(94Z*D-14$KU1[BS0ZP$\=LNDUU5#<"IX^DA"7*V\VJ_3J] MTQPHCURYTO8'/L>PPGS9!#TR7U0X>++IC?TD(&L&&"E(4I"D(%^1V#UX00+2D+42N!5I2$KLDCZL#_>1 M/CP5?=COD\=8!YR4$;CD,=8,,-*0I"%)0VZ/=*>U;<7;D]20 @LU/9+U_=R+ M.JU7W U]6=/UT+=N)\';J'3,CWPYM%EQ^-YW(8M:5[TWQ?5$8O^32\%W8 M)P&\@L\H'5_NMMZOH-OZ\OTA;P8B.30X>-T.19#P2(*GK^K$@216SCA.S.BF] M$\2&FJS5'VIJ8ED'E)06EELQ'+D0)%]/ 6IJ8ED'E)26KR0^27R>KO@D\U1] ME)06G[LP3T\0/)*F]8>:C-$ZH%1--!L63NW4=W%JY7J&I[0"+?2T6>2;$R/( M'_=2];#NGIL/UO=4$36V.5EDJ#%4AM:PUVH,=&I%J!@LZC,1M2)4&!OB&D61 M(=4C711N=1N]T:&O0A$3U8Z)J,&Z,D@0CRB*#"F:#*U!M]T8C Y=I8F8J'9, M1,$T99 @'E$4&5(T&5J]]J#1&W14A8J8J,)4V\YSX">3:KN 3X ",#=GKME! M$/'Z +G:"M&,-P P)P8\IWGC#,>CIHRT<=.?M#\,T[1=]EV[\3TK,L.@H7V^ MT2+7#H,#9_W)CE+EA!2I@-HA0W94AI;>T/N=AMX]=,=<8J/:L1&E)17&AKA& M461(^>24SVC8.'R[=F*CVK$1)2:508)X1%%D2-7D5,V@U6AU#]U9EMBH=FQ$ M(35ED" >41094C5YKV;4&+6V/>E/;%2GY"3= Z3DY&&2D__LO"H524>Z5-'. M=!KE9)$ANTFVFSKZD$X/JP>,^FQ$J4B%L2&N41094CZD?)0'1GTVHE2D,D@0 MCRB*#*D:4C7* Z,^&U%(31DDB$<41894#:F:S6QI-4WI]?VN-Z10CB!RP^'^ M+%P^K:*FVE5UN\YWT[[Q/9,Q*\#O?\+TGVO"NVY\^\D(V8T#^V,*4Y<[9 ]6 M=LC61ZT![Y"-/W3T-YK%3!L@"'YY<]9[PW-G_&N__]L.O&Y;'_Q^]_'-KWIG MR#=(MNYR\WKM6H:ENWWKI=D=?27K&6>":WS &J63>&'\[O M41X;)B\O_&$N?W+^W0[^C?/Y.YL'(0CK>*+XH(<^]Y?=)+]DGV]$MOU^D60,\L!3F<^E\RTP& M4MRZ=B5BR23OK"!YX(>W>!*#TP%^^6)\MZ?1M-2Z^RLV5V>10S::?44+[Z[? M:VLV1:H95^Z,P182I-]7@$"]RIGQW/GOA('UY0?G0>"9-I]'F=W46J,"JR94 MGO%09C/KTS(Z]4ML)#"5^,:X_#.RPSE:3R"3W##@I(D?NN GH?C[-Y%-US/F M?C'\;RS$3S?:@I^^7N4(^_W!=^R K_G-KYVAWNLO(>U:^E1#V57VWX[5P0X! MVUZ9K,2K"\;6Z)!HK;)PU>"#;D+7_B9\H _ZP^$A";O*WCYF-M@.KG:WV^Y6 M#%>A*@%WMQBPP2JO8M=[>955W][0JLBOL"KJK')8U#;RZTOS$H[5SJR,E=3I M*$&>54[0GDW=L\YRAW&0NHR')5<)UTE1#M[Y6%69]4C+SU/HHQV82!_<(/*BR[@/%2VZTO1H@3FW]<6'$)N[[Z%?\*/^EGK>%9J[-L#\OSS:]+,O4E MT,6/ 8@[OB$^N:;/\H'=X:LMXE>"NXR?\[[#J-G5V[V,+!LM5]KP%^>WEW?G M9G@]QKF;FA(&"]+V0<>T4AYEE O9:@^2'84XVM%?$X$L'8>K;-G #[,1F,6' MACTCNZO%KPC71N6@ 3#S'^C2=^< 1 M^%2P H\53GY''W07,^\KUK3M^DO8GI6M7Q_I[86#(*O6W]=WO_Y1"8.TS/J1 M%6]9P RP2=//MP2^.QKM8>$E#,_7+WPSQ+O=]AX67B($NL&.OXI\6 WXA_#8 ME?V=N[Q;XKZ0P=[-ZDM$.*M:_6;@[V7U):R^#58O#C\R_Y4,WQYT]K#T$C9@ M)4O?"/6VO@<=-UIE!6Z(U: ]&NQAQNL.O&Y XH'>WW[&YZ8932-N!G]D,Y_% M^0OXV6'X WP=/'L_M/]KQ'&$XJ'EM:T] %L>C?ZPE5>55B[P#NJU5=LBF&J0]&&;^\IHY;#?;57;#IJJ^W6MO M.-N$ZI?3F>/-&8M=\\^V\8 NK\V"@BFO4O8;$I@;IA+Z:^?QBFFO4M2;JM=^ M^S73CJ$!^3!F0<#C%%>L<,X5:EA]V%H49BLFL>V$JU2P+U30VOG*&S^):Q9, MLD)-.>J^X+B%%^1U.F!\_N'J[KKT$LH$8RSO\J^>PY7SUU>IJ,^0'6\_W MP@@FH&KQ/ZANGPP'(R57ANW_83@1PX"JXP7@3LE3+^&RIR-\F']A!@[ D]$^ M^S-BKCG/^6[)H]*#P2VFUS"HEH]!7MFNX8*V<[+DH#S4%\]E\S@(&;G6E@YP MO]W/T;,TC2H@;8F@@$3:],>_VLS'R,?\,WMB3B%U/[G@* 7\1"P MM=B4"%E43Z)G^H!X7JSLWN/_;?.4^1B/ M-R\<;>KJ)5*+^U T);/*FZRR$OJT2Z0>=[%CE*!/._ZFOH(^!W!W*MX_RU99 M#7TV\UE4W#_EZ',)K[8LC&7S2@GV$TO'NAZ__#!QO>)3>?":=M- MK/KEK0UU+AR#71'F[BU$#%^S1!YN2DX'@"'S$<'V1+[0=A@_2'5CS/E6DY>S MRBA?=4H1W_?'/^\G/H.9F,PM.ARL#_3X1.( "Q"4//?>28MY;+(FB0KWS)\& MU^/%:?T^\US\",S+A1Q&>Y7U_%HB+![*^S6<, USNH8[UYYMQ^%].9@6>KS] MA.=K-B!DL"]]Y&%_!F6U8J1#J*OV#FK3/L=LL^RD^'YL_4Y0#L^?3XBALGH[4GH0N6N5T%H6Y[E<&^(Y*4K4BQ M1 .7J4:T,1TZJPQS-2\6[(8.JPSP'5T66):7/R@=]GW1Y/67)DI7Z4I*(=P; M_B,+L=[?(\C]\T?#=H/P'Q,;39S0?O L7)//[KT/[!,6%K3'-K/ ^KEC#C-A M9)E<:^^81$@(U-[SK\8T.T9Z%_EC ^2^BP4<'^>?7+.,UEFD"(Z46\V;7]NQ MNJEJL0MFW?4X,0?C>U0R,599YEL1XT4M+MO-U>):)-6O-Z,ODC7R8K*;+&:M M7?[JQ2P4%GNY&+U=8C7%;. XQH/G&Z'GR\Y&9ZV=O<5VW>: T8N3D,53WV*% M:^W!K5:X3$0M7Z&H\K";-:XUYS9?8]7FR>L6N-8XVVJ!E=H=2Q<87]Y*M9%A MAO^PP\E%!,[2E/FBH*SM/F)H"/ZQ[HWOTM*[:^VQ/7*HO'^W6%:E=%EKG^V) MKU6CRUI[;0LU!3O=BLSPVK]C_A,XQ^F7+K^#WV4'O)"K>&26N_^XU4Y;+#9R M:(I6;M*MIBA,)K"?6/Q$'(MX'45UQ2BZ"[OP-7MT#QV M;[$4^OQ5U&X3C:MNVN/,&\1N&WI2:IHS42D.5_/ M> TQ]Y%?H_X"4YHX\UN,Z3H%6;+>^IKUI06/=#J\Q"0VFK(\XS4&:UHSX0Y( M9/BVEX0%DM^O/)^91B#GL>+X0+NMM_('85:MMJ?KI5>[<,X\]WQP%>&5US@$ MDY#GEDT-;+_A7X^O[, TG'\QPY?)L.G-GQ66=P=6+IU WW9VFR_R(QYTNG_V M\-NY75E=IET?=/7.AJO+36O;56$"[,6Z-KU-M&;_M;995SJQE2O#[7OY?8:* M!82,O(;55XNVTL(+5_973F7+6:^]7+2YRM073ACO8MKEF]:H1.S5=XZV#/MM M3.QRU=.Z*SO0Q*_;31FT%:O5.YW^9H70RE0)[*YL45/]6K$\8/NLU3MK227/ MRY8'W*:^:7=E YN*%CA<%>-,>_\8[XPOOH&#\-5SS1-VQ%,/)RNLL<8/G=>OZ:O:KUOF[:X@J"^&QJ1U-^[ \>C4\J M<>6+AGDUF+Z^\3-'BG:]\,!SE@P7R;#HGAV,5%OF<6FLS#Y2O'6*-/- MKV*R+&5MO:GWENV0I8N1I7?Z1S"_\5KI[YCD\?"K;'H=A4%HN)C_*93EI=I% M[(L2K>S,]^:+6NA6PK?97?3P'["'[[TO!A8<]OQY1M [%H8.CR/SX_.65;PX&N(&5+V) K*1M7E@';_(OQC?UCXF4GBO=,X4%?#HY40M\* M+L&5::,AW8=,A[APC""[_Y*2-*'Q%3-X/+X2$A_P&AX6H8JKC'NN*V()>)H@ MNVY3J$;*=.S@)_^ ;(:3DE'ZTZ,(GB2&O%\9)3;[]GYL2U_XRDTP?C,2[U29(;X<2S:KY!=^,,5$7-O6Y2D=+V[4?; M-9SDL<2/7._^K^P./:;;TU:G M2RYD#V#/(.P8=.UF?\M'\LMT"-G?'EA0NVL7LCS8)*X""N,]/L!G77F^.'V2 MR$N9#J_O4L??]3N>/7(P R,Y^_Q!<2AY54'"E0V?AR-]T!T6QYU*+;8Z6I7I M*E(MK5X6@EI)J]Y@-.CH:M"JC#5<@E;G3X;M8+XV?9E$*-Y":NN=U6X-.Z,E M$ZO=:8UZ;36H5<:@30Z=\CC (K4NOX/3ZF*L\@_#-&V7 M?8]/;@>?;WX' FR]IW2]!]-39%.5,5@K(M.&FTG7!]@91@TRE3%U5Y(I2WH MH?[9>=T&ZNA#D.)J4*:,G;P]93;=,RI1YK4]\'(KZ_0&G>% $:&Q[J3H1IAU M.JWV:%@=GR=]&>/OGIO<[>?;*K;'X3,FU;6Q*W]K/+Z/5Q($*F6W9M):DI?_P,&-UXSWC?9)SQ^%XL@11K*"" M]:FL#W-A63(F%?I*;J7R!+B\[#7WMU>4/XD7A)V,!!7=J/ MDY Q-^F%(K8.?F-K3DM#;D4Y[LHH)"&0^_MYD$NI9^$0"=5K8=/C^9M/X^1% M\-Z ?WJ+O8P"+'3C/G[Q?'8/MIS>2F^JK5Z!#-R::^** J=GP*E$V(($](,1 M, NE'',#'DH_]WVDJ>C1EST2'\\^?S9\Z_+[S/9%GR_FVUY.4J^YA+X>+_Z& MQ8!7 I#D46Z LH.7GC? ^->;WK\6DM%5D&D/U%]S8?T@U-^X:CU5K81JXPH&UG1[7P68TM?[X6IE1PB MQ83Y*^A5IB7Z80S,5KO P'S%J@NX_,/ZO?MA<>\F=17/+<>[.,@.1U2YB@4K([\C1S/K(J[*()^-C MF5*R,'%NX#D'MCQMO4IW242;"VLL-6)!CVJMP% M!4O8HQ!96S?B-7EZQ85(O"S'QG.^8?C-L\ MUOD3\\$F61;86]ESK$@9E>LH,&RV*J1:R65M2,M@(RE?EIYK&P27*URUC+#= M9F\3$5;=&BLF;C+VQO2MJ##8,OKVFOHFQE2ERZR8Q/]_>5?;W"8.A']1^U.O"5;8Y11;X20NX6(2V4M7A /$ MNYM! "=)^=>'WH*#S_8DG)+=6*B M-%BRUYP\1O)M3C<16FLTTKDQ;GS^05:+MT5_'F=4#+H)L=:RKT8&W&;HQEJ! M@U@TY'&<$.[E:_3R/3L/Y\ ;'>O7D3?EV1BL@I-O^XR'-X0MRAS#@\6*V%;BID^O;($;?7@X-5 MOGY^)7ZOC_*OM#B07HU=/V43+_\YY5O[&F=/F-BUC-<1?67$'Y/SR.GCDO8L MQ_8XP YBBF'TVG8>8F(C:$+Z!_I6*Q1EWE; M3PC=(_OZ "#76GPL: /:4#JC_7Z3;3U-[JW1D8"M/'GSJO.[39'Y;IF,H[@5 ME"H!Z@MC1]L.O-4X$R "&L;[1&<)HB'\5%)6V7U^Q"&Y#&U1KY)4VE)%0UW1 M".-NTW(^"0?!*.J XJ_>X?M_0WT6I/]\3C#F:4.& MQ, @Y("F>YUA+H/<&BK. 9#+"I->?T_2DCSAX3<.4HG)_.HS'#+B5ZH<-B<& MI O&X)1>[OE/RA+'O_ ^S>((YY6;16_9W=V5OO[!<3$BQEWJ(H4#VTZ8"7B_ M\1%<$20"'[^6/)/$#P>_6";((<7CW:FSJ*Y8_+B\4?RUG*F!]>/EM'D7:Q+) M]$8J_GS',%9Q:">G].EGE(I>#N2G;O"(]2\-5>KR)LGB#R[",%[2[]3/:CEM M$X\/8&=W&RWC#2[#[H[>@4Z17+A]P1$C7HS\"W\31$&:)8P.*+_AL.-"\6AS M6HU)&'1]X0;L]P!PSW(%>B::\ N'\9;-!Q6PI71FLE<^K@%8 #LX;;!(9+ D ML B"4H>!!; ?TQDM"B\(/1.P #9,.J.E*<.4:8%8AX=%*LZI>RI7G5WLB0%@ M #L/C<"HS2\((0/( /84>D-&88JQ!0+"PR #H/'2&S,*LXQE8JUN5R55F!8\ M$\$O+\-2',9&7*(L5RH3\G),^*15P51AF(Q'7F]+OD=)^?)HOGBY).-Z%63I M_'F1_8QWH7^[V9)=3$EL3+XB''^UJ)RV]^TTL-.J/9ANX]KJ>-I:/@S4_+F %=M7V-6VD&*LH;WQ]_CZ1M-B(3)DGX(+()59)ER@N$*2E2Q-+^C95$7BRI:JB7?B M?Z)W%&]$;,PY^YH>I>9I'_&:E?HLHL4:)Y1SXF&;5^6D#\7/T7J&TUV8\75I M4E7PSK94'X,=!O9XS.K **XQP]LXR6C_[+__JAL-7-<^].J6-5"_ NS2NS8&- JKD*,*Q&ZKAX[@U2U>]:[(0N5 M/]#"1&MT-D)G%JHM9A,>M=&D,IJY"L;;J+X.$2*/;;8DL (16")BXDQM9UP+ M8RL\C< 6PO9B&2!$"=LXB"IL3I7B\087LXF'KHE%R M5+%W9C?7YMA"-6HK(HT%J'R D%"_ED[&R1+ 64&73T'>'7S0K(JFET]K%8D+)->QNFWK47Z MH]&VRYAV:J^N@P0OLSA)KYX70;(16($[F#?V+*]>PZ[9O"Z#62JUK!*5M28V MU]M.//9/>=QULK4EB^L5L"IV.X0.!>=E:1=M M*8Z3+HO5G[MPSY&&S_\E(V;?OH*Y(Z_\H4@PW;.&=7V(!!.BMZP-P0&3!1WX MPS4B+<=UZCM:]&>O$#WHC^TA%>H?7C9-?VH,T:;^V#ZI=8XD[YZ(76"0Y>"/ MWYA7?Z?_?_H/4$L#!!0 ( - [;5'>O9C$)!, 3, 1 =F-N>"TR M,#(P,#DS,"YX[RS]MG9E'Q+G&./7+9F M=M^V8!*2D*% !2!M:[\^#9"@0/$"DI)LNL)Y&9GH;G2C&]V-!D#^_+>7N8>> M"!?49Y_W!OL'>X@PQW"T4/"X?2O;_]\C]_^OG/O1ZZN+K^@H9.0)_( M!16.YXN0DP\/MS^@W\[N;]"#,R-SC"Y\)YP3%J >F@7!XK3??WY^WGCU-^)P3+!O0!0X(4O].T>'!X4%O,.@-CL8'!Z#O\"#@P.#P+=(!F3\.T7'^P?[@_WCP9$!>(>=[WA*T/6% 7@R.3XB M'P_)\?&G3Q\/?SS\:7!\>' R./B(R8^/SJ=CDU-_L>1T.@O0!^<'Q2+(RQCQ M/+)$5Y1AYE#LH0",*?B+L?4WT1[JF(1@ZTP<0I M WKA_/.>,7@OC]S;]_FT[P:\'RP7I ] /8 BG#I[,9Y+:(*D$ 1Q]J?^4Q\: M^H<'@Y/>P:!W--#@%?I(TP=[D(]%@C7!XE%AZ):^4EFJ%Q$L>#Y7LD6R]=,: M @^*NDF:\OJA3D$WU,D!?W+82TKZ)^PXE)$799D2_N#DZ$!#2X)ND*8O&0*H MXW[4:+"?RW@.#S!J4XP7N<,I&W)0&*:.R)=3-J#%D_PZQ1R>4N. 7/2*= M6@K : XPGY+@"YX3L< .J6%;PLT;!P :]'^[O8E\ZAXX"H24JZ#SA<\#%'F, M&]]1?K-DY.5?/:WDGGS4&QR"T/M ; ^Q7(:++*2_(1O:"AJQL3*AQFSHR2K[ M/R[J.7]V5^M3E$T8_4=O97FE/)1-NJ;LF+,E^:LV0WESKB%'.C;)'[U5D*K$ MQWI<:V879DC]$D4\:1\GTCX'/U:RS_RHO"D[F_)2CX^,9A(GJ7[5M9&,BVTV M&A[G?@UB/K56ZU&JAG*^@JF MX:B8^7XT,O&3.N.2MVC8)C^U#4?C[(RCVJ:3NTPU.,*,^8%B0SW33Q<+RB9^ M_ @>RD3T5(HV!F*(0OH^)G.() &Y4**LV*\^*G6QIJ2]#C=DPE2:\K3./Z7KSS["^XO" \HF(JQ<%4$9IQ,/N_) M\D%/J_%WD' ?]*9!,AVDE:>4OC8H,9.:0D #2>)\!:0T)OZ*L)=T(TWY\YZ M:>217:["^V\SJ*#]NH.:-IC\,;U(8*Q#^D:">_BQKN" 0KQBF6]D2 6?+:X@E?*ZXVE/! MXQ[ ?Z\$7N;M!SGN/OD)U%!$#AGTZ@6 QFZ\>>38/ !LK,8'X%O5_1$PNQL9&,;25K% M:#*"D*AD%."+S_TYB#T#!/I$;GS1P'4TH6VSH:.*-K3J&_D3M.H=828AC?Z1 M9*!S/+LRJH? =[[/?,\E7%S^.X3P+K-;AP:;V5,%LC93^MC(E,R._Q60L1G+<2-CD1TAU5-G$S67)LG1'>FL M,5M"V/B" _A[-#D+!: +82Y-JH#;=/RC6IHDE)22%3$5-")R4JN:8*?'.GI\ M".=SS)?@NNF44?"4&%:0CMHWIFQZ!S/(@>5XKDXKHMKT^RFCWYBP\NLKTFA% M&VGBG:[KZ-I<+<@YY#/I$7-U6P!JT^5/&5VF5@UH1:K37!W-76'*OV$O)+<$ MR[_CB)D<&C0?Y^JS%@&;ED\R6I;DD:*/3$IR!J\.-IHMG?KKJ/^&.C*I@>CY M0/@3_"&&4T[42.9JNPS>HMS!04:Y,345;C4]E!#L-%DO;?(\_.A'R]YD#(MR MIGQ8FP8'.0F306FENFX6UDUYYS10 Z>J)2H5(:PP/RJ#M^GP,"_IU=3B:HE! MKU-D+7?JL^F8R,.XCP7^TP2PJ>HHZS !O1< /I($.MW4FV3L26X!/GH$!@\$ M@F<%LRL'T*:KCSG3*B&#$CJ=RNKZ19^I"IR^H'+E\VLAPNCH=X%K+$&QJ?$X MUSM":%,4DVLR"&@B3;33::VR@!S(,ZRJ=?,%I'^976<;J$V'V;*.(M13E)!) MJM-<'ZNCE"PGDEM8=X0\SS,DPOC:$ M(?",?<,?QIL8N;JK2\.FWVRY!GJ(=MZ@#Z0Z068O*/!3KC;NJ+.$6KZ53.-S M.G\G_I3CQ4SNFA<<[JF!9=-VMFP3TU3K"9-J=]2GJ6[OB3PD*T]@!,LQQQ#! M'+7!G:O20F"+)@^S-9J8%%*TD$FLT]_VMT.VL"U2=7OD,%O-J;X]@C[H7]WN MYA9V2L8R!-;9+XD1;"K.%GN*=DW0AXADI\Z=;9^4*+D!&9OJL\6CVELIG4UL MK=!4HOL2<)N.*Q:=.CWNH/I4JM$*B#;=-JE$=8K>8DFJ1,&E"#;%5B]/=>I\ MC7I(B9Z;4;(90+;VU:PVTIG'EL\7#EU7,9DJ?ER0 %.O[MG#4E(V \D6S\K/ M)0+ JC^SPB*/**LN.Q/9P5J]MKEL@:S-='(J<=77])T9O<9:_RZZBBJ]AKQ( ML% W+$NLICX5BY$<98M\A56!'M(=*=^3=-69Q#9-HK8G:4#&9A39:F")471^ M8O=&(5^RYX8>)!7@JWE(W,L7N3(@HKYA6$G9C*-&';&'=&\RY,3](=UA9R*[ MKS,F:4:"9 .A2"!.%O>D"?B_4J#&64)V#\HX9@[LV69A;T-)S8#W4:U,Y4K M&>@IC(AK]+A$BF_TK!@WP1/>.UO?O:W7CIQ;(VZSR&QMMHE%=H'VE6X[U#:D MIK1L=I.M^Y;?DNB,9.OUH=S+$0V*0_7IV(PC[\9J_@6,SBRV;A:%=RZ:U T; MT;*91[:R7'JWH[.1;<<7XW9'_8!2%=EF!=GRY+?>N<'(#DL(J]"J1,-7%HOW$4_-IO*NT5L/=E2!I0PA"*. M$JRNW+@3\VN4[S8D9S.F_.O,5F/JO-7N#U#5WQ^O3\9F'MFZ<.%AJ\XH7L,H M5F<@9/-HH30L/]Y'U5YV?-MD(X-IW(7-F+(EW1)C,L]=*%<4,8(T)VHYKB_7 M=.:V(W/[.\2!0(@Y2\B E4"^6*(;JQ3(A)93:;$-:K%XL%S($ZR;/5D] ^P'V M\IOB_?Q[XOA31O^0[G3#5P+7GS=OPIYMRM0XW=U#2H)B@%@*M!(#4;:U%R!W M,V7#ER#4SF^KXMILK/SE"5TBNV65U[P%L!9V#0!Y>O()>W*.7KXX7NC",IC[ M<^.+.J/)!?5"0%[O4XQG9/D/[ Y90!4(S./+R80XI27D]\&YS=RW]2X)0,SD M#JEB@2$ETF*B"@7>-1[6%X=OJ MUQHVH&;QL_]]>\=QD_2 MWT547T6,/X>NM"@_Z/6[6I/>DR?"0A)]A?'S7OI9],4M]3WZ4X@$,)Y\>0V) MM.1@#XGP$5:I01@MT_UPH4$I@.RAZ#>DVM1WQXJ0&T9I-W1&Y<$<^Q/LJ:^/*>3'Z!SUYSV'$]!QZM./&7&&[K]"$9WF&/LKF[C#5"YP M\(+*!9$,0X_K"Z)[ K%- -?Q ;([Q7.\L%!%,XDF]!B]0D?FP OU['6&O6Q\ M[[CO$.(*F=OHS8+19&UW'8*^3':$NC^E!ZP)9FM,SR6/-LN[)RZ):BP9J?00 ME(*T1M8JTVP$F1JG;'KNBT!!?O[V;JWH)&I,0PMI!4NY[$ :PHYEB_XN M%ZWT51OK>JP,WE95GF%!Q6AB?D8T.D$:%P+E-@#\:F.56-&TJK0C\LI8@4816?MT2MA8Y^(]'&J;QM"Y0:#) ;G,Z@G3OAHQKF M'0X5I&.WF'\GP0/V2!+(;\G\D?!D%,J!4O/%]>>8LC-^%W)G! MRK- M@J K91/>C2;:*4P;91JZ/TQ(W1.N!@*X<-LDB330I6"M%&F_R=+$<#Z M)JZ$R)(= ^YO;L[3@MGAVB@=K&"=&0$SXWY 5 D2?DTYGJ>%LX*U4;8K^D3 MF_,SS+ZGQ46QKZ&R74=U1!;LYZO4*%:24:S MI;?HED*2)U6#W;+T%))TK"J&.RAFR"K;:A6@:XSWD+9HF3(96WUT)I M=8*^RG#A54Q'\S_(*1'%+TR,+>!O#U3 8STBTT+C"#O5HL%R3KAB@C?+( MBH-\NTOR)K2T-(7-;90EKM^?>Y3);W.,.2QU96G_/.2P]!FLA:91#D:=HH M)1C[%T1>?9?AT-B834J(7Q<^&ZMVS8XNESF-83GJN_*%,!R6Y&?DVI57G">4N$J9 M'G$"XNHAV!X]TQPH1,$IX6\_I:7/&4UTH(I+%Z:ORFDT!=%LO+TD#R&?8(@? MS/$]?[J\9LY:>;>PO8UF?/D"3H *(G>5?3>$U?@BNWJQ +53+L<+Y4V9F./8 MM:S+50K41KGN_27V@J5.Z>ZB6L]H\B7:!%JEA%:X-A:,BM^IE8G[U6!;&/=+ M&$_%?3M(N_DU_EQ69=65BK@=D!VRA?PJ-F M^HJH;Y.DA;-!M5&RZ*X6!/>5&H*9[ZYE .5 ;91+'?$$9K$WG$:WG_16&$_+ M5@&PC?+%J0J>RA>-A\P57P5QQ[X\FD[FHS"0SLL%CYFS)=@ LX59T!4A(KZE M 8J)MN7ENR!6E:NLZ/5PWE5T?606QF\C>X@TI90A_F^_7:4(UX91!LEB@YJ?&4NX=X2 MW)'AFHAM5?NX1.FBD1RWM?@7YWXSI6\!EH;9<]./)UPK$E; ;"- M\IFA]YL?;>8_RW+FT//./2P$$?&[O&3A3% M]2T2;V'H3W$X%*F$9O5B*6/C:K1Z\]3U1(L,(R#BH_7Q;5_U2BE.QA &!@=) M+:A\+->+?^W@J85*,T?DFD%* QFVS,.2 3$OVXK"ZPYYUKX1N18.U?C9'\_\ M4$#@NO3DQ1[]7C%YUB)8WD$*E':'-1#:Z!9-]M5;2^I);$5IH\S*+K-O .5< MIJ 2]&RY HF+7,-GS-TXA3$CO7(D1JH3;9*E,H,=]Y2JL6YZQ;WZFF G [QV M4GA=^NBQ^KG:EGRESK8ZS-O:Z-NIZ#JLOM)(&]W]]XWUN0R(WFL-]:JW-HYT MI8K!.ZP3P,K_XC)?F)R6-DJ@C2OY_GC\EN'U$R+9]E:>^$CF2O3>K%O,(*7E M N;*ZL66(YYL@$$B&WJKC;&FV*T);6G;T5B?A MS,@<__(?4$L#!!0 ( - [;5$R0AA"5@L -&1 5 =F-N>"TR,#(P M,#DS,%]C86PN>&UL[5UM;^,V$OY^P/T'G?NEQ9W?D]TFV+1(XF1K(-D$3K;7 M;PM:&L?$2J1+4HY]O_Y(^D5R+-FBY-"6VV"Q<61R./-PAAP.A]2G7R>![XR! M<4S)1:59:U0<("[U,'FYJ(2\BKB+<>777_[YCT__JE:=SFWWBW/I"CR&#N:N M3WG(X,>G^Y^ !-._5#( MQGC-I4'=J587I*\9(/6%TT$"'/US[K0:K4:UV:PVV\^-QOE)\[Q]4FN>MMMG MC>:_Y8-&(T;@]YD43NSGW#FM-6K-VFFS'2OXB-SOZ 6<;B=6\&QPVH:3%IR> M?OQXTOK0^KEYVFJ<-1LG"#[TW8^G<4[I:,KPRU X/[H_:1:EO(2 [\/4N<4$ M$1-.#SBP,7BU.55?XG;N+\"374*X_O.B$D-O MTF=^C;*7>JO1:-<7I2OSXI.U\J]M7;IY=G96U]\NBW*<5%"2;=;_N+][36D+]55T4JZI'U6:KVF[6)MRK2#0<9X8' MHS[T8.!HWL_%= 07%8Z#D:]8TL^&# 87E;%+)E75"XVS=D,1^>$99"FI17=: M:$7G:Z^[PO,8N2XF,-%*N*A;5R7KJY7K"0QE)RC0A!(:3&>4GX0DJZSBFA(/ M" =/?I#V@#WYW+M"OH+[:0@@^%>"0@_+I]M$[4G"WXH07L4U+JZ+?#?T=7\K M+%;*PT2 ;&I)1N2T,B> ]74]3OR0S 1*2-!&[(],CH")J:/4OV%Y$GQ,U)6(D$V4[M-=*SH M6UZ+V8=MZ";-F;2D[Y1('TU@:6H=Z!MAN5;5TDC#0O#N,.IC'PL,N;0@G8C- MT?(13=405V"X+*WME5B[;L!HM ^_1$K3*%9 &(*V<(4Q-*)6-Y7LPY(5KG M4P)5S**VTUJ5*!:VN&3N2D.(N8M&Y,>UF,5JF&I>HL[#(-#4JEA L*@_8#0P MX7'.!DWI%,IDX8M*L]%H-FJ-1L49,:S'OHM*J^*$7#)*1[,9J.*\@HHBZFAM MHZS2;S2E"(W67P.-78VE$7#M\@&WXREL([QQJ$[^AFJ3SQ4!=7H,0*4-1JNN M<23TAV,5.LN:)H+AX['"D+1 C<3^.;O8U7+)G26\$.%P5K[N3_*5D]VO99!H M*:^4^.CD30GG13*7V_-\&R>,CW0I<=A(]'*[F9M%3XNA1]*7T%?,)OW:WD MPQWE.\V/*M#JP29/Y9')0ESX,Q#)BR_YN/0"3# 7BK,QS-7:)"R\E92='5\. MTLS5T-R!,?A4ST"1-E0SB?SG M/:.)F=[F(&]#;CT]RG4NG0U^*N@I!],\ \TV2C:D641C<["_5M4*^JM8J7G& M"/*DZG9P5NU))9VC=24GF8%9VDXJ"7O\*[P6%HE)*'&,7( K&% &2R:!WTRD MU4K'$1/$IEWI-/#BJ0'ORH8-'.6Z(I)AUXD3.8A;RCN6>FIJJO%:UGLF-^J' ML.1+EH0F0UOJ_("MDN:PB%PI @>S19-@:]32\%GJ%($LN"5,O;GV^@]&66Q, MZG2+\U7J) #+ *YYW+F2"?ZRZK=EN57JE(1-ZR):<%6=*VFA), D!$]*G9N0 M40_60U6Y,A0.9BA)#=O1U&ABJ=,3LLB[)?);ZAR%+/)OC>,7SE,XH$TMM7][ MZ]/7=]N_2F^@%%M5">S;B9JI)$#HP.QWEZRGS1B&OS+0LQ0/7.^3%!,W6PGY[-,J*V$VGQNGM1[(.,,F F@QV9H@I)*V< MT!LB!E=(CWZ!TA\]XIJ(DT;!UHE^T,Y#H X8_$\W_3!0ET!I;9&V((TDP&' MNV0LUW9Z1#>1+F\+>]A_,[V#(;&Z#;X[,&+@8F--6ZWW]^[#LCTTU5KW3"_= M/T/,(#4GT4@* ZJ6^L(%\'2\YPGY:IZ[1R)4/O?#X!ZQ[Z"#\T_@JF>&8W(. MXM9E5@]H?T% M1.0S9&8V#^G]Z7W.2TPR$-N?3(_:+P]-VIQI.F"=4]2CGSRW#-SYVL/HB5?)3K:>JMK[/G&U0W$W>(R OTI"'># ;@FEU=9YFS PB8 M[ZADVXXH=4I60;0,=JIRY6T=NLUMBOUL.[I3 MQCMGBL&PNHUFZ)FE3&_ MJ_#%.,>$45*"WQ*@UA$YR+D1RI;N&6%FX#4?+69KN< 1/,?C)A=!9RT!/ +H M4 \V1*_XC+^,3TT_E.C8_-S[CSO^'76OK+^$9>.YAAW0W^.QAB+WW3WF=FGH>ZD=*QOC=P3W< ;)!O/I>7%.<9=S6-9&#G@BVRJ"K?O<=O): MR6V4MU+Y:Q-#\*E MWP\"ELXMK+\28\E2A(#ID8.,1*WX5AKS@C)M('( H^=6";>^!26Q;J#O@7L3=ZK8?RV<%-V+J:(,[EXB]%ED/74;C8Z5EYUG?,0 M^J;CYGMYHUJ2'#0KTJ5>UYJ)GL.BWC%6/O]"_=='''[Y/U!+ P04 " #0 M.VU1GIA!_V_,W)R!TH>>' MTY_?Q/C4P:[OO_G;7__S/_[R7Z>G)S=W]U].^F[DOX ;'[L!Q#$"__WT\.>3 MWZY&@Y.!'WY_=C XN8%N/ =A=')Z,HNBQ>>SLQ\_?KSU)GZ(81!'9#'\UH7S MLY/3TS7H:P0<^L7)C1.!$_:?SR<7YQ?GI[W>:>]R?'[^^5WO\^6[M[WWEY>? MSGO_0SXX/\\ ^+:BXB3SG\\G[]^>O^V]?=^[S/SPT7&_.U-P&GR?M+ M\.X"O'__\>.[BP\7/_7>7YQ_ZIV_<\"'9_?C^RRF<+%$_G06G?RW^V>&(J$W M#$$0@.7)G1\ZH>L[P@/D#V1^_/UM]F?YT M!_2/2_;;WJ=/G\[8M^E/L9_W0P*T=_;;P^#)G8&Y:D2(IKA@_S-F'PZ@ MRUZG DGA;^@?YVN?W9*/SKM79Q>]MZ^8N\-8=S)R8IU#G(1#, (3$X8^I^C MY0+\_ ;[\T5 L6*?S1"8%&*SYA%=Y#T%_RN'T9GGS\^2 MWYRQ!\Y:QHHL"$*ZS4\],''B()+#,>=QC1C#N>.'R@@G3[>.+UOG= [FSP!) M(KOY:-N8S@@(Y,;/X#3EDAR^N0"R6(NB_.*&KZ=4$)Y_NCQGN(T!^141Y ,F M3+8QHK2].*[KA^"5W0/K9\\87IL/YR$D#C!R7F$(Y\L5Y*>(@*47TS4,/4(Q M\,@_R)7D>^1S+_T6#R=/$72_SV#@D5OE]H_8CY8W8.*[?O0U=&+/)[^N8L&( M+/A[&PMNOH\BA]D.?BEW*NHV?@]<($ Q2()0=9MG'\%YC'D W[Q"PK3MQ M\#/;OT0?F3K.@F%W!H((KS]AC#\][R57PY^2CW]_1'#B1P.(\2;O GHY0;3^ M,'">0<#4G9VGSC1@R7AUCW$,O)L8$D\S!P',OAPNF")Q^TJ.JX^W M=T(Y-2K0#5+]S0EBT!;19<#+:=X]WO23W_O>OV(H$KUZ0"-&Z M,-&Q*UHD@[U\F4W4/B[&I0L1WXGQ-YQ\):A)R4E9R-;L'XXW_5]JN5Q#+$=[ MO76,O_UO8\-?>\^ M=(.8(O ($3T<_2A"_G,<.<\!&,,O,'1A&!&MDJ RO0\C0+".I%]8 ROJX$[^ MV@^)G2A.F2 X+TY,]4AP"OT6W /W\!H,I_0?_ M/H#$H/WY381VC=1FF9'K@2YESN:.S&-,_K'A?'I7S:X/S;DZ M.Z?4].%MD-(BPXH3NT=;>=/R34F\$+BNNT)BN5N"DVS_8175P9IQ/7'.?-@7 MSNQZ'SF1/^T+D6*NXI3P=WOS=@4# )SR?7GE]<(]*3\^',1.R G]I1SX:5\X MT'YP>,TSLFTZSC-="0J<8_LB=Q3R6%(F[(]2H9#!Q+FP+ULAFY664B>N6OSE M;(LXLMCW!C,K>3D /;I.N.R'WA_TYC$.A:'OY\YJC<"O%(O*) M4<5UC$=$K@1B?U'OB52H0A*P#EIOP'-T'^((L>*9![HO:.8L$0\RA)5!4TO#2>8-DJ7($K%,\J08,/T[X,YQ@?A9 MK8:AGX*ULX.^:7;/>>3R=LD7SK3&GBZ'JB7FZ 0@R7*G*? ^N8\37=4%_@O# M9XP5-2F5 MGU8!233*+T256403>3C]5TWGL>TS,M+2H/JY.;E M0=.2V0FB:P?/"*-?R)'VKI9?,95;PP4[WN&4U4H3;5XN&5D&JI*DN",BAUR< MZ,H))7+;"A_5P6EJ'!/5# %B'!&=Q@^(3CN@!AF23Q2KAK5O%.G*@LO#0S8! MKAB&FJ7@+-T9(-<7@A%@UVMR@4EN_$HX6O@+PRG1?>=4'QX3C!5V2@&$+F.O M;7=OK2Z]LW.?5]K5_P!+',$0)!K*HX.B$" \&%Q+;NMJ0&J5D<&_9\"?$TA] MC*'K,V57$K52&'IT%J914)XLY?=JWM-=Q%K7ZJPJ MV+^J COR\D4L=F9"SZ7*JP2 J.$%7.HT)@9&;>2J(2EA2&RA\,%!WT%$/2NJ MV%5 T>U;<^;DGQDA)7_01*#M(U7:JGSB9^Q[OH.6&9RD)4DQ$ 4:,(HR^)._ MMG$G'_W^X+SZ\UC"Y,EYJ#7<_% !M\V'VL)MY(13((?9QB-VXJ5X6L0Q$ST1 M6P^HW01HZH3^OYEQP-L1T?2-T'M$ -.P4,22T=+>?+Q3D7"!6V-+Z:=Q(%,6 MU^AR6NOHVF 4;/#%[WFE7M-G$>Y(AZZ4\.5+09@KA3M2G"=*4C?*[HHN4)BK M6G2AP*Z*HDU%CM=9&2Y",B%4!)1PSI\+:PYE::UPI5$"96TI>RHLQ8J&F^5 MM^HN)6QM*.;WX-3;*\1K4"_@D^I2*:H*!TI=AM84J1J]'P3[25S8@1GR;7?'*A(LH.BZ8PIS>\/V H8%.:BS MB3G]IN]Z,0G0(/E9XNV__*NIV9(,>1G^G\KZ8X)8"@"I%&;SCBVEKR!B[ M1"IT.)M,1_2,L4FT1"MEU4?3MJ45K,JKT>--A@Y.1JD6::8L^W1P+%,LS.4] MAHX<$ZK:3AEF<2S)\!;;+NE/66;:TV*.93+]'E)V':YN6MSR(V7.AX-CCD1K MEY1+'P^32V7M>5+>')Y:E7^\-CLJI>PY7!5*LI/6FF,7AZ<1E+=32QDC'D/5 MU];O*9[/';0D>HP_#7UBP#MA1&QZBCGK>QT0DQXTV>*ON05M:/?7 #5:FG=- M $+$Z)F0_R=X2<_%+ "@5/3P"]&)HQ%X :'8W-:!WNZG <1C=L00[AX8V2K#[T7@&5KFPZ^B( M;)N*8@C[6&I["(6VE4U-;E \968247&7=^06]^HU.*F U\6V(<>F(6WK&,2N MHCKE%0A90(W\4_YJDX7<5MDP5V2 QW @VK#X+JR"T$6LVRS2SEM5IF:[^'FU M=B-"QI%U M' FA4GY[*C/,U+';7[B@4,=_3E$49+]58BP5!9!8VMJFD:5O_PO2#*!I0J2IJ[[BYC< MF>G:2KWW\T'HP/\N1D3N$+E ^'?GO[*T97D2RJ HA4!& -RR\T4V%K^O)9I M+C0==08#[WZ^0/!EE;8IS]12,$9/JMJ('2%P^TF7KB[RA:A<+57&"@F!TY*T MX\Z %P>L@+6(V:)!7'F81M_Y\4-# 5W%[$F)#*"3X07!4V)C(=#A;R<[3'#HIBH@!=0YIZ'@GJ7-2VNFZ>_ M7''N4L13\<6763'6!#[;([_0#NU2UV8U!:/*D\!C'Z;S'=KB0',^).X=WU=> ME7L9.?W"R7'Z7.-WCH^^.4$,'L@E1_YF=UNFS#3[<1H]2!_*_+"/,8CPU7( M7D#PJQ_-_##]V=]]@.@=LE1SKQO%T087O1D&Z'".,WQ2%#C%4M[N8B!:'+X. MGI$S3_^/GOL7)Z"OH29-$D"U!#&*6-Q_QA%R7+GH1#4P'30]P! LDXR>./04 M_+%%$'1@SS*6)K1A=.@] ?3B$W$RS9QTWD0"4R4/YW\E[]ML=MTCI\36U>4N MSL% UD5<"$(+_FNA,W3TC-"1U;1R M-"=I(2$)^'!HU2;QUNM?+7=181M-6@ *0C3V+D=T*!5-W:IQ$$OAF:+L#H$_ M8A"Z#>W-'7#[29>!DY:'3(UC5@Q.*UTKNX9H>P/?>:85 C[U%C/4O&&8GA+R M@R\P1.L_KQSLBQ<!X1!Y.\R#K6PF'@T4*/_H;KB]^3.? M]SK*))N-]<=E\7@9Z9_'B_+[R\;LA))X?'O,R++B)^NC+3+*3@4?=K50:TJ2 MK9,JI6:)/?D,TH)%Q("KVD9E]JB-T[K%I$R;G,GRQ73W#S614^W=R.--GB_* MGB)P0YRXV.5$-Z^AVIRXW.&$Z5012^ZAHOB -67THA=/1:PD0W/3H:".%=D; MXE263_9?3*V$*3.<+0I6%&26L3'Y D[8.S,ZFMPD$+3RW8M]\[T4(5;LOT]CR;LLJF._@O'?CC9 M_7(M/)Y9J'IS'0U\EPAYD'JA >Y/$6!BJ$%/40"X"'[\B)N"8J%_*?XPAX26=;&:6Z"I*YD53#'[0[[\Q?9 >TBQ,F M 52I7QV1'\ED]#$D;QZ@.94E&,>TUR:=#IX.,OZZ@.&8?<^VB0@1=5=0HHA" MP,/)>MNO][HJ^J+@:G4+)(?SAEYE<-6^P@\ :_'\Z"R96B6,K#"\XXBVRG?S M[;J 36-GY1G2@*8_L%J4D1"88;O MN5=(;O]V,Z:S.AAFC8'-S7MA[4]3B195CA3>-$]X,^GR$US @*BY$ M;..F]#:9259C!1M\@RKH:YE-@:,'LIT)K50E(!BRE9\1Q(]JT M[CHF%^LF/G588F)?":>K]GA,-Z*T$DV_*]"(BR_V\X M62L[!/H4.7,I=U_.TTJ8?(FI,!Y.Q@Z:@JA/;I$ID<']*=F>./IUYE-5+/*? MH4=-% 3&\ K<>^3\^1,?>$Q2!\"-^&&O1+ZY!97H91L1^R^ L,V+W2BY"8#NX:S8!D8&ZR%* MEI3Q/>8_VQ:F#\ZK/X_GXALXYZ'6<"/*BSQNFP^UA=O(":<2 FGGD5;QDMEN MF0>4).)3C"8.L?1"%P9PNKP/74EA6 R@-1Z!14SN9"=CM%]3 Q:@!1V72BFE]CQNID$6P#(Y9V.@+:^Y0*64 MAPK7D8V]P@JCC W2WIV H[RZ BO516M"CQ8)AXQV;T\PKO)0[!HQ,,>$XB$3 M>QL3%)F*,-=8Y139.V&LBJ)-UP"GR+ DMNA,YCMX.*=,MR6IOK!+W5M0P.]F M3[2S4A;5HC5+J;V9(&)^5BCFO.9Q7+NEL@S!I7$$3K"]0KMM0['AH!%O.63: M>#',TH(@(F_%<[C\$8CZKMG4ZT#A8]ML4@K]IPR\/#)P)Q\D98ZXD-*9L#2? M^]&:?OK&R;L%H4M%;Y-)2[56L2-Q28T$#0[Q(;%8'(H.&\>-1P3'V]<%53W8 ME%5Q#W<%(!W._2T4[F(Z6CJQ?M?YPC>TG2Q++O\GN>ZD?/A*X.VB^P=LD>H4 MN"TTCP 5Z!Y5%^_(670"BE_3M!X@ JZ#)0I0RYYN&]NO(5X E]F(<@D,)0"ZAW.; M219/D1,Q77B]NDR61<'#>A(&5G9,IJ9$O@*\!(B66;T$16;@1RAVR15&!*[" MX-UB(-VG0=>TOHVEJ2@FY@!UO* 7X:PC85!*]V:)I2)71%X-J&G\=@WK&C@. M3!:12Q$)A1F^Y\DPC"[,1%-7ZZK]3UUH'ZI.OY"+D+-@S_:]L"N7<\#>#*!:)[^&*]Z> MI#>#O-D*T7">[)G0K!6LXUE6>R9*!8.TG'X+IV\-8#BEMLH->&ZT9[(D6!OR M"81QUN#23-L.K?8114G&C9G[N Y7['IA(@RHC7@=(T1.0Y+'L_I#A8Y2<#KH MHASDHRMOB.5$;T.$HQ'X(_81\!+I)Q5!E "JG\8UZT<$+68J>FK-JV6@ZJ?R MP:$.G6A)F:].U284-1=\?W3[U'>)#4*_Z_N>^#2T\N>5L"$;SYT!]_LC@A%@ M&79) JMD@X!*.#K>.)7K42+7J2]//L)5!,$$]K(1K?SG]9\TZ6+XW,?UX[VK M^4GC/C!<8UY%$*Q@^IZ'N$3V*ZPZ4#9<JB.:52I838+L9O*N0_%+VKK(G? M"- L<.3+U0;N^K*WP6MM^;:IMW5INKPRR>4*>!?Z'==F0:FAQ3E@6HXWR@$A M0[H+[LL:M&\X0RSO61R^ !3YY$T1; E]Y#->W/X$0H+J$YW^!KS-GT:JQ4 - MK6>#&Z\^,9JLNK6O4=::X\_IMX:^ALX<$H[]&WB4XU17>$1@[L=S-E& _#1I M'\_BR)+%3K67TL^/:P>A):V]E)Y=7PY'4Q)V=O5=+VSO*QCJ@# T3-U]$PI>*8$ MO.1JT_XI(7=<79*[Y9RJNOQ@I8IA3YIMBWZ*;9VP"RF9M8E6T/KWU%6Y:>I9 M/8<]S^1NM%>)&GA;O1&FDXMN /)?6#>=7\A^'4",AR'_3-IHKP2F,_&H:PE3 MQ=[YV\F$AJ%>0--Y-[F U;I6('_JTVVWO40'"UFX2MC? 8 ? M'=^[#PG4?XN=_D?G"'D[LX]/!7VO8-TL7 ?!A'."+KTS)%^?VK EJ_G.1L?42^VXB$ M+ &IQQF;#EO-R+C5/_$:J?O0133%7,Y)*P7XF&BZYXFF6['PY&8=":)5"4)- MGB4#!=A>K*L\B '3OP/N'!?4#1-E82AV^@@"\IZ0$_2GJP2 -;N09&JO "1M MHX<8&O(1E-UGNX:QKF!/YF5+1GFVGU3:M:G%LI;J#R":04]V=&Z'9WOX-<9#, =<%A=I=SV MK@*C@[.IU;>V\'R 'XAB29-MAN&(9MW0]BE7#O;QUQ ^T_8Q-)IU'RYBHH&[ M,'3)4XRS5\O42KP.'"PQ.E8C,D>>-HV,+AF0$K*-AJPHJ "D)!'ZKHMB-E@A M/KJHV,%NCGB;)FA6'W%!PP)6&W5=F*:I2+6 D6W-:,W6!%V% M'X0SP'3RJIBT$_,/Y='?IF>,<]'T(1*2FO8Q,3N@U/[4<7VN7R@81.#<,]ST MN34Y5A3:X8-;3;=&$!-@%4&N4HIS!,Y'TZ=%2.#4)SI+LKU]S86CL5 L]LUI M-JR-MW:LM_,04HI_ZL9Q+LC R*4PY_C^U(GC*T]DED3[CVMAZ@\43ZKB])HV MG"4=1*4^T^(TMY3>3Z:K5YN@5R)#D1-NVF)JC/"RQ-%T)O>Y:8'":9N^O6U04ER1DM\S[09O3KXKU-!P-NS3 M+E NBTK98?'L&7EVJ)?)I?QXMS=:D%RE9,J #KCM!!D@7>6:\N##/LD(R4+E ME FF716-,J&T1V7/N/7>[/NN;!B0$O[)RN:K.G)":E]\2R?J(H!>[$1X\JB H#$]+YCP-3R?O3:%" M-N?I+F*MK8WK>@IT%@7I,U<,1'/./%WX:I7A4"=E?A>,[CVTJT)+;J.!X7SY M*/_ 6+$"8& M3W,O396^"SL/:^EX\4=,2S/@? %#FALGW[@C'X!6'](6#M*]="H *?E*=XV* M=:Q5UDLJ *F+GL:CG_'H9SSZ&8]^QN[[&8].-V'GD\!=9HV[K?7=G:]M<$O; M=$&"W XO5<)@I<+(R;:_GJI<:Q3Z0"8^X(N,!_845J&=^]8BZ=$&0]MC?!AKI3@7<3TX8A M! D?KO877GU^!]$30"^^*S9H0Q6RGGE7BP N 4A6S3]%7^AMB,GFZ_]PD(?' MD-R6V>_I=,DO,/HG8&U4IB&=1[FBC="3?$1_UY-RT6G&K-/-F* .%/ OJ0E\.EN,,=3 =2L MYO>7F)I.PPE7@Y.,@CB:$ %YYHT-PU22W4]6@@^ MX8\0)TD6"_(B:;U<.'V "(QG3M@[3Z .)]\@_>(1_F G.@B8"P:LG3 2124V M(5U;^I0O,(97%%7@72W7F(_A#8@ FOLAV&"%DBQJ<'4=I_07$+(F5J'7]P@* M/HX0J^Y-G!?R61F" '701JX%. >INWU \58JNZL M#^TZ*IE*D!"-LN@%(Q: M72KS>"5=O_I3!!A@V3+44B#'JM.]JCK]!UCBB,CQ1/5:QW4&@VO)75,-2 >/ M1R!@O;_(ZDOYG9+WM&ZL,YL37RVSW\AN%1FHQVS)8[9D.]F2N;1@%&7H(']M MTT ^^OW!>?7G\5Q\K^0\U!IN1#64QVWSH;9P&U%C40ZSC4=:Q4MT[VT]H'2W MC7_ \0S&V F]6^9] ^'::;_:R8^!$TI>&<:Z J*4>@*Q'%3%Y M8;K]9)>PU66;K%>5%?*;SVF-Z/%XE[Q>4 +$"G\Z+O)DL_]AD]M"3WV/M;/^ MD7-JZ^LZXQP#R4.^]:#N.:.J'*\UE+3FHE:<('L/=9&7'N;&"3A%]A[8*HHVHS)\ M1'<7A[LVKE:(U@>_.\SZX'>FE0]-]<'ONC@2M?'#().U8..L]Y*3H9#F4<"8 M+LX8+TG-@<(Y1-T>"][\S2'0W?1#-VZ-UKJ;?K#_^E#IYUF:I,F)/]XI58FV MG%>F)]Z)N7%$DH^K:<]Q\GPP;5X("8HFR<\2;W^76[$<^@SM@K4,*0\^VJ]$ M-!L";+/ZA8]/-^U8,<)5NXJR^,LP;2CH?ADM5!;R>?&F0[*FF%FCC3C5QP^+ M:#Y8GW4M2MEX>FE9;^\JO M[*C#>6MOC*U=WFIJ_I0R^MVAWG:Z6YEQCA^:GL;C=W*M]E*.F7;)F^.89"M& MSK%#%9]2/71[[P]5,1+MT,HY)>S%--UM>%<3'DYR$E'Q+8[\.67!5TQ$T57@ MN-^?W!E9 :]^0/U+S"?D@>!7/YIM*=Q](J_F*TA-MC(VCKV]?9+-L<;F0IV4 M&1F\Z?%U"44W_@NY,D)O1+BQ^7Y;JN,11\;JXJ<\,D8^_GZ' %@/F3#*TWQD M.L?3]=;X!@,")B#7BA4[=1L=JYL"EA$R!FBNIU6N !;'PN_#+5\^%B\?BY>/ MQ-GJXN5C3>ZQ)M<>=ND-; GHOUT:6699-%;&6+.G[' OV)SO M:>!,/MA85OLN,E[+*%QG8=KWSN*C^5\E(04>)J5)6J%'/_-H; L&OL<"$NLL M9#R<#!=)O N3JXT"0V!&M8T7,("X4;>[2<3M];@;X%?CCE1,QA'$8R.G!#"RH-$/GVV^7-[>#Q*]EC6')2 M2-ZC:C@D^_0102]V(ZR(3CF48ZY2G=VOEG=4#6O?*-(VU*&>R+A:Y@.0SK)J M$PV]#J&:I-3P"C6S<@=VG9*#J+DUC;B)&F=9KK.HF2UT8:"8_75;Z4J '0/9T7WF1C6Z^AG=EF9 M">,E #3G+JW8MY))Y!1G!.S5,OFR3I:2.'@M=!>CH^10$H-G)J=(AM3\K"'Q M=W=PWA[Y8P,K#WY7G#%B A *B.>.^$Z:(;@;K@ZQ.QEN*C1= M69PMDRYK!2@8Z)UAC(A%QVO@+"S/*AH(U:!GHLX2-K@DE/#7H,)FDJ.RG3%E MM-9"$#I4\$<$70 \3#U]Z^[J&_,89"@1 *;%K.!].-G8"=Y*4L*4*(2AF8)4 MX&>VQGVXT4=4B2H!N)HIS0Z[DFTL5@)%!Q6TL? #N=:(R%N-)Y Y_5N/ZBG, M>P%A#%;N?:(W$G[1WHK7,8[@'*"5^Y_)6 -)3;$G[DT,D MGSJZ_:0>*5$XJ5-(".P^K1MKP>FJDM140562 O\7!\O,'/OQ#[(]E^73'06/ MNP+DMASU5Y".E9C<^(@($"(QKV>.3W1VB51J$2AM87\]\\'D]A6X+%H^G$R( M7BAQE"M!M(7W(U'P:*<2B8V3^UA;^(W]*&#SH#S:425V6)]G=JSH"9OYBS&\ M);>/C!!2 KO?]+49@-M!12;X5O"P'KU]9PR[DMVNM1*E=,:\2!5*/@ MUM[: M;;^%@W1U0@4@I1NXD@")H6JBKG@HL04PQ$:<"&YF[$$0,LX M#]<#D60NP/QGU618C":."X:A"P,X7=Z'KJS\*@30%N=&8+$M+J]I,!.@!36I MY(KY) &V9BELK2>S&_*?U9N&)&;MUDA$DEK H-=@H)*&5 W+2 J2,(FYZ4=2 M;^S@$I!4#@PL.^\V9A\5Y.*4"CLH+9.[DI8C?V_!RCO6FLP=O4<@7P'B*1NF M6W!7'H%2[0]6*J6\=["]U5=BBCD4LQPXP?967\D27&K$<8(-IU;J.]@"1G?* ME7?"25DFBW6K?1#YPV +'2>EX!8W8NCX^F;\_JDU.24@F+DSTYA?9> MCW6B#!69N2GY/YFVAYHEO^%D[)1-G^Q5)NKLDI*\^S7IO=Y^DJY44)$RY7(_ MF;)3.9,2;+$V72L86U+EE-+^DVDMH'7:!2K74FY\VGMN;%4GKBFG:0[[2+E MB6G*@@[T %"3>P7UPBGAXL-TBVK/\#7L^+C9YXMMNRI[?'/3MS4?KFT6U9I97*[IGKN)B@2)3$:Q110[)D MU?SU#P !$JSB%P $2)2\>[?;LE25F UP@\P32+ MO/T.P"3$49P\_/F[;?8ZR,(X_@YD>9!$ <()_/-W.YA]]S_^\G__7__Q_[Q^ M#9R'"V3:%W]]]^CWXV^GM',SCY+?[((/@'(?;-4QR\!H\ MYOGFYQ]^^/KUZYMH%2<91MN<<,_>A'C] WC]6I ^2V% _P#.@QP"]C\_@W=O MW[U]?7+R^N3]\NW;G_]P\O/[/[PY^?']^P]O3_X_\HNW;R4"7XIA >E_?@8_ MOGG[YN3-CR?OI0_>!.%OP0,$5^?2!S^L?GP/__ ._OCC3S_]X=V_O_OCR8_O MWGXX>?N' /[[??C3C[*D>+-+XX?'''P?_IZ)2,:;)! AN .7<1(D81P@<"=& M^@I<)>$;,$,(W-*O9> 69C!]@M$;3A41O?V,A/((1DG&_OGG[R3M/=^GZ U. M'WYX]_;M^Q_$I[_C'W\^^/S7]^S3)Q\^?/B!_;7\:!8W?9"0/?GA;Y_F=^$C M7 >O"53$"D+*((M_SM@OYSAD&"G(!5H_0?_U6GSL-?W5ZY-WK]^?O'G.HN^( M-@ H])%B!&_A"M#_?KZ]:N7YX0?ZB1\2^$ ,)YH']Q 1F1F)QQ2NFK^'TK3V M-2K'!RK'R;]3.7[71"W?;8@_9/%Z@XA6?A@LZC7,[4J[3]"VP#MMA&T/8$GB&[0K^B%)ZT+C/$"6A3X@:5%H ]O(#^4<:@BK M(+MG;,B4_! $FX(5HD1_")[C[!RN@BW*&\5D(AX0H+/4#Q#E&?T-I9:]9G/K MVQ,>>7_70+==<"8*G>WY)RG%CDFA$+^8@B3*\#F'201YU"]IX_!@7)D86 ;# M-P_XZ8<(QH3TR0?ZPVOZ@S02\JM_7"1YG._.2 J2!NB*,'G^3[BK?IC$I^HMD33%Y_OE,E]@]TOV<>* M'OAF+>-613@ 6JQ#EF20JCC7OV,<S#OJ^7JRM*?GJ<&Y6,VQ3ABT*1EBYM M&..,\(DHKTL4/*A:X]Z7S+17(V+?'DOR@-*?WB";%8U;=>&-4I&>/FU&R'(1 M1LLONJ%R[\O#7+Q&S&'P+/@ PHB5G*8WVVXH<*^6O%/[?HA5UKA-P[Z,LS! M?X=!>DE^D^F:]L'7AVEYCYQ#\RXX &GP3= TFOR!QKR$H<7LU1"P6./9IBEA?PLW.,WC MY.$N#W)UV^^F,:CBTTC37>&G8 =*?J!@.+T3*,&$557G*R1H(!HV'&*9!G0G M]VZWOL=(U0/VOF2FWQH1^S;.R8."_O0FW:QHW*H+;Y2*]/1I+TK?PH>8UOJ2 M_#I8*Z\OF[\[) 34:3F+QA4;0/E,;[&=*. ^#?FF<62N[&EW;)Y@>H\'[ME, M.P)D*KJ5?9MB6JU6<9KUJO;O&^[FM-"S'U=$0B&O+?VI7/7B@E7TY2,&:(CZ M[4V?ES&"Z1EA]H!3S6WLO:\.">4U4L[F3L8%"#;3&W<7 KA'/9YI&QDIVIX9 MWZT#A$ZW69S 3'.)OO?5(8JMD7)FQHP+$&Q\,>-F!'"/>CS3-C)2M#TSOEC# M](&LGSZF^&O^>(;7FR#1C,HM)(8HNI&D,_,6W$#!#G!^OMAY-T1846^>PH&& M(6$QGC]"A(SLO_[-0?%%HN0NF%,FOMEXH_9QMV[\TC0R4;+%./Z\3(,DB^F5 MAF+;0C.(-WQ_4,@XH.E#<\>LD]*@39H.RNYVSQA3P+B^ @5?(#'VQ364 ,1Z MZO0;+-2*DQ9,=DLQU]OU/4SU/$;^WM"R0$'':04&%#Q\,?P&K1_47F2M^*3A MPZI+KW+MF>LR>+Z*(/EQ%1=W-TULMY7($#6W$'5FU80?J#/TS,;[H,+*VO,6 M%C04$7N.,8LB,H*,_V<>)_!$SRD:"0S1? -!9\[ F;P2/]"K^Q L$@\VD_KA MP4I:\Q(*U(1"#823$8W_C/RX2)?X:V)D^O+7+6B[(N?>["DO@%- N7EF\@V@ M-!G\OK8\!*#9V)GJ%WVJMV[K] >7*0W*7Z*DU#S"%(;#0M*WZ/IWO090VK[ M@J5G]M\&5),3-"K/5U":W:& 8Z$"AW6?N,%DY8S^5[PYPY&91^Q1L*#Z&D7W MWE"P X0?H P]\X5F@)H\H4%M?H+1[ 7*,%@Y1D8'F,) Q^KKWS$\JB31<'&> MD,VLE($GIMRH9]RF"U]TBO24:<,@:5\M=/.($\W*XN'WS)2X3\=^V&4< &/A M3=6E5>NX2RL^:1CI*]=>#G&5$("#HA=@D ?\B*1>%M%&8\C4U4S3628AL:/' M00-Q]V=Z^U:"":NJSE=(T$ T;#C$'0RW*6%_\NY^&>=(.:DX_)Z9EO?I.+B! M17,OJ1 'W:<@WC2,S9=ML@O!?VR EP*-=.8?M#TI._,KQ]*;=APA64)6'VD?&BK?:SZX\/69FYX??']B6;8^>RYYW MU<$YWTR]%97]9GB-VO(1@7UKUU"^S85FB%/"C)T08.7R,[Q-\G2G7[7N(35L MC=-!VN'J4^(J[>UPWIX4 G5PQ)I*]1RS_>6IQ)"CI095@SNI-7NFO]GO]^6$U+?K&W=KP2[?<80O22G[I MT'1YT='<@@\(#%7V'D%W#2H"QNYGGPR[#8T#^VY4DI>:KUN[T/UD5G\69(^S M)*+_N?CG-GX*$!$GF^5G09KNXN3A2X"V2IFZ)D%S;)08./ 2P@\$201"^@.L M./OA+WHX8B-U'@5F2(*+L 3L!XDIF.5 L 6,[]CS3!C294-V"T-(A+I'\!KF M&ENP:G0&Q+X.N@Z2*0.3#!)G7N2/,*W-S3H.HT3.'"0%\O;=AS,%L.":L1D*4\8@K*5U?CB5 M#J+80+5'@!ZJ \<9LJF*L03US'#*19#QXL=:ZFW)8:IGY_["GJ#STC=ZO<"J MO;NS[$GM]R;%&YCFNQNB@9SX%$W\-K0Z1F8QO;FBB\Z0,--.U\7L4'!CLP(4 MK%Z!!$Z\]:8%%]91G\_0H#U4&"<6^4M>--N:).3KQ_KAT<=!=%\L9W/@7X&V M/9S;B>,. OC(5CB/@_L8Q7D,,^(0K$O((T81"6;4-_*=24%6G::Y_E5Y.#B7 M?S4[O9I?+:\N[L#L^AS<+1=G__G7Q?S\XO;NWW[WQW75V=7R]_[X1/:6&-3?1\+KMSS)*9L6I#9@H+O=)5B2;@!FR1=5*R@-=IV M":IX>K)GHH!0LR=9WCUQC4:#MTR^CR(J9S?!CE;-!M1S]RD,+QO6*3JLX6X* M1GYX0P\B#:7;)CWYJ?W]]N2HBGQR1<"PQ8 =E--UUL&4MKO MAVVKQ7;[0=UQ-)\^BL]Q\K"$Z9JZV#7!P<#66R@,4'HC11=-'Y*'U^07:Q;) M/3'T;CRPFI;\U#VJU XH#Q;70<5ENA!O&-LM11976P12\=03XV[0>'/XMABW M707LT=/M]3K.U^Q(81*1[(@^VPN34--Z.\D,R01;R3HH3E;,BL.J,COP_37. M(?C)DVT %=BPAAX]A@@=HL/.ILJ<1K] MK^E<96$:$M[\=_0AZ]Q,LOS-+[? MYK2RM,1T+B+BDN$041Y8LQ:8&6T!V.8\Y%*:34D<++ E^<26'BRV@;Z/X"H. MX_SWGNP].#(G[!:LEV4ZZ-!JQ*YA*1S@T@%9/+#$H"X@$!).>#.E>J!$_Q+* MP7>'30XR+3>3-D$D*YZPV00I>**,:,^F__?MF[=OWYZ #4Q!1A]-^1,X>?OV MU=OB?XM?D9E^FS_B-/X7C$"0T:_=$6^%M)L<>/_V%: *?L72@7,8\E^?T%^? M?/@3>/?NU?L_OGWU_L<3]HF3/[SZXQ]_>O7APP=!/,ZR;0?A9KJO /GJ!K)N M7FA7+H*CD+-C%9U$F#UMIL4J V8+NCE[J#[:>2)Z#GRE_'"0@+MGYX MA 9^6%^3_F.%#F"B_,@T"SC'V@-9(SO7,H5!MDUW9I-MT[?- 3FD-A" #P4 M"7P(KJ%>1 G,+H(TH2D,-DL#+?K+:(6=UXLU'0\2H6:.1K]U)V MZ2GFC#PY7]&* ^[3D6\ZYZ8MB)#'MH*_VPF>W2HT/-S20LO=;;,1CL&\L#N$/8=H.K3L.XJ'QVW:[@I.MV%W M$Z2+E'4FC5@UY@:F=[2H9KB'UT[.RG9)&_G1=OK\<"D=_)KWL;H5>018->UV M$8[TC<^"9U%G([@.F$S&AR3J1"SMJ\M$';PBN7=@0IR,8.S\<)5^G-H..1RJSEM,FH\\ M"(?I06///9["Y)D9_=L/[]\RDZ>_^CG(MS>"^J#!BOH:PXRXW5Z2 =!K3I3Y+W'^>+8E$\@:IA?/? >!=ALD M_S]:!L]Z1Z0,R \YCJ/-SOXTTABSNFFFZ M6'AG_':RZ)7ER1W&7FBPJKI\A0')"+#&T^+=B FO^67Y8J6QW&CYXC"5EX3< MF#N].* 4%L*5AR9+I Y_3Q/);F$&B=/JTU3D1 &'6PYW[E%XV MVTEH2*[30=A%AEJP8]$]JACZ8?1J<&$M[7D-#=I#9<8N*I6\1/0?V6L^P@2F M 2+"S*)UG,1TWJ&WI S\II>4.3P]I!TDSP5#YCI!C:4?WJ,*&];4H><0H3HZ MU(7JW";RHOU$<Y'@>'$PLF4O-I!Z%CW. M3&N8&[G)7W Z_Z4 MP\BF+H[%&Z0^!U\=LK=2(^7BOGW93@CV39;C[J]O7W$=3Y.0 ML-D2/_%*$@I_+Y$0'&,+N#W-0LERMXZ'N]?F759USZP_@7(C8!H\P.LM;36^6#'AI(O1 YS3E(,YI&8< M[;NRD.-U4 @B6@%LZ:4;^HP"B<=;MCV4O&BG'VACV ZRQVE/J&Y*@,L "B'H MS%W$$4F. 3&EY=[V+/H_VZQX76Z)6]ZU8&(0 X0133-(CL$V"V[IHV)9G,,[ MF#[%(6VJ%>/H%H;X(6%4U/L=C"6)X0USYY(YN;8N24V#3%!_ZP54;[WPJ,2$ M9X%+2 ]2(3[("OEI$",#('\H1\ CGP_WXL>S93RN98QQ];J\]4VBWT$32K,7 M&Y4(#FE[J\# &%K>^W?W7 Q4;Z794XUS2G,G("ODW+9@;H^3B MW0\A"\IO M(FS?Y'G4K-AX9O*=.#5Y0+O:O,;DP#\.@"$S&^$VML/LC?@-A,8 M4%)J(NC>,?SPBVXXL)*6O%0]:M8Z^+5@,N$CQI_8^X":^TK[7[;2O+$@YJRC M9L\+EB/O'K6HO[EEIJP9[U2-#K4,?BT8C&W6+>MC?1/O(63]75=7IK_WKBM] M?O?L")[?;7<*!?UY#0YJQ$5^;WL.?;.O?V_ H7.)CH.07G^KEFUVR]7E?PLV./N37];?B CN MTIA/VN?V71">RJB;3TCK&WDWG0$'53OH.G^W]LJSX_DJ6&$=W?F,"^J$9"I_ M*0[+^ M I+;9X\F?^F(.7SQ--GY-J5NSHR!O7EY#;^ROVC.8$H$![Z7WZZ$;?'GL6^@M>BBB 0V M7>Z HG7\]CB,Z'2>S4QZD/9[7Z-BCP.^?O_C<]YD#JAT[+?2F+!!UB15;Z-S M")\A6VWF?%WT.CB3'9<]1LMRHV!_P,G!Z;?G\)$(R>9LL5L M;E(<;4-B"?,;P/BRIE?'.J6W6X+JU-Z"PW&AKCS55_SIU0LF@8]SOME5'[:< ML)X7#)+%\>PQ0#87]6=B?:\/K[_Y$49&LSO=[&,PAB_=QO2SF%)D(,L,2J$! MEUH$1TGNHB8Q_/G$([GKJN*_:NG "U+*N :G^6ZX^V(S^]MBPQK97CS#-(PS MO786!L3=%#0;F;G(LPO2-,]FW28 WGCTBH@YUHK%Z0XU'QVNJD7KX@-T;IK:DX]H23S4I7L5?GP0*R^/M;U:YU2B[=;.#1W17NC) MDXM$5+![SYU,?YZ@1>3^"*+6:(B840AAQ)Y)$!7:Q:JHZ^0Q >0L-^)Y MG(5XFR@U&S$F;=@*2)^5D]X^0HSB^;=R0X3M<9:B@(C(POJ/D=]'7!P?^O0, M, 4\$(?N9B4MIGL+([AFL?6 A;*-=M(P-,8.FDZLKN+79&D^6)8*4EA5>T:V MLEBM()V@V=[353(+F?%E-\%.M7.-$AE#B^DFZ\1H!$O^%FN<@(!S!9N"K0^& MHP@;UM"C)?-)2=*G\URO$AEKYB.3'<]\*-?R15\_S:<1MG;S.=3CR#W?SH+L M\1+AK]G 5F\-=*QT>#N@ZZZQ&V4%&"^?^[FU ];A=66$&)'N+"':!LK2!>RJ4MX MN\ZNDB?(YRVME-20PX ,P(BCJV=) TD(NE.PX:SY\S5<)D#^N [2WV#Q#DX& MPVW*)G4_G'"@F6 [X!R92>RE?4($(,M 2VRE%.PI&R$'D 29HD/#Z?[I3:T: M: N%@7T##BA^:^??>Y#9;]S0HB\_41#59_%4)SN/@/D8L/.NEC8HDAZ0L2BP<5&&+.VHDBUP%<0J>V/%*>M*B9 \0 MY[_SPY5T <:&6CX2,,NI*"H0M23ZJ4!TIW.V:WKXT&URT6K>F#9G'NJ8N"A6L2)D%L8 M0A)(-!^M4J-G$\9#^BX6AX(+W6_@;'SUOPX .SVO39%>@Z7@;25TMPK0C>1D M9-U(G[(\ARN8IN7Y&;*B7.2/,)VQ@#_,[=0XV,16A:,+U^1\RU-5;*+$E"<( MMREK'US,H+XZK)8Q=+JP.@1'!KR"FPLS$&*4A5I:IV&2@%F/&8P\PVJ],$UGBO1\Z?6:CQ-]"PCMD?? MB4_53AE[[%-MV/6Y5:,.CP&G'N=BN$U7M5$_.JCC93I4QSCV:,GCZ(L@TLYA M[VDS/]S0 &*CTZSCG6*=]O2J'QY:[#ZZ.H_>2=TZQ!WI1\?S"H>70KAQ<%,^6;P78#H"OI3D-.C);O%ZE-YWN2N/&ZBX]L& MQ <\!Z7+S,'1 ,(VHYN:'A_4,0<<#];UT8&+1+6/]P^@[ 'ESPH\0@)Z1*>2 M =PI(.[H.;R=:+H6_G,;IY#(3=*'?'=#%)P3B6F;CPW]B)83:U =\IB;*A@: BTX8Q921<*KIXXKS["V%S'1X#F_L-]NZJ/7\$8",Z L69^>]$/ MZL2)M)L$>IR,RN%2]WN^UOT]==(BL;K?D7^+A.I(%KY=@!NES>.ER].FR7[X MZV6BJ)GX_WP8$U\ M6Q:W?5H^#BP;E['ENR]D]U^]>^%Q M>%T3D+T.=Z!3[T'K=3/^,-==/UX^-]=4M7JFE> M)-WC&SYT=[TL&^MCW:TL?1Y.'3)I' TP352N)>9)F!N_>MA)9G@)KX&LDPJL M*-TU->7U\0E#%?0::J^MZO01J9;J*HUD%)9)7PYL#OYSG#PL8;K6;=BA0LUV M_B%3=STS(\+K-?GS6B%@3YLK-B+8FRP>ZM)_M'K3",H24)[3SD[E[R?'+J *]Q=FI3II= M<]/U1L@7DQ0@]_H42!FZ7#%."_P MU&)9+/7-#C?[WMNT>VXC>RF5C?XO/77S%"#(;F)G>1J')+FB?Y@E4?T7TB>+ M=[L.[\KPAZK$T^>W)%&[6*V@W@[\V)*9F]:XDCJ(.!=+<'5]=GLQN[L@/P!V M$F!V?5[\/R_8=,6.#P.(<0 Z$%",Y)@B<3F2\SC;X"Q 'U.\W9!OL$V-)(^3 M+8SX;262%(X6A[7EFLC,->6T^4CA71ZDN7P&JRGR_MOO_OCNY.1/I_ A3A)^ MJJ/X^@N(R:;&:RLB&X'_+1FJU6A? M"(2S.3B_NCN;+^X^WU[<@<4EN%Y<,YBE"Z@$>9]/Y6I; #8&X6C0%F6 @JM\ M;I[X:K7^9YRG.V[+FPZR_DA1G&_)2$G HZVRHM-M?HWSO\/\)HBUBN+J-(=, MI6H\IKF5UO0^J!^NJHTW-M6Y]]CNISA%]TV9*Q!L >$+"&- . /*>OC1JC'> ML)4GG/X';(]C3&AO.(R77C\J\^'8?R>V%R*-]DV^C*D+(C:-4IB+3$TCZ16!+!K%))$H":2 M>$.C%(J>%RC% I5NL!/XQG@@=Y"X=#6-<$:FW25\SD^1YN42^[PG M\KH&61S<^,3K39 42>LU[9;!]F9-=ERL%:D7IKE6 S=E8S@ M5RHE8&*._MAOD2J2W.2&C"$T?;*W@\J@!Z]:J-I^U(JS 8*/=_.J DQ877%C MS(!W\4,2K^*0-E,Y$,=H7E.E..!E*"4.#BJ@V_4Z2'=TXI%$ V&Z8U6*Y@BJ<;"*(&<)&$_ MF4JSM'^3@B:PV$R]HTP6V\T&L;PH0+)LDE!F4X86W0$!1X./_>FC;KET08.3 M[AO)PX& 2M^DF%?.3MQ_>OV5>PK:MYG'(WY&Z@^D3^4T@A U_+ M4S2(Z6M>F;@=[4V[OW#&K*:;<=8@$+S?3.LB^B!B;7V.$:IO80;) M<.F!P7/X!!%FQSU,4H(^2N:.WTW9GG#"/R75P<\2U9:"T%U.@86E0/72?S38UG M-=%D/LPTJGAA'?WYC(TXQ%;#I&(VX?G22J(G.$M3>M6*BC1PNU^+[("3B.IL M7&S2-X/IQXQJ BP>H-DC O'0&9_(+%4Q]F07G':]C/,B&"71&;O*\@ 3NG-3 M"6B2VFH2'H*L!B/+V):<6?Y1XUW#U[-$V QT/$CG8RS,E,0RG&KT*#LV9[>G MPDJC#O:-^HC,MV?BT5?R<4&J':*FFX)88\R$Q(JM\1GK5A+FH+60M(I.T:BS M8N+=1-$'#5;4UQC!7^X!:13C6PB8FU C00E?*EO[Z*WFYG MH94?,V<7X.\>@Q3>!QF,1$-THXQ](*4#9A=ZWN&3)=K!=I$99?JC*>2K+:;9,&5C!JY.,.<0=9*W"5_ !A)'/ M!3 5K+"&\L:8BQJ$,)IHNNE8M3"'4T1E9[YL_"KATVU4U@*Z>RRZW7VZ*'P1 MI+0'->T-SR8(HQI&*XT!U8P6FG;K&IP)[2K/YT??(F\O/EA59Z/4P?8D, JX M'43LV9/#4$N?B9GC3+:J69ZG\?TVIUT,08YKSU,_8A21;_MI;IT1N4>GWH+5 MX?W3!>([^$!3\ENXP2GK96P0B-MI#+A+WD+3[KWQ@@DHN7@7AWOAP:HJ&Z41 MQ9X$ U-@)7+V3&R4A%B8'#T6^1'BAS38/,8AN$I6.%U[5#W1@;+#!ATDS:/! MUAHD_$BA>9GE)DCSW3(-DHP^ZX<3H\V ?EI#;I%VT[9\C[2H/3%N0&;G76A7 MQ@_KZG*<^\O-D@P,^5ID[=OD*%- NXWZ;9B*4X"V;H\(QOXHX^@0TFF0Q=EB M);=&+:X!5+U36;.\G?YY)!/2AH<9]%DY.:7$Q"C>W) ZS=*,+)1%\>&HT@#< M\4"E'QG&]99N'.";?8!K<@P_P#+58)$\SL7>.&?[XRSZ:.ZF3%8_9W"QNLCR MF*QQ]%[KWO^F^6Q1IV3?ZCX7#_F4'/R8S5LTC[OUXI>64:7@A9*"'=T,).*M0\3H1Z 6%^5_H/5=F55XFOC3L]H MXT&=0_%@$KV&7Z475%*:O%SLF=#%2^UMF)H8?LS! MQGCCH;H^-FR1.+/VM1U3X<#3^_$-?YO[!M$WD9+H0CS/;>2Y*M3,\>RG;M\[ M!4]6[2D9^N&3&MAA?2WZCQ/:@XCQ8WL$)<=)SQ^&CS#:(KA8\3>=YW%P'Z.8 ME@J7]-RJVW._ G+X^ +[&^6.2>)6P,BTUQER+,XZ7N=)U2F$O!'PC^K' H3M7[=Q?.GO4T5CN&X73\EM)0'9&[ M!M6:"\GFDU7VXV6$X>V.9E^#-))U25=1Q5EQ$B#7Q>_L1ILAG.W:D[DDKHZ& MG9,@LUR==>STB>'CRP!;,8H[\1S8*U]D2WH;;PLBRS)^IQ\0"3;\\P2Q%E MR_(I!@J'XJ]I-D\O,\0"&_EIL;J%(7Y(XG\16& :XZ*7W+Z8@.+T^?B4:CU)H6/ MY&OT53O:N<:WV.C*BAO#I!/#>+$6VQ \JTF\$+0]AZR$I=^3++F0ES>N]"*0 MSI(\CF*TI2\_LFHL*[5?/(=H&Y'5/C%<.K)MSE5OI1&6"^Y6MFHM26,_9AXD M?+72"#UG\10@%@:%M(#&'' 6H'"+RDM4YW1PY&\-G;P",KT_PAWX:Q !JH?7 MYUP1X&*U@J$G%7F'=MM\3,"J1;P\&VTZ=B )""H)*\.\9(99")9%\LWFQ*K>UJ\QB'B?PBORL=*G8*CO#>K4=]DYV*F31 MZKT06,96:Y= XM6J/&20E0+ZL(=AV9ZP ^"Z6_2X\!.V.AS'1SBK*?R#L?YO MWW#D&W4;LN(7$F!';B]R0E@SEGHO#GH>IM:N8R&?UI)6S+\RV7J:E1V3@M"( MNE%9EF5I+BW)R+_VEV/D5_^X);J%L^=8*;W8^X*^0=<(N'BP@Z@UR^.0:).? MUIK^H'ZSEG&C,KS0*+=C1A7\2NF.9HB?X/H>IEJF*+XR0'4%B6_-'/=TC5L4 MXHE>ZT994![#+#_%2;S>KO4,<^]+9BJL$;%OG)S\],;8K&'Q>7+"RJKS%0%2%2RZ (;$09_-L MI+3Z'E&-]#I8DQ^EKKKG>!W$B99K*% ;@$\O]6_#6=0AP_K*\Q\>)"%3.@_E M2/\E\02_%ER'[Y-L8/(I2'^#.>4Y>T@A6R^IISDJ5$RK<%U4W11D"4>P9BQ! M1C$(!%,OZJQ*6&%U[?F+2ZWP24$I^!6S2LG10AW3_5!0WRCT$\867ZZV7F^( MD(]!9NS/"I0,;:>7LA._EC:E-YRM7ZZM#AW64Z3?,-5?,2HQ$CQM>OI((T(* M@['G\#0]&.SKG41,[:>#J!L/9YF2I\ZM A-6UIRWD!R\X^[&D9V/ W4/8:H" M3]O+-*<[^2^Z%1\=JO9?U3GDXOAM)#^6N090*KR&U*;,XX$--2!6?POI= ?J M?YVDLB2/7K^2U/1M.QBYJA1Y[D+ME:$VY?BG[D;3MU7EF:%_/<)X31"=91D. M8Y8T:>:)G30,_L)&5I+'V$G M?BR8 LX5"+: \/7!CY5QPUIJ]!HCV:U; 7I%$1KNWN.,"/4,!LS)_SN;:CTX MQ\D#T?F:M08C8]1=^35_WSPS:J)GW[(HE]>4#>M3]@I03GYDI)UX8!4]^:A[ M5*F]U#I3^C0KK_V!ZJ^^VBC84[ZK5=CQF'[[@JQ+5WXBT.$ EE9G-\$N?(3A M;SISG4)6^0]7C3#R\V4H4+VD'D#Q(3X/D M-\W EZR9"^ #*R(>DKT/]N$*]7O_+$ Q 5^8II"'2A)3T#7,SX+LD2PRGN((1J>[SQF,KA+> MLS!YX)V&8^C :BACL$+X:]$5#)=]$JV,[!;F9#Z#D6CB- M)Z-ZRG>MSN(K# M.!\XH@_%B!+X0&F*O<**"X@*-E9/4/+5X/661A3>UC5CQ[Z66'Q&><(UH&SC M8)\*IS$.8/):#4B8(#2#S9@HQ[JW>OS.&/OZ=Z2T*ML6%TD#,VIG:03(V*5_NK)^5<@XAP!F4N]B%L*,&%% MW76;B;4WCT,(HZSH69GD:7Q/FY/R;76=(D\?I4%OZ'90=O+.,>-7Y&DA/V$0 M"LZ]AZ'&JO$H8H?U-.DW3F@/(M['M&0F#H18OM0P7@YW>&/#(($[VM$C>>!E MQB#VA H!RB<4LN(""%CB\J/3M3.@*URRI"R6=+%M:EZBI M]YB@;/32@XFU8 ^N/''3QA!V U-'L^L^97=AN,[)]5(F?X1%#Y4R=?3.8W60 MUIA;F_1\7*CJS*[T_8;I_+9>UKA*B#W"C)4UV,X.U4Y(*SH/2H4K$ZKFR*IS ML8/J$TSO<>FM>]4M\F/!GQ6W_'!5 W"QN7J/!T@D(5CQ!8(QH)R+G4WFGISW MI)YY&81PMJ8E1W,_E&G8 JNB:7\^W/>P31HG8;P)$ @81Q^=K &G5I?:UYVO MF+2X"V4#9@I(^+735YCFE\:&]HC",[7"<-[=SBT%SO*G6$A+TM)?_' MTN)*@A&;>2:=9SX%.6V\M3M7W*I4H6(KKLE4'65TA5. -><$(D]SN4:86B>: M0\7Y"TF+APA&[*GPD3VD>#E2K"!%#"U^S-B=&Q)AKY(PA8H'G P)FX.FQ&):E"6%8TRHZB8\XQ#L!]ZQ/!L=GMQ-POS MQ8K^;19'ZLN@[N\;'J)IH>?D! WC!8(PIZDI90>"..*K'Q_.S_1A@U5TYB,. MM18[C"Y% .% =:-S\A$(?P4S< LNP!T@C$#!"1!6O0LWQ?._V_4Z2'>+U5W\ MD,2K. R2?!:R7#9.'FXPBL,8&KP'JTW7].RO'A\G3DZI@YB2)[;%WZRL?LH MBM?B[W0KH)"8_5C)3&*$$!ILN-1O?(@0I@:"AP!D=&13C9/>DZU:-)V:L+M' M6 GE+0I2MA)'F#X8IVFF1V.ES4^M:NO_6'"N'?WA<-+-+ G.BC\0 MA[(W7T M 2/[8[7V?%IU)PM&%T0*>NM)YPG4]N^;/0/61L_%XK'B! 2KZ5];ZP4$JRC* M1^6C#KV/][9JTQC5FQGT4;"G=U>-"X[([ ^;%*@HRT\(NHU?MP^!G?KCER"- MZ3PC]J>9/+N;-*;3U"E,V%5.\J-Z2P-3RN85*SU.]MWI"\D\R2+AF1Y/C[9A M[LEA*D-H\3#%'A>,2"!8L*Z.:13, ><.)/;6^@=7[8G/T^T#VZ9[@NGNDF2" MT; FX#WT!O>>[J0_4G-P*@,HA0"5%#ZL^72A/6P;KJ#B8X"Q5NL\/[^TV3Q\ M!/%Y>) :B;>:G;VPD"\?8?$8G>A5I!L(VBF8VDP;13?.OOP$5IR-%][+^Q:I9GK?O0)(5\TPK9W&8WH4E&;E J M4QKTB.NGJX0LZ@)4:W;TD:SN%ND<9UHM1,WHVT["N_G9-WA*&^ 4($*]N+'R MY>K"YU65(N"]:RL511\CN'WK+"[#7GLP9@:+%% Y1C^YN()I"J/%BOR7!)LS MG.5:CMM"8,CAN :"+D[!%FP YGQ 2!GYX7S=J& E97F) -I3OF !SKJ5[ZH5 MS :F^>X&T>D^B2[^N8TW-#^?W6=Y&H1:UT04B UJ--)-W':O$<8-,':L>6') M$/PJ6/:D72/VA%$$$6OK;Y@S$G%XE><0HNEIO4OQ4M!S7/_#026; 8QGM M9%V\^<.9 9F;'YZD A/6T)O'D* N-*SM--["#!+]/Y9>J+G/V/I]PWVN%GI. M]A@%+P %,Q]V&OL0P2J:\E'[AD_LUX+^O-5%Q7SV-A.U<'S.((7"$@R(;CY,5LI8(35M>8O'F@?BID$Q50. M-EO#K/L9WJY7GK? MKQ*1.78@R>:'4ULW).P*K*,WFKW#V)*=R%*!4BP69F3!.G>WK3R)V3KT:VBK MIP_. ]0SYR5=6U**=T/",-W"Z(Q\,@X#M$S9NE.AFZZ; MVR(%3Q!RIB"G7-FI11 6?'TH[:I"AW54:=2,AE,61W -;>?@Z\-,9H^<4TLI MNZG[9QYMH& %;8WR2F"PHX>-,CJW4%$"E!D="NTB,R!U;B=K-V_F?(JIC'/R M[P2H E980WD^SPFU.VSM$X*%*VUCC ;5!R*8 <:-'0D'G-_(Z[.+]0;A'82W MD&5X\SBXIY?M8IAIS"(:Q,Q#02]Q=W:W"7;D;XBE?VG!'MRS_@&^G*10AQ%K M:]1[R+AS"6Z LP,2OXF\BQL063^LR)J;I"P!NH1&KM5':="BLX.RPV".DVR+ MV+5/ZE<(/O0][3IBJ4$%-:RG0[\1VIN@9%Z ,NMW(!^6!TUV)M8&?DN^I__R M-N4T<6N1/\*4RS(L)>BC9.X5W93=V1.F?/T(5(HP83VE^0T)=Q3&"@A,M&9Z M_P"3K.O/DY@!:$*=? K2%[* ]73)*@_X$ ]JI-UK09Q") M LB<33YPC9-4_/,TR&+U;L<.F XX3F5+" >GX8AH@,E6W'\HRA.RL0OYZ*O+ MI83L4[*,@ GIURU!^P:'G6'Z8HP+36-7;B/6Z8Y+RUZS2^$_MS )=[K7%97( M63"$=O+VXX?$"92L/'-_!?2:'+M/C4> U*$SGNY (V33W%0L%=&D!OV;BDKD M+,#63O[;=# %])H-G9QVZ?O- >6 M^599B;_NU@IFC[\U*_48@.OT. FSR:Y957-[^>-?8YC22V"[.7PB]F*>-G92 MM)*/='!P<7&8D 8GGKF7&G#-&6.O^HX#I,:\4?I7R1<4$'J3/&:'JK&31G80 MMAPUVQ@YG?&C@K-G-FQ$>.I<]"K9;/.,!8Z3 M 2EH$QD+V!V2_5;FO0Y8W#H+06G8A8[F3QEE,;]SHYGO'/C&>_< M>L8[?SUC'Y<>SWCGSC.L8M#M&>]\\HSW=CSCO1O/>._6,][[ZQG[N/1XQGMW MGF$5@V[/>#^99\1)D(1Q@*Z2+$_9A07MND(;B0%H-)-TL'01C$#%R1/7Z $& M*VK+4Q!0N_ZGJ0(LTR#)5L0T9DET!].G.(R3A\6J00D9;1>8-?])OTA@EZ\Y MVC;E&,=//3G/[L1PL$M@7I*1\#A2"L8.?I2BT?;5C:;#6GYF[7^>J+;Q"2=P MQ]^LVB:105^U-@KFF#=3=+!!3?F4#VE13G[X=P\F6$U3?NH?M:E^\H7:@$-H MWRX!W*WDQRQ8JC4 M;\!-=]4@>R0^3O]#.^D\!:BV.UJ)J.-5&D0'M/]49>*@)ROAR;H!<::O"E2? M&*I1R=@/W]-'&!LK^6C01!*0=(IC/TB,F]W4EYG.R@SG)'+:OQVWI#^#_7G- M#]?J!TAE.G,VC8TV?4V[JBU."2QQL2=:U=36]&WI 8O6'KK65@F=?%RFB %C M_PJ@XMP+R#'_\1W(A12O:$/(K3>[.";(MR\6%31_3"BW+O7X.9HE%N<&I/IN M#[JC.? [KIH3RP[<3M1A'M59N2C#F/GV"IK,7J\(^BS+33<69S'D/:5IGQM._D@AF(2FX M"79^^/)@(\"V%'^L@*,]K"M&P%NQIRT#&WX=.M+K0[K])IZ1B MH\;%IT$&BZEKB<\AB7QKNNV195N2VA#7.\/K-4[NX&!JAD. MX&!HF,8GV4,*V0T@4Y-6)6=HOVKDG1@K8TT-$A7,02"X>VF5FKAB M P4;V9N@+(Z3P:QD,M<=65M/AB7%HA86Y^V M#4NY]YLB(?L&9;&-UDLRIH,>:AIZ]!JDVOT/Z,#-D9 ME)K/?_G;DOP=[L]6F@^+]U Q-*1.JDY<_0OX&V \#U,4'_Q<#2RLKCY_@9'= M^\O?WH/2&P2SX=X\PBBX*U=F=3 ,A4/#&I6N+T$:T[ @^DM?)'F<[V[2>!VD MNU/VI$$8DQ]MCO$)IO=8QLIIG+6<-^K,(G/58[=^#5%Q.K$ZNE&K=S*&;:6[ M5PVU.UHP"?%Z$R0]M7;O1HSV!DLQE;B"DBT0?(.7RZ-6!)$T48M#-WU(0("2AUE'( I@P&H;A9&.X M.Y4P\DC47\I$DBPD(OE()V:\+$4&00CI=WY-YNA235T8+07VHDU@W,^P$ M3>/=QL5*I/[$91_28*VUN=CP[0%[B0?4G&T=4CM-Q9)G4S#SP=JZ$<']NAKC M'>"[\!%&6\2R6D1&@E-VP&B6I@3BHF-E<4\U;/DS.XP8A!0._9> 7' WSR#L M2V,_710R%KF_) :0Q10W=\.V3P!95+]>"')HD=@]UB_/^M"4AJ<2\[(TE^(= M^==^K"._^L<974;#=!.D^>XZ6$/5QFSMW]5'NHV6@SNJ$A= V4SKVKT X#[E M^*9LU*)G*_W6E SZ%FZ(T(^!5([<'ZYZ S5-@F9H*#/X)OQ!'S]LI,:CP*K< MN!!3L=Y9]+I#[T< MKH/ ('4?$ORV3+P#$:RD*"^U7[?XK'X$R%:2=?$,TS#.X&(E7'=#TP_-3*N' MBN%4WTG52C(_BN:'*ZM A=65 MYR\L=5<6F @7X QM>++SD:">04S52=K"AL3R0+HY/O31]H9JJ2,I:B 6$7( +!IADH!*- MF!>DQZ%/B255JBJ6KK94Y?#\TOX5AJ;#2UX/ $FR$]C*NR8W?;([R4SJAV%% M%,*I5IK10<0\G+<2M0/#!F3^!URM7L+K,]$,*GV"R]:0==3]<6%F# MWD)3E=6*4].4#:CQ&3U]S_)/ ;U30'M'ZC5SW__JD/RF1LI^.)TER39 8%WQ MH)[@A^&W08![]..9NLN,D$S,$O'!3>CP+D#Y3EQ*Y!PFWYS!=,REK\"FX(O31H2DBQEE+4/U29E +&6/HT.PM,;<7$N5D[T MADQ,5B-)2')'K2*$!C%#HU(A[L2P),9LD1'*K'VP)RT,L;8Z;=N57A>D?D+V M[7S MU(\XNXE>#2>#8D6K2C*#)\#;B0QXJKF-J(.:(*%"T_L:,S\\IA\?K*PR;[% M$@R+/1BF>LF:W?(/PESJ[*'_F'4'D2%%AA:B+M*8@I5ZXYOQ:CM]\&!EC7D+ M!6I'8QL9B,Q%_=]"^K3'X7M5CWNU8IW M:N8F77( @L5X![X%Q\])MH$AV\K4._#=0=GKH MCERJURC=S6T>IQIOA&HU/*7!.5ENG6XSPCO++I[CG%9&LA.==5;3M\VS^D-J M;HXAB52>;S7ZL;#J +WJ\@_I7/#%^0!I0\*!A8:#8^R0UVK["IM3Q_+R%!] M4(*;Z-Y(BT&$(;CK'I/:5N*"*"J@P6X.@PQ^(H'O$>UNZ9X:XGR5-Q-52!EN M5?63=K*A6+(%B/(%ZX(Q2!EG86T^["QJP(@U=6JT0]U/7/W@@Q(M9X;EYMB# MFF5YL6FM Z6Z;1E78L:%39YD/C5C-'Q6&6TT?&*IC(\Q!&)@!4N+#?G'"MN> MH#0!2".O1^HZR"ZW^3:%G^(D7F_7PFQN(:WC1/1^QV6 PN3' FFX96!K8!RM%32[?@:X17!!J@5! M*0I=$A3" "J-AU'A? NODN573,73.H!D0-PM_C5F4WM_SVK=)^]OM@!-KV]0 M_M&AK>OE1 1PE0 B!'/NL:_LJ&N)/A_GT+\E\F-@7K*;VL??'9N/']J!D9?O M 7"$F)MZ.GN'T0-?IVN-B^<-[?=Q#94*@8J$K&%9)^SBR#!Q0U@P(.X8;M,4 M1F#+&E1 /PG]N89'8\$]0Q!GF6/TF.4U@4P&U-=3UZO5H &P)AY1O42LFG(%@+1:@ M'<5$)^XHX@]A3U.6,[JX2G+>8Z[XAXXC*I$S1U"!O(.@&8;IEB#DURN\.L!A M PT> 4C/.&7W MQNCHZ,U'W?OJ+00&O(771-#!^7S*YC5]5AU01J\\NI[>C0E64I67^D>2ZMDM M0J9ZIOEIKIT?C%7_TGDK"8L(.+N%=40^T'[=O%-=GJ+0Z0F3W31_@FD>DTF5 MRF)TR[R)P*!KS8<$'7@!3&),7_PAN0-D=U$$5PH*22;(K_UPBFZ(L)+FO(2# MN\.>ZE4N<8U0MC@+TG07)P^S-7V-T+Q2L4_'UMJV3M>9?V3B#^'PK\$_A 2\C<2R4A $[CASBAM5_.&$1<+M:F M+Z(64_XII$+YZ+_FQM/JXH9(':NA= <*V6*$.(#+P\HIQ1>$G3"9)MC8G^/D M0:3A.N&A_CUS"&4ZEB97G >(N^V2_KP_IWI2=6S4/.[2C$]:YE9/"548,,Z:O09(F0! M'2?><_%,SY=MX^R1SE>+%15%MSS=3L,-+U4@9*AG?12 M=N*UXJP1K+J;Q\%]C.)\=X:"+--=\/40,D^:.@G;-[N2 M!V!,_$ADU5#"6DKS&A'N-)038*S Z0[L03/-2K _$0#[0-1\IAF&7 X5OWLO9V&30Q< MYJ@89AB=5)TD?R7' MZHK_FO'T(?53@PJK*\]?6&I[T24F5>;$& [/^D88">H9Q%0IWQE&*""2!$@W MU=O_YI#;+S(E%^_]"/K@KQ#UV,MX%XX:%8^[U>*7DM&!?B=)U"K^^@G:X7=M MJ-A50N:Y);?G7RDY2 M+4G9 67+5A@;P=B'?$L=.ZRG2;]QDN/.^]C&2WBCB'WHPXP=VY0O&4Z5;=7. MF<]-&@NV4;!T&7_NKJW@P<'WN6]M!7O0:>N+,+?55- E$F@(""-<9[V%$5QO MZ)1PD\8AK)KWZ3B',DE;MPY;63CIREGR1 MX(=*Z&JW0RNN@+$%-PHP*I[7+BDM5I?;),H^9S!:8LH1KA?;/,M)>A4G#Z4U MJ3]=9T+:]&RQ-BLW1[]+,>C-AQ45!&R))"#'S GA&N!*F*IC@Q_GP\TM 0^$ MX[QX PO=O> M_Q\8YDO\B,,8LAJ9\12X<=*G.",_^9%T#+4(; F&(T6_7!E0&0 7@GI]*8:PBG6[&HD?4<-;28>(D2Z$"@ V1@#ZQ%)8R M@*]$B*H5#9G-_,I/C!#'QDHW>_F9-_L19$4KE\6JWK!-US"UZ9H^+:S'Q\WK MT.T-DXA--G8\\\(^3;''0W1_-#&H=J)>/P -SY;''S*21DLYT]?-*MZ ,J\Z M.A67L:V-=A)'EC%N]^(C'1S:&U>)7-FNBT#8V*]T[ 5/O6(EOW-2'B:Q42WM M)6RKYM;#R-EC+?#P3%?WLRW3%4Y506XMGRKI^*@ ;2FEEJ>H*'-0G:XRJ*C: M\M8T?@JH#!^#.)GC+%LDU>^TVW#V$AL"8@]Q!\=7'HE4U/_ BEZ/>F+7HUAB M(-@").XW^>*7JG!B;GWX[>NE'JWY3C\[;2XR#>D M^]\A&2N=Y?;).N[]1]G1>X+\=J"GK?]:(6ON_->L0X_A0<.1<>,U]&4\UC2; M"L&'K_TL33N1 9"T$74P"S$ ,(?$$]_H!08KZ\I;$(17""[<%4KGF.;PL#14 M@^/##=\><*KU@-JW8?T=&.!^[?BG;R2KNC)O6U>UGD.61R]67X(PC!/X?)/B M:!OFV?SFA#H0'[JOT ,P)J[ M%B("M7R)AJ%;\:X<2BSR;BS \D$PP5J0]3,OA9O84Q(B6IBYQ M>KFE^YW24#^F@7X#<&VZ@RQ3F8_+H!,((< *IV#%Q*B%'/# )/$G\.C#CH>H M_9@@;@@_I02 B *&6I>"0HQ;(6@D4>,C 8[60<+J8@S-[E2V4+ 3EEI[NY" MY7YY:>[;?W-;MRD=HM!2WU,"P%$'C/4:)TR,LV 3YP$JG/<6TH:B M,"KCACCFI.4?^L2'-';09&;?KXIW [,B^K$SJE0D/G^G7 Y//,P8=SQ8Y4>' M<;EN9W 6/LOY S[7"0GDJ4X(,32_/JPKBL-+NAFU B7#!*N7LI.LN;FP*T[I M>9$EJX.']53I-U#U9I!-*)5LA^>Z(XT)M0R'%=Q+CE-ELS=!FB=$ZSPPS4)V M&)D5%OEI9!CI3-YJ],QCN0I].[AMUD(5FVCW&!#DGB<8EI,O9\G+YR53F[T0OF#Z5MX-_@K3Q6J&$$O=H5@> M+/$I7'Q-8'2Z*Y:T$"[Q.23&M"8AXN*9$(HSR'HU*$_2CKA;N%MO39H1FBX\ M,5G!A@I+_QT@!,)"7OK/(B?/,;@GGZ9"TS<],!>;_CX2@I.(4$@.-E1T'W(* MM_;9U,3!,O)&=RIK=&99K>N!>.&#WOPIEPB+HL)U'N3P:B4$(W)F[*^W<$.7 M9 D=V">%,DS_" M#8AULMQ729C"((/TPJJ#8IU=?A:RC '\1\@K8BY=<659"@0ASTEY^4^4^^2- M/'$%U@-J>[ZC.\ MW\WL:Y!&0VX/#65JY3++,"$?;&#Z8HP+36-73B)6H1NB"MW[5WM?- >W1LC!O7NF7$K?#X]M5CCNU(=7 MRD7[>IWFQI1Y)*ATDD0W1(77P=K@32TW_ =V;[,LS\OW1J=6M-_2SPDZ+]%B MY*-?PR95*4JQUOM$6$"EU;\&9R=J7:PW".^@?').?=M=@8BY-;02=7"=BK/2 M.2D]5D#H!P@KZ\Q;,% '#I-M.?,XHIN'UK\W8 -2HN.@H:T(/'Y8>:.R<9>IH+^ESG:YY:K;M>9;=#,EA;C,@$VDI\R^_XN4CWF9!$ET@ M^ 03$=XO_KF-\QUEJ'G"3X.B8:E>F8.38CSA#G+.'D#&'T Q)T(F =@0$7PH ML>NCB\UT?!Q(RD'JW=N3$U#F,@4_END//PPX\JAX;*!V*=B"@F_C^*Q=NI.' M&3\\YM!R\.BE:<'H>GB,$$"X!$<10E11;@HB2IH^%D3W LD?P6*=Q/?;#%PE M=.N1=?&T'DI&&5EC,!$V:B>0[80=:^ M!1;,0-6;3+#S(_]600IKJ,YC5% /(-.L.5N&K;\$[2%D'1A7"]3C=)CV]:N" M^KS&IM]MIJF[?X0)>_,WB6;1.D[B+$]9S^"+9[JK /5K\(H$S<%28F 'M">8 MWN/2I3AC]@)VG37@O#TIU>MABHU4>Q3XH3IPLU;@IGMPNF>GL6VC<6[V./5P M;@YW57NY.VH8TK.1VG,X:>Y;6P>+-J6S3Z^(WO';C\8>O"W3.?(K9.TON-J[ M/Y8_[M\A>]$J10?:I$T."VTR(>F_B9B RUFU05EB<$H^S;1)S%.(2W]?"@S* MJSHW=C3IWX41J\;?IO*#O:_'I/:E"QX MDRU !PFN5I57T7'R#\DC!72HH!BK8*/JP5.DJ/?]T^[]_K1+4NLX91\F XRQ M5EL$BTP')APVA'"0M\K]48OX :-79 (4C,$.!JE'^:A5 ]I/2^UA]&*,14Y2 M[]5RU/N&%+42#A32V4VJ)K^$V)Z9YL.[C!V=-AJ32B%5\9ZJX]Y<$U=5KK>T M"$02C2B*Z5>$WF?;_!&G\;_T>OLX%6."=72_6 ZN192\6GS1HSG.L<79*,:H M0OB"KD'L3LS6*U*F\&('RP:4Q1!G2 M>=JI:.[ZD8,B\0IE(PPD([S?%:&/?V[#C3!@1BB6 /66YD5!07Y0(6&#\.&P MU8@&C4>V#J,F)(,#YF$/N/Q=+0O8_K23.VF^M(YZFG%Q[,"GG%'-/@ M\J_$WWA%X*C]W.GYI7Q'[/OB3V(3[!MP_D,S M'\?]]\S%PP!P1JLNR!O_K\3QTOV%>$?L_>7,'_*QO'SO/[#Q<9R_;BPO?+VZ M847_NSQ(<_G$E/SJ$#7!CX4)G@:HN]K[TM1CK98D'HNK/^94["G+3\L5PD^H MX/$74IWO>TG&QYE^4[IQ4,L\4'%EB/Q/1Z)HRSF]JAF6;+\Q_4QBBD>C;+L9 MIJHM"J[?EG8FL<1^5?NUT\T3#J/-((?,)]AW;!/&60(MM_92S)F]W\;N-2<; MF]?=2+TXT[&^N-!92'@9K8J';*_X0;F/*<[&N?[4Q7XZLVL0Q]5!TS):*>7^ MQQ*MNLS)8KQJQ>D%FH[UF,7?KKX2YT\!$W900ELJD9HV/:$(H_-M2F\9%',U M2^BD_I+65DH?"ATE\"$@/M3L8 HK&B]#,TF(5S"FASY+LQHS-#>RG\Z_&L09 MP7:*-4CO>N]8PG.725D,SZU8O23S<16>)4FK&&TG.ON9E!?KN8NDQ05[5W-> M!F\^Z=#*QOA5@ ;FTWG>@3#.,VJ)X\L(V^W&9#%HM^#TX@S'>L"6Y#S.&H 4 MUW\I&DM&LR>8!@_Z[P"/+I(7):HN$5W5/ 7/UYSI7G^!EUL%53)1-[71?IR_ M$7-T6D<5XH-FR_8MN+8^7--8&!HMP-H4:XIG?[3%M)]6]H;8XRK=.C!4*X]. M&2+]#1FE1KCM>:*JM0;\PH*ND-Z_N*LIV816KB7I!-%7\:32T<1?,YNU&8(- M$/^V[--^("X'\7)C<4/IW9MHK"W;A/:N*>L$$5GM<.31!&13P[49DHU _]:, MU'Y8;MR$,P_,+[4.M+]U-[PHZ66!7*KP^U(@5Q;)B_T;S^:IE[Q!.'9Y7 OE M;\08G6XQ>K@ZN._'Y5Y[NKJ%].T6\OLSG.1I$.;; "UANGZG'6;'%F^"CJ?F MXHX0?DO>0&(.YO$*@N__#H,T^[V/NY43&;6-1KQ#K>$;-& Y9-^K1>Q[T_W, M9G]@@SFRZ-T^J[;!=3)F]#82;SKC-Q#7D^CM9T(]D6%;C.#&%O$-&K'E"-Z9 M'*BJ"^7J1-_LX2%E=U% R:]X M&\7'[-BIR;DYO=>$XHLU+ZJYIM;0.12:\>/E_.=+2_43@DU_%R4OD",[K2 M2>C;4S D/RXQ_96TBBB'/-U,,T#(Z4* L=!3S$F>54 F-6B+4]5 &_AFC=?Z MI%:,A[WZ+D9$7[FEOZY53%H]YN=)__(-UO*1UC&#N;9HOO3&Z17585$[ MX 4\Z7G@^CO"6=,KH/19;+C>(+R#M%4X,?XH3HGQX[2G;SONO 4EO,%>/-7NQ8G'6<(N,_!Z7H6-1#P5'MD%;S-="2:4YCKH+ MVR[#=+M4;3*Y7#,HSCE/3#2/YA67YF=QK[0;TI=J:I9W/7E^7TT(5= ?>V?S M@B=<=S!]BD/8/%UU'R*(HNDW2DE_]49^02 12B *>B?>GZ'X$SW$-&$]B!]^$L?(8 M*R0&7&30FH>78A?1->-U_]IGJ.CD@SD@PH-*>E#K9?920BZ?^W#*?T4_IY6# MCBV9AW;=*.DQ1.-7X.M^^26MA@ V"@TNCSYD=SO &+&[PWR^+6,?-9J++!JG M0![)L501RM7*+,NV:[$ESWP M_0B>(UB9C7*!(FXOUZ(LE0RJR@"0Y)6V!8_I-'27ZK]@DNS$*,YWMR3I&66+ M3T><"?9 U,5S& .?2D8>A;^1;,_&OILNB-^ G5G;7^N+C97P@$I_S%'R-LY^ MNTPA/;X"B<[S26-DLS">6&Z3D78@)CS 6FGB1UMC.RT/%<1LAW$ M%V]EKJ,CE1Q0T8&0_>B#HPCXY_%3',$D\B*!K OCB=DV">
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end